Viral vectors, components thereof, and uses of the vectors and components thereof for production and delivery of a payload

The retroviral vector expression system with reverse-oriented regulatory elements addresses premature transgene expression in producer cells, enhancing vector production consistency and clinical safety by controlling expression in target cells.

WO2026236521A1PCT designated stage Publication Date: 2026-11-12VYRIAD INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/US2026/027142
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2026-03-27
Filing Date
2026-05-07
Publication Date
2026-11-12

AI Technical Summary

Technical Problem

The manufacturing of enveloped delivery vehicles (EDVs) such as retroviral vectors is hindered by premature transgene expression in producer cells, leading to reduced viable cell density, lot-to-lot variability, and off-target delivery risks, compromising clinical performance and safety.

Method used

A retroviral vector expression system is developed with a transfer vector containing a transgene and regulatory elements operably linked in a reverse orientation to reduce or ablate expression in producer cells compared to target cells, using tissue-specific transcriptional regulatory elements to control transgene expression.

Benefits of technology

This approach reduces premature expression in producer cells, enhances vector production consistency, and minimizes off-target effects, improving therapeutic index and clinical safety.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure US2026027142_12112026_PF_FP_ABST
    Figure US2026027142_12112026_PF_FP_ABST
Patent Text Reader

Abstract

In aspects, the present disclosure provides retroviral vector expression systems, retroviral transfer vectors, and methods related thereto, wherein there is an expression cassette comprising a transgene and one or more regulatory elements operably linked to the transgene, optionally in reverse orientation, wherein the one or more regulatory elements reduce or ablate expression in a producer cell compared to expression in a target cell, and optionally wherein the reverse orientation reduces or ablates expression of the expression cassette when the transfer vector is in a producer cell compared to when the transfer vector is in a target cell, as described herein. Additional aspects are as described herein.
Need to check novelty before this filing date? Find Prior Art

Description

Leydig 775537Vyriad P-63-0061VIRAL VECTORS, COMPONENTS THEREOF, AND USES OF THE VECTORS AND COMPONENTS THEREOF FOR PRODUCTION AND DELIVERY OF A PAYLOADCROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This patent application claims the priority benefit of U. S. Provisional Patent Application No. 63 / 801,718, filed May 7, 2025; U. S. Provisional Patent Application No. 63 / 805,244, filed May 13, 2025; U. S. Provisional Patent Application No. 63 / 846,680, filed July 18, 2025; U. S. Provisional Patent Application No. 63 / 882,873, filed September 16, 2025; U. S. Provisional Patent Application No. 63 / 904,457 filed October 23, 2025; U. S. Provisional Patent Application No. 63 / 904,491, filed October 23, 2025; U. S. Provisional Patent Application No. 63 / 979,558, filed February’ 10, 2026; U. S. Provisional Patent Application No. 64 / 008,025, filed March 17, 2026; International Patent Application No. PCT / US2026 / 017725, filed March 4, 2026; and International Patent Application No.PCT / US2026 / 021378, filed March 27, 2026; the disclosures of which are incorporated herein by reference in their entireties for all purposes.INCORP ORATION-BY -REFERENCE OF MATERIAL SUBMITTED ELECTRONICALLY

[0002] Incorporated by reference in its entirety herein is a computer-readable nucleotide / amino acid sequence listing submitted concurrently herewith and identified as follows: One 164,407 Byte XML (Extensible Markup Language) file named "775537_SequenceListing.xml," created on May 7, 2026.BACKGROUND

[0003] Retroviral vectors, including lentiviral vectors, are widely used to deliver payloads, such as therapeutic genes (for example chimeric antigen receptor (CAR) transgenes, cytotoxic payloads, or gene-editing machinery’). These systems have been applied in oncology and genetic disease settings.

[0004] However, the manufacturing of enveloped delivery vehicles (EDVs), such as retroviral vectors, that carry’ payloads can be hindered by premature transgene expression in vector-producer cells and, in some cases, on EDVs themselves. Premature expression inLeydig 775537Vyriad P-63-0062producer cells can. for example, erode producer-cell fitness, reduce viable cell density, manifest as lot-to-lot variability with lower functional titers, or produce any combination of these. In addition, producer cells can retro-transduce (self-transduce) the vector they release, diverting functional particles away from harvest and shifting vector genomes into the producer population, which further exacerbates toxicity and process inconsistency. Because enveloped vectors bud through the producer-cell membrane, EDVs may acquire and display membrane-anchored payloads (e.g., a CAR) on their surface, potentially altering apparent tropism and creating off-target delivery7risk prior to administration.

[0005] Downstream of EDV production, inappropriately targeted expression in transduced cells can compromise clinical performance and safety. Ectopic, excessive, or lineage-inappropriate expression can, for example, induce immune activation, cause on-target / off-tissue effects, impair cell fitness and persistence, or produce any combination of these, thereby compromising therapeutic index.

[0006] There remains a need in the art for improved manufacturing-compatible vector compositions and production approaches.BRIEF SUMMARY

[0007] In aspects, the present disclosure provides a retroviral vector expression system comprising a transfer vector, wherein the expression cassette comprises a transgene and one or more regulatory elements operably linked to the transgene, wherein the one or more regulatory elements reduce or ablate expression in a producer cell compared to expression in a target cell.

[0008] In aspects, the present disclosure provides a method of delivering a payload to a T lymphocyte, the method comprising (a) transducing or transfecting a producer cell with the retroviral expression system as described herein, (b) recovering an enveloped delivery vehicle (EDV) produced by the transduced or transfected producer cell, and (c) contacting the T lymphocyte with the EDV.

[0009] In aspects, the present disclosure provides a method for reducing or ablating expression of a chimeric antigen receptor (CAR) in a producer cell compared to expression in a T lymphocyte, the method comprising: (a) preparing a transfer vector comprising a nucleotide sequence encoding the CAR and one or more tissue-specific transcriptional regulatory elements operably linked to the nucleotide sequence encoding the CAR, optionally in a reverse orientation relative to the transcriptional direction of the transfer vector, and (b)Leydig 775537Vyriad P-63-0063transducing or transfecting the transfer vector into the producer cell, (c) recovering an enveloped delivery vehicle (EDV) produced by the transduced or transfected producer cell, and (d) contacting the T lymphocyte with the EDV.

[0010] In aspects, the present disclosure provides a method for reducing or ablating expression of a chimeric antigen receptor (CAR) in an enveloped delivery vehicle (EDV) produced using lentivirus infection compared to expression in a T lymphocyte, the method comprising: (a) preparing a transfer vector comprising a nucleotide sequence encoding the CAR and one or more tissue-specific transcriptional regulatory elements operably linked to the nucleotide sequence encoding the CAR, optionally in a reverse orientation relative to the transcriptional direction of the transfer vector, and (b) transducing or transfecting the transfer vector into a producer cell, (c) recovering an EDV produced by the transduced or transfected producer cell, and (d) contacting the T lymphocyte cell with the EDV.

[0011] In aspects, the present disclosure provides a method of producing a virus-like particle (VLP) produced using retrovirus infection with ablated, not detectable, or low expression of a transgene on the viral envelope of the VLP, the method comprising transfecting or transducing a producer cell with a retroviral expression system as described herein.

[0012] In aspects, the present disclosure provides a method for reducing or ablating expression of a transgene in an enveloped delivery vehicle (EDV) produced using lentivirus infection compared to expression in a target cell, the method comprising: (a) preparing a transfer vector comprising a nucleotide sequence encoding the transgene and one or more tissue-specific transcriptional regulatory elements operably linked to the transgene, optionally in a reverse orientation relative to the transcriptional direction of the transfer vector, (b) transducing or transfecting the transfer vector into a producer cell, (c) recovering an EDV produced by the transduced or transfected producer cell, and (d) contacting the target cell with the EDV.

[0013] In aspects, the present disclosure provides a method for reducing or ablating expression of a transgene payload in a producer cell compared to expression in a target cell, the method comprising: (a) preparing a transfer vector comprising a nucleotide sequence encoding the transgene payload and one or more tissue-specific transcriptional regulatory elements operably linked to the transgene payload, optionally in a reverse orientation relative to the transcriptional direction of the transfer vector, and (b) transducing or transfecting the transfer vector into the producer cell, (c) recovering an enveloped delivery vehicle (EDV)Leydig 775537Vyriad P-63-0064produced by the transduced or transfected producer cell, and (d) contacting the target cell with the EDV.

[0014] In aspects, the present disclosure provides a producer cell comprising a retroviral expression system as described herein.

[0015] In aspects, the present disclosure provides an enveloped delivery vehicle (EDV) produced using retrovirus infection, comprising: (a) a viral envelope comprising a recombinant protein or protein complex able to mediate delivery of the vehicle to a target cell; and (b) a transfer vector comprising a nucleotide sequence encoding an expression cassette, optionally in reverse orientation relative to the transcriptional direction of the transfer vector, wherein the expression cassette comprises a transgene operably linked to one or more regulatory elements comprising a tissue-specific promoter or enhancer, wherein the enveloped delivery vehicle has ablated, low, or undetectable expression of the transgene on the viral envelope.

[0016] In aspects, the present disclosure provides a enveloped delivery vehicle (EDV) produced in a producer cell transduced or transfected with a retroviral expression system as described herein.

[0017] In aspects, the present disclosure provides a pharmaceutical composition comprising an EDV as described herein.

[0018] In aspects, the present disclosure provides a method of delivering a payload transgene to a target cell, the method comprising contacting the target cell with a pharmaceutical composition as described herein.

[0019] In aspects, the present disclosure provides a recombinant promoter comprising the nucleotide sequence of SEQ ID NO: 33. In aspects, the present disclosure provides a recombinant promoter comprising the nucleotide sequence of SEQ ID NO: 3. In aspects, the present disclosure provides a recombinant promoter comprising the nucleotide sequence of SEQ ID NO: 30. In aspects, the present disclosure provides a recombinant promoter comprising the nucleotide sequence of SEQ ID NO: 31. In aspects, the present disclosure provides a recombinant promoter comprising the nucleotide sequence of SEQ ID NO: 32. In aspects, the present disclosure provides a recombinant promoter comprising the nucleotide sequence of SEQ ID NO: 34.

[0020] In aspects, the present disclosure provides a recombinant promoter comprising a nucleotide sequence that has 90-99% sequence identity to SEQ ID NO: 33, wherein theLeydig 775537Vyriad P-63-0065promoter increases expression selectively in a target cell compared to expression in a producer cell.

[0021] In aspects, the present disclosure provides a recombinant promoter consisting of the nucleotide sequence of SEQ ID NO: 33. In aspects, the present disclosure provides a recombinant promoter consisting of the nucleotide sequence of SEQ ID NO: 3. In aspects, the present disclosure provides a recombinant promoter consisting of the nucleotide sequence of SEQ ID NO: 30. In aspects, the present disclosure provides a recombinant promoter consisting of the nucleotide sequence of SEQ ID NO: 31. In aspects, the present disclosure provides a recombinant promoter consisting of the nucleotide sequence of SEQ ID NO: 32. In aspects, the present disclosure provides a recombinant promoter consisting of the nucleotide sequence of SEQ ID NO: 34.

[0022] In aspects, the present disclosure provides a method of increasing viral titers for lentiviral particles (LVPs) production in a retroviral vector expression system comprising: (a) preparing a transfer vector comprising an expression cassette, optionally in reverse orientation relative to the transcriptional direction of the transfer vector, wherein the expression cassette comprises a transgene operably linked to one or more tissue-specific transcriptional regulator}' elements; (b) transducing or transfecting the transfer vector into a producer cell; and (c) recovering the LVPs produced by the transduced or transfected producer cell.

[0023] In aspects, the present disclosure provides a retroviral transfer vector comprising a nucleotide sequence encoding an expression cassette, wherein the expression cassette comprises a transgene and one or more regulatory elements operably linked to the transgene, wherein the one or more regulatory elements reduce or ablate expression in a producer cell compared to expression in a target cell.

[0024] In aspects, the present disclosure provides a retroviral transfer vector as described herein, wherein the retroviral transfer vector is of a lentiviral vector.

[0025] In aspects, the present disclosure provides a method of treating a hematological malignancy in a subject, the method comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition as described herein.

[0026] In aspects, the present disclosure provides a method of treating systemic lupus erythematosus (SLE) in a subject, the method comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition as described herein.Leydig 775537Vyriad P-63-0066

[0027] In aspects, the present disclosure provides a method of treating a B Cell Maturation Antigen (BCMA)-expressing tumor in a subject, the method comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition as described herein.

[0028] Additional aspects are as described herein.BRIEF DESCRIPTION OF THE DRAWINGS

[0029] Figure 1 shows a schematic of the BCMA-CAR construct used for the transfer vector. The BCMA sequence (SEQ ID NO: 1) was disclosed as PR001046 with SEQ ID NO: 25 in International Patent Publication WO 2024 / 09797, and SEQ ID NOS: 27, 29 and 31 correspond to the CDR1, CDR2 and CDR3 respectively of PR001046.

[0030] Figures 2A-2L show the annotated sequence of the BCMA-CAR construct in Figure 1.

[0031] Figure 2M is a schematic depicting the problem of premature CAR expression on the lentiviral vector (LV) in the producer cells during manufacture of lentiviral particles (LVPs) with transgene payloads of CAR and how the transfer vectors disclosed herein with an expression cassette of the CAR gene and its T cell specific promoters oriented in reverse to the transfer vector prevent premature CAR expression in the producer cells during LVP manufacture.

[0032] Figure 2N shows a western blot of LVPs analyzed for BCMA-CAR transgene expression using an anti-CD3^ antibody and anti-p24. The LVPs were normalized to 5x107LVP per well calculated based on p24.

[0033] Figure 3A is a schematic diagram of the hBCMA-CAR-T constructs and shows lentivirus doses.

[0034] Figure 3B shows the experimental study design to analyze ex vivo BCMA-CAR lentivirus transduction efficiency.

[0035] Figure 3C is a set of flow cytometry dot plots showing intensity of GFP vs. CD3 in human peripheral blood mononuclear cells (PBMCs) cultured in media containing interleukin-2 (IL-2) that were not infected with lentiviruses (Mock 1 and Mock 2) or infected with lentivirus pseudotyped with wild-lvpe Vesiculovirus Indiana G glycoprotein (VSIV-G-WT) (SEQ ID NO: 72) containing a BCMA3-CAR transgene, lentivirus pseudotyped with a 1:3 ratio of anti-CD3 scFv UCHT1 fused N terminal to VSIV-G with a deletion at residue K47 (UCHTl-VSIV-G-dK47) (SEQ ID NOS: 70, 71, and 13) to VSIV-G-dK47 (SEQ IDLeydig 775537Vyriad P-63-0067NO: 13) or lentivirus pseudotyped with an anti-PDl scFv fused N-terminal to VSIV-G with a deletion at residue K47 and UCHT1 -VSIV-G- (PD-UCHTl-VSIV-G-dK47) containing a BCMA1-CAR transgene.

[0036] Figure 3D is a set of flow cytometry dot plots showing intensity of GFP vs.BCMA in human peripheral blood mononuclear cells (PBMCs) cultured in media containing interleukin-2 (IL-2) that were not infected with lentiviruses (Mock 1 and Mock 2) or infected with lentivirus pseudotyped with VSIV-G- WT containing a BCMA3-CAR transgene, lentivirus pseudotyped with a 1:3 ratio of UCHTl-VSIV-G-dK47 to VSIV-G-dK47 or lentivirus pseudotyped with PD-UCHTl-VSIV-G-dK47 containing aBCMAl-CAR transgene.

[0037] Figure 4A shows the experimental study design for in vivo studies with generation of BCMA expressing CAR T cells in an OPM-2 tumor containing mouse model.

[0038] Figure 4B is a set of bioluminescence images ofNSG-MHC I / II DKO mice injected with OPM2-Fluc (human multiple myeloma) 2-3 hours post implantation.

[0039] Figure 4C shows the experimental study design for the mice organ processing analysis by flow cytometry.

[0040] Figure 5A is a set of flow cytometry dot plots showing intensity of forward scatter height (FSC-H) vs. side scatter height (SSC-H), FSC-H vs. forward scatter area (FSC-A), and FSC-H vs. LD780, a dye for cell viability.

[0041] Figure 5B is a set of flow cytometry dot plots showing intensity of mouse CD45 (mCD45) vs. human CD45 (hCD45), mCD45 vs. human CD3 (hCD3), and human CD8 (hCD8) vs. human CD4 (hCD4).

[0042] Figures 5C-5E are a set of flow cytometry dot plots showing intensity of GFP vs. CD3 in blood (FIG. 5C), bone marrow' (FIG. 5D), and spleen (FIG. 5E) cells of OPM2-Fluc injected mice 15 days after injection with saline or lentivirus pseudotyped with VSIV-G- WT containing BCMA3-CAR or lentivirus pseudotyped with a 1:3 ratio of UCHT1-VSIV-G-dK47 to VSIV-G-dK47 containing BCMA1-CAR or BCMA3-CAR.

[0043] Figures 6A-6C are a set of flow cytometry dot plots showing intensity’ of GFP vs. CD3 in blood (FIG. 6A), bone marrow? (FIG. 6B), and spleen (FIG. 6C) cells of OPM2-Fluc injected mice 29 days after injection with saline or lentivirus pseudotyped with VSIV-G- WT containing BCMA3-CAR or lentivirus pseudotyped with a 1:3 ratio of UCHT1-VSIV-G-dK47 to VSIV-G-dK47 containing BCMA1-CAR or BCMA3-CAR.Leydig 775537Vyriad P-63-0068

[0044] Figures 7A-7D are a set of flow cytometry dot plots showing intensity of GFP vs. TIM3, and exhaustion marker, GFP vs. CD39, and GFP vs. PD1 in human CD4+ cells, human TCR3 / y+ cells, and human CD8+ cells from the spleen of OPM2-Fluc injected mice 15 days after injection with saline (FIG. 7A), lentivirus pseudotyped with VSIV-G-WT containing BCMA3-CAR (FIG. 7B), or lentivirus pseudotyped with a 1:3 ratio of UCHT1-VSIV-G-dK47 to VSIV-G-dK47 containing BCMA3- CAR (FIG. 7C) or BCMA1- CAR (FIG. 7D).

[0045] Figure 7E is a bar graph showing the percentage of GFP+ / CD8+ and GFP+ / CD4+ cells of OPM2-Fluc injected mice 15 days after injection with saline or lentivirus pseudotyped with VSIV-G-WT containing BCMA3-CAR or lentivirus pseudotyped with a 1:3 ratio of UCHTl-VSIV-G-dK47 to VSIV-G-dK47 containing BCMA1-CAR or BCMA3-CAR.

[0046] Figures 8A-8C are a set of bioluminescence images of NSG-MHC I / II DKO mice 1 day before (-1) being injected with OPM2-Fluc and 7. 14. 21. 28. 35. 42, and 49 after OPM2-Fluc injection and injected with saline (Group 1), 1E6 TU lentivirus pseudotyped with VSIV-G-WT containing BCMA3-CAR (Group 2), 1E6 TU lentivirus pseudotyped with a 1:3 ratio of UCHTl-VSIV-G-dK47 to VSIV-G-dK47 containing BCMA3-CAR (Group 3), 1E6 TU (Group 4) or 5E5 TU (Group 5) lentivirus pseudotyped with a 1:3 ratio of UCHT1-VSIV-G-dK47 to VSIV-G-dK47 containing BCMA1-CAR. or 5E5 TU (Group 6), 1.5E5 TU (Group 7), or 1E4 TU (Group 8) lentivirus pseudotyped with PD-UCHTl-VSIV-G-dK47 containing BCMA1-CAR. Stars indicate mice that were excluded because no human PBMCs were found at any time point during analysis.

[0047] Figures 9A-9B are graphs showing the number of hCD45+ (FIG. 9A) or CD3+ and GFP+ (FIG. 9B) cells per pE of blood at 15, 22, 29, and 36 days post treatment with saline (Group 1), 1E6 TU lentivirus pseudotyped with VSIV-G-WT containing BCMA3-CAR (Group 2), 1E6 TU lentivirus pseudotyped with a 1:3 ratio of UCHTl-VSIV-G-dK47 to VSIV-G-dK47 containing BCMA3-CAR (Group 3), 1E6 TU (Group 4) or 5E5 TU (Group 5) lentivirus pseudotyped with a 1:3 ratio of UCHTl-VSIV-G-dK47 to VSIV-G-dK.47 containing BCMA1-CAR, or 5E5 TU (Group 6), 1.5E5 TU (Group 7), or 1E4 TU (Group 8) lentivirus pseudotyped with PD-UCHTl-VSIV-G-dK47 containing BCMA1-CAR.

[0048] Figure 10A shows the experimental study design for in vivo studies with generation of BCMA expressing CAR T cells in an OPM-2 tumor containing mouse modelLeydig 775537Vyriad P-63-0069that is rechallenged with OPM-2 tumor, using LVPs pseudotyped with 1:3 ratio of UCHT1-VSIV-G-dK47 to VSIV-G-dK47 and containing a BCMA-CAR transgene.

[0049] Figure 1 OB is a set of bioluminescence images of NSG-MHC I / II DKO mice injected with OPM2-Fluc before being rechallenged at 56 days after lentivirus injection, 2 hours after being rechallenged at 68 days after lentivirus injection, and 21 days after being rechallenged at day 89 after injection with the LVPs containing BCMA33, BCMA003, BCMA1, or BCMA2 constructs.

[0050] Figures 10C-10D are bar graphs showing the results of a human IFNg ELISPOT assay in splenocytes of mice after the end of the rechallenging study shown as SFU IFNg per 5E5 cells B in media and +OPM-2 for mice injected with saline, or LVPs containing BCMA33, BCMA03, BCMA1, or BCMA2 constructs.

[0051] Figure 10E is a set of micrographs showing the results of the IFNg ELISPOT assay in splenocytes of mice after the end of the rechallenging study shown as mock, +OPM2, and PMA+I treated cells of mice injected with saline, or LVPs containing BCMA33, BCMA03, BCMA1, or BCMA2 constructs.

[0052] Figure 11 A shows the experimental study design for in vivo studies with generation of BCMA expressing CAR T cells in an OPM-2 tumor containing mouse model that is rechallenged with OPM-2 tumor, using LVPs pseudotyped with 1:3 ratio of UCHT1-VSIV-G-dK47 to VSIV-G-dK47 and containing a BCMA1 CAR transgene.

[0053] Figure 1 IB is a set of bioluminescence images of NSG-MHC I / II DKO mice injected with OPM2-Fluc before being rechallenged, 2 hours after being rechallenged at 56 days after lentivirus injection, and 7 days after being rechallenged at day 63 after injection with the LVPs containing BCMA1 CAR constructs.

[0054] Figures 12A-12C are a set of flow cytometry dot plots showing intensity of GFP vs. CD3 in blood (FIG. 12A), bone marrow (FIG. 12B), and spleen (FIG. 12C) cells from OPM2-Fluc injected mice 59 days after injection with saline or lentivirus containing BCMA1-CAR and cells from OPM2-Fluc injected mice 3 days after rechallenge with OPM2 and 59 days after injection with lentivirus containing BCMA1-CAR.

[0055] Figures 13A-13C are a set of flow cytometry dot plots showing intensity of GFP vs. CD3 in blood (FIG. 13A), bone marrow (FIG. 13B), and spleen (FIG. 13C) cells from OPM2-Fluc injected mice 63 days after injection with saline or lentivirus containing BCMA 1 -CAR and cells from OPM2-Fluc injected mice 7 days after rechallenge with OPM2 and 63 days after injection with lentivirus containing BCMA1-CAR.Leydig 775537Vyriad P-63-00610

[0056] Figures 14A-14B are a set of flow cytometry- dot plots showing intensity of CD3 vs. CD39 in bone marrow cells from OPM2-Fluc injected mice that are injected with saline or lentivirus containing BCMA1-CAR at 15 days post lentivirus injection (FIG. 14A) and at 59 and 63 days post lentivirus injection (FIG. 14B) for mice that were not rechallenged or rechallenged with 0PM2 at day 56 post lentivirus injection.

[0057] Figures 14C-14D are a set of flow cytometry dot plots showing intensity of CD3 vs. PD1 in bone marrow cells from OPM2-Fluc injected mice that are injected with saline or lentivirus containing BCMA1-CAR at 15 days post lentivirus injection (FIG. 14C) and at 59 and 63 days post lentivirus injection (FIG. 14D) for mice that were not rechallenged or rechallenged with 0PM2 at day 56 post lentivirus injection.

[0058] Figures 15A is a drawing illustrating current challenges in manufacturing lentiviral particles (LVPs) for therapeutic applications. The figure show's the use of constitutive promoters in the forward orientation, which can cause premature expression of the CAR transgene in producer cells and on the surface of LVPs and the use of tissue-specific promoters in the forward orientation, which reduces but does not fully eliminate premature CAR expression due to read -through transcription from the 5' LTR promoter.

[0059] Figures 15B is a drawing illustrating the advantages of the retroviral vector expression system and retroviral transfer vector in manufacturing lentiviral particles (LVPs) disclosed herein. As shown, positioning the CAR transgene and its associated regulatory elements, such as a tissue-specific promoter, in the reverse orientation relative to the transcriptional direction of the transfer vector circumvents read-through transcription and prevents premature CAR expression.

[0060] Figure 16 is a schematic diagram illustrating the relative locations of the proximal and distal lymphocyte-specific protein tyrosine kinase (Lek) promoters of the human LCK gene, including their associated splicing signals, and showing the approximate 40 kb spacing between the distal promoter and the proximal promoter, as disclosed by Wildin et al.(“Developmental regulation of Lek gene expression in T lymphocytes,” J. Exp. Med., 173(2): 383-93 (1991)) and Wildin et al. (“Functional dissection of the murine Lek distal promoter,” J. Immunol., 155(3): 1286-95 (1995)). Figure 16 further illustrates the relative sequence positions of the distal promoter variants, showing how- the short version (approximately 0.8 kb in length) and the long version (approximately 1.5 kb in length) are positioned within the sequence.Leydig 775537Vyriad P-63-00611

[0061] Figure 17A is a schematic diagram of the plasmid design of the transfer vectors disclosed herein. The transfer vectors comprise a 5’ long terminal repeat (5’ LTR) of a U3, R, and U5 sequence, a HIV 'P packaging signal(SEQ ID NO: 24) and Rev response element (RRE) (SEQ ID NO: 25), an expression cassette, a woodchuck hepatitis virus posttranscriptional regulatory element (WPRE) (SEQ ID NO: 26), and a 3' long terminal repeat (3’ LTR) of a self-inactivating (SIN) U3 region (AU3) and R region (SEQ ID NO: 28). The expression cassettes of the CMVenh-Lck-CD19CAR-GFP and Lck-CD19CAR-GFP transfer vectors comprise an expression cassette in reverse orientation to the 5’LTR of the transfer vector with or without a murine cytomegalovirus (mCMV) enhancer (SEQ ID NO: 21), respectively, and a distal Lek (dLck) promoter, CD19-CAR (SEQ ID NO: 55) GFP transgene, and bovine growth hormone poly A sequence (bGH pA) (SEQ ID NO: 43).. The expression cassettes of the CMVenh-EFla-CD19CAR-GFP transfer vector comprises an expression cassette in forward orientation relative to the 5’LTR of the transfer vector with a murine cytomegalovirus (mCMV) enhancer, a eukaryotic translation elongation factor 1 alpha (EFla) promoter (SEQ ID NO: 29), CD19-CAR (SEQ ID NO: 55) GFP transgene, and bGH pA.

[0062] Figure 17B shows a set of flow' cytometry plots illustrating GFP mean fluorescence intensity (MFI) and GFP expression relative to CD3 in human PBMCs at 6 days post-transduction with lentiviral particles (LVPs). The LVPs were produced using the transfer vectors shown in Figure 17 A. The LVPs were pseudotyped with wild-type Vesiculovirus Indiana G glycoprotein recombinant G proteins (WT-VSIV-G).

[0063] Figure 17C shows a western blot of LVPs pseudotyped with WT VSIV-G and containing the expression cassettes of the transfer vectors of Figure 17A. The LVPs were analyzed for CD19-CAR transgene expression using an anti-CD3^ antibody and an anti-p24 antibody.

[0064] Figure 17D shows a western blot of cell lysates from peripheral blood mononuclear cells (PBMCs) transduced with either mock treatment or with LVPs pseudotyped with WT VSV-G and containing the expression cassettes of the transfer vectors of Figure 17A. The cell lysates were analyzed for CD19-CAR transgene expression using an anti-CD3^ antibody, with anti-GAPDH used as a control.

[0065] Figures 18A-18C are a set of schematic diagrams showing modifications made to the human distal Lek promoter. Figure 18A illustrates construct LCK 1 (SEQ ID NO: 3), in which a splice acceptor site is inserted between the 3' end of the intron and the first fiveLeydig 775537Vyriad P-63-00612nucleotides of the downstream coding exon and construct LCK 2 (SEQ ID NO: 30). in which the intron and its associated splicing sequences are removed, resulting in the non-coding exon being positioned directly upstream of the coding exon. Figure 18B illustrates construct LCK_3 (SEQ ID NO: 31), in which a TATA box and octamer motifs are inserted upstream of the endogenous putative promoter-responsive element (PRE), in addition to the intron removal described for LCK_2 that places the non-coding exon directly upstream of the coding exon and construct LCK 4 (SEQ ID NO: 32), in which the endogenous putative PRE and transcriptional initiation site located upstream of the non-coding exon of the Lek promoter are replaced with a TATA box, octamer motif, and a 5' consensus cap sequence, in addition to the intron removal described for LCK 2 that places the non-coding exon directly upstream of the coding exon. Figure 18C illustrates construct LCK1.3 (SEQ ID NO: 33), in which a TATA box and octamer motifs are inserted upstream of the endogenous putative PRE (as in LCK_2), together with insertion of a splice acceptor site between the 3' end of the intron and the first five nucleotides of the coding exon (as in Lckl) and construct LCK.1.4 (SEQ ID NO: 34), in which the endogenous putative PRE and transcriptional initiation site upstream of the non-coding exon are replaced with a TATA box, octamer motif, and a 5’ consensus cap sequence, together with insertion of a splice acceptor site between the 3' end of the intron and the first five nucleotides of the coding exon (as in LCK_1).

[0066] Figures 19A-19B show a schematic diagram of the plasmid design of the transfer vectors disclosed herein. The transfer vectors comprise a 5’ long terminal repeat (5’ LTR) of a U3, R, and U5 sequence, a HIV packaging signal and RRE, an expression cassette, a WPRE), and a 3‘ LTR of a SIN U3 region (AU3), R region, and U5 region. The expression cassettes of the R-LCK 1. R-LCK_2, R-LCK_3, R-LCK 1.3, R-LCK 4. and R-LCK 1.4 transfer vectors comprise an expression cassette in reverse orientation to the 5 ’LTR of the transfer vector with a mCMV enhancer, and a dLck promoter, LCK 1, LCK 2, LCK 3, LCK 1.3, LCK 4, and LCK 1.4, respectively, a BCMA-CAR GFP transgene, and bGH pA (SEQ ID NOS: 49-54). The expression cassettes of the F-EFla transfer vector comprises an expression cassette in forward orientation relative to the 5’LTR of the transfer vector with a mCMV enhancer, an EFla promoter, a BCMA-CAR GFP transgene, and bGH pA.

[0067] Figure 19C is a set of w estern blot images of lentiviral particles containing a BCMA-CAR transgene. The transgene was driven either by a CMV enhancer with an EFla promoter in forward orientation relative to the transfer vector, or by a CMV enhancer with various modified Lek promoters (LCK 1, LCK 2, LCK 3, LCK 1.3, LCK 4, LCK 1.4) asLeydig 775537Vyriad P-63-00613shown in the expression cassetes in Figures 19A-19B. The lentiviral particles were pseudotyped with WT-VSIV-G and analyzed by western blot using anti-VSIV-G, anti-p24, and anti-CD3^ antibodies.

[0068] Figure 20 is a set of flow cytometry plots showing the frequency of CD3+cells expressing recombinant BCMA in PBMCs, four days post-transduction. PBMCs were treated with either mock control or lentiviral particles containing a BCMA CAR transgene driven by The transgene was driven either by a CMV enhancer with an EFla promoter in forward orientation relative to the transfer vector, or by a CMV enhancer with various modified Lek promoters (LCK_1, LCK_2, LCK_3, LCK_1.3, LCK_4, LCK_1.4) as shown in the expression cassettes in Figures 19A-19B. The lentiviral particles were pseudotyped with WT-VSIV-G.

[0069] Figure 21 is a set of western blot images of cell lysates from Jurkat cells and PBMCs collected four days post-transduction. Cells were treated with either mock control or LVPs containing a BCMA-CAR transgene driven by a CMV enhancer with an EFla promoter in forward orientation relative to the transfer vector, or by a CMV enhancer with various modified Lek promoters (LCK 1, LCK 2, LCK 3, LCK 1.3, LCK 4, or LCK 1.4), as show n in the expression cassetes in Figures 19A-19B. The lentiviral particles were pseudotyped with WT-VSIV-G. Western blot analysis was performed using an anti-CD3q antibody, with anti-GAPDH antibody used as a control. Image #2 is an overexposed blot image showing CD3 -CAR.

[0070] Figure 22A is a set of bar graphs showing the percentage of Jurkat, HEK293, 0PM2, A549, and NALM6 cells expressing recombinant BCMA at three or seven days posttransduction. Cells were treated with either mock control or LVPs containing a BCMA-CAR transgene driven by a CMV enhancer with an EFla promoter in forward orientation relative to the transfer vector, or a BCMA CAR transgene driven by a CMV enhancer with modified Lek promoters (LCK 1, LCK 1.3, LCK 1.4, LCK 2, LCK 3, or LCK 4) in reverse orientation relative to the transfer vector (SEQ ID NOS: 49-54), as shown in the expression cassetes in Figures 19A-19B. The LVPs were pseudotyped with WT-VSIV-G.

[0071] Figure 22B is a set of How cytometry dot plots showing expression of recombinant BCMA protein and CD3+ in human PBMCS treated w ith either mock (untreated) control or LVPs, pseudotyped with WT-VSIV-G, containing a BCMA-CAR trans gene driven by either a CMV enhancer with an EFla promoter in forward orientationLeydig 775537Vyriad P-63-00614relative to the transfer vector or by a CMV enhancer with a modified Lek 1 promoter or a modified Lck l.3 or Lek 1.4 promoter in reverse orientation relative to the transfer vector.

[0072] Figure 22C shows the results of a cell killing assay with effector (E) PBMCs transduced with LVPs with Lckl, Lckl.3, Lckl.4. or EFla and co-cultured with OPM2 multiple myeloma. K562-BCMA+, or K562-CD19+ target (T) cells at the indicated E: T ratios (ranging from 0 to 4) and the viability of target cells (%) was evaluated after co-culture by luciferase assay.

[0073] Figures 23A-23B are a set of flow cytometry dot plots showing expression of recombinant BCMA protein in Jurkat and OPM2 cells three (FIG. 23 A) and four (FIG. 24A) days post-transduction using spinoculation. In Figure 23A, the Jurkat and OPM2 cells were treated with either mock (untreated) control or LVPs, pseudotyped with WT-VSIV-G, containing a BCMA-CAR transgene driven by either a CMV enhancer with an EFla promoter in forward orientation relative to the transfer vector or by a CMV enhancer with a modified Lek 1.3 promoter in reverse orientation relative to the transfer vector and the cells were examined three days post-transduction. In Figure 23B, the Jurkat and OPM2 cells were treated with either mock control or lentiviral particles, pseudotyped with mixed 1:3 ratio of a recombinant fusion protein of the anti-CD3 scFv UCHT1 fused N terminal to VSIV-G with a deletion at residue K47 (UCHT1-VSIV-G-AK47) and VSIV-G-AK47, containing a BCMA-CAR trans gene driven by a CMV enhancer with an EFla promoter in forward orientation relative to the transfer vector or by a CMV enhancer with a modified Lck_1.3 promoter in reverse orientation relative to the transfer vector and cells were examined four days posttransduction.

[0074] Figure 23C is a set of fluorescent images showing GFP fluorescence in HEK-293T cells transfected with a construct containing a BCMA-CAR and GFP transgene driven by a CMV enhancer with an EFla promoter in forward orientation relative to the transfer vector (SEQ ID NO: 65) or by a CMV enhancer with a modified Lck_1.3 promoter in either forward (SEQ ID NO: 64) or reverse (SEQ ID NO: 57) orientation relative to the transfer vector.

[0075] Figure 23D is a western blot image of HEK-293T packaging cell lysate after transfection with a construct containing a BCMA-CAR and GFP transgene driven by a CMV enhancer with an EFla promoter in forward orientation relative to the transfer vector or by a CMV enhancer with a modified Lck_1.3 promoter in either forward or reverse orientation relative to the transfer vector.Leydig 775537Vyriad P-63-00615

[0076] Figure 23E is a set of western blot images of lentiviral particles containing a BCMA-CAR transgene. The transgene was driven either by an EFla promoter in forward orientation relative to the transfer vector, or by a modified Lek promoter Lck l or Lck_1.3 in reverse orientation to the transfer vector. The lentiviral particles were pseudotyped with a 1:3 ratio of UCHTl-VSIV-G-dK47 to VSIV-G-dK47 and analyzed by western blot using anti-VSIV-G, anti-p24, and anti-CD3 antibodies.

[0077] Figure 24A shows a schematic diagram of the plasmid design of expression cassettes disclosed herein. The expression cassettes drive expression of a Luciferase-P2A-GFP transgene driven by a CMV enhancer with EFl promoter (CMVenh-EFla,) a CMV enhancer with Lck_3 promoter (CMVenh-Lck3), a Lck_3 promoter alone (Lck3), or a CD2 enhancer with an Lck_3 promoter (CD2enh-Lck3) positioned in forward orientation relative to the transfer vector.

[0078] Figures 24B-24C are a set of bar graphs showing the percentage of luciferase activity in Jurkat, HEK-293T, OPM2, THP1 and A549 cells at 4 days post transduction (FIG.24B) or 10 days post transduction (FIG. 24C). Cells were transduced with lentiviral particles containing the expression cassettes shown in Figure 24A and the lentiviral particles were pseudotyped with WT-VSIV-G. For comparison, luciferase activity from the CMV enhancer with Lck_3 promoter was normalized to 100% and data were additionally normalized based on vector copy number (VCN) as determined by digital PCR (dPCR).

[0079] Figure 25 is a set of bar graphs showing the percentage of luciferase activity in PBMCs at 10 days post-transduction and PBMC derived macrophages at 5 days posttransduction. Cells were transduced with LVPs, pseudotyped with VSV-G WT, containing the expression cassettes shown in Figure 24A.

[0080] Figure 26 is a set of flow cytometry dot plots showing the expression of CD3 and GFP in PBMCs transduced with LVPs, pseudo typed with VSV-G WT, containing the expression cassettes shown in Figure 24A or Mock (untreated) control. Cells were examined 9 days post transduction.

[0081] Figures 27A-27B are illustrations comparing undesired (FIG. 27 A) and desired (FIG. 27B) outcomes of LVP transduction. In the undesired scenario, LVPs pseudotyped with VSIV-G-WT or displaying CAR transgene on their surface during packaging can transduce tumor cells that express either LDL-R or the cognate cancer antigen. In the desired scenario, LVPs with ablated surface CAR transgene expression and / or pseudotyped with VSIV-G-AK47, which is blinded to LDL-R and retargeted to CD3 via an UCHT1 single-chain variableLeydig 775537Vyriad P-63-00616fragment (scFv). do not infect tumor cells lacking CD3 but instead selectively transduce T cells upon CD3 engagement.

[0082] Figure 28A is a schematic diagram of the plasmid design of a transfer vector disclosed herein. The transfer vectors comprise a chimeric 5’ long terminal repeat (5’ LTR) of a of a virus enhancer and promoter, a R, and a U5 sequence, a HIV packaging signal and RRE, an expression cassette in reversion orientation to the transfer vector, a WPRE, and a 3’ LTR of a SIN U3 region (AU3), R region, and U5 region followed by a SV40 poly A tail. The expression cassette comprises cell specific or tissue specific transcriptional regulatory elements (promoter and enhancer), a CAR transgene, and a bGH pA.

[0083] Figures 28B-28C show schematic diagrams of the plasmid design of T cell specific transfer vectors disclosed herein. The transfer vectors comprise a chimeric 5’ long terminal repeat (5’ LTR) of a CMV enhancer and promoter, a R, and a U5 sequence, a HIV 'P packaging signal and RRE, an expression cassette in reversion orientation to the transfer vector, a WPRE. and a 3' LTR of a SIN U3 region (AU3), R region, and U5 region, followed by a SV40 poly A tail. The expression cassettes comprise a T cell specific enhancer CD2 and a dLck promoter, LCK 1, LCK 2, LCK 3, LCK 4, LCK 1.3, and LCK 1.4, respectively, a BCMA-CAR transgene, and a bGH pA.

[0084] Figure 28D shows schematic diagrams of the transfer vector transduced into a producer cell and a schematic diagram of the provirus in the target cell after reverse transcription. The transfer vector comprises a chimeric 5’ long terminal repeat (5’ LTR) of an enhancer and promoter, a R, and a U5 sequence, a HIV packaging signal and RRE, an expression cassette in reversion orientation to the transfer vector, a WPRE, and a 3’ LTR of a SIN U3 region (AU3), R region, and U5 region, followed by a SV40 poly A tail. The expression cassette of the transfer vector comprises an enhancer and a Lek promoter, a BCMA-CAR transgene, and a bGH pA. The provirus comprises a 5’ LTR of a SIN U3 region (AU3), R region, and U5 region, a HIV *P packaging signal and RRE, an expression cassette in reversion orientation to the transfer vector, a WPRE, and a 3’ LTR of a SIN U3 region (AU3), R region, and U5 region, followed by a SV40 poly A tail. The expression cassette of the provirus comprises an enhancer and a Lek promoter, a BCMA-CAR transgene, and a bGH pA.

[0085] Figure 29 shows schematic diagrams of transfer vectors comprising a chimeric 5' long terminal repeat (5’ LTR) of a CMV enhancer and promoter or a RSV enhancer and promoter, a R, and a U5 sequence, a HIV packaging signal and RRE, an expressionLeydig 775537Vyriad P-63-00617cassette in reversion orientation to the transfer vector, a WPRE. and a 3’ LTR of a SIN U3 region (AU3), R region, and U5 region, followed by a SV40 poly A tail. The expression cassettes comprise a CD2 enhancer or a CMV enhancer and a dLck promoter, a BCMA-CAR transgene, and a bGH pA.

[0086] Figure 30A shows the experimental study design for in vivo studies with generation of BCMA expressing CAR T cells in an OPM-2 tumor containing mouse model.

[0087] Figure 30B is a set of bioluminescence images of OPM2-Fluc injected NSG-MHC I / II DKO mice 1 day before (-1) being injected with saline or LVPs pseudotyped with a 1:3 ratio of UCHTl-VSIV-G-dK47 to VSIV-G-dK47 and containing the BCMA-CAR trans gene driven either by an EFla promoter in forward orientation relative to the transfer vector, or by a modified Lek promoter Lck_l or Lck_l.3 in reverse orientation to the transfer vector and 7, 14, 21, 28, 35, 42, 49, 64, and 77 days after injection with saline or LVPs. Stars indicate mice that were excluded because no human PBMCs were found at any time point during analysis.

[0088] Figure 31 illustrates several transfer vector modifications designed to optimize transgene expression efficiency in target cells. These include modifications in the promoter-proximal intron region, transgene promoter region, and transgene enhancer region. In the promoter-proximal intron region, multiple endogenous and chimeric introns are being tested. In the promoter region, insertion of various regulatory elements such as TATA boxes and PRE elements is being examined. In the enhancer region, multiple T cell-specific enhancers are also under evaluation.

[0089] Figure 32 shows the experimental study design for in vivo tumor rechallenge studies with generation of BCMA expressing CAR T cells in human PBMC-engrafted OPM2 tumor bearing NSG mice.

[0090] Figures 33A-33B are a set of bioluminescence images of human PBMC-engrafted OPM2 tumor bearing NSG mice 1 day before (-1) being injected with saline or suboptimal doses of LVPs pseudotyped with a 1:3 ratio of UCHTl-VSIV-G-dK47 to VSIV-G-dK47 and containing the BCMA-CAR transgene driven either by a modified Lek promoter Lck l or Lck_1.3 with a CMV or CD2 enhancer (SEQ ID NOS: 47-49 and 54) and 7, 21, 28, 35, 43, 50, and 56 days after injection with saline or LVPs. Stars indicate mice that were excluded because no human PBMCs were found at any time point during analy sis.

[0091] Figure 34 is a set of bioluminescence images human PBMC-engrafted OPM2 tumor bearing NSG mice injected with suboptimal doses of LVPs pseudotyped with a 1:3 ratio of UCHTl-VSIV-G-dK47 to VSIV-G-dK47 and containing the BCMA-CAR transgeneLeydig 775537Vyriad P-63-00618driven either by a modified Lek promoter Lck l or Lck_1.3 with a CMV enhancer 1 day before (21) being rechallenged with 2e6 OPM-2 and 1 day before (28) being rechallenged a second time with OPM-2, and at days 35, 43, 50, 56, and 72 after injection with LVPs.

[0092] Figures 35A-35C are a set of graphs showing the body weight as a percentage of day 0 body weight in mice from Groups 1-6 of Table 10 as labeled.

[0093] Figures 36A-36B are a set of flow cytometry dot plots showing expression of recombinant BCMA vs. CD3 in peripheral blood collected from mice at day 14 from groups 1-6 of Table 10 as labeled.

[0094] Figure 37 shows the experimental study design for in vivo studies testing the efficacy of CMV-lckl.3 BCMA comprising CD3 retargeted LVP pseudotyped by dK47 VSV-G in an OPM-2 tumor containing mouse model.

[0095] Figure 38A is a set of graphs showing the number of cells per pL of blood collected from human PBMC-engrafted OPM2 tumor bearing NSG mice that are positive for hCD45, mCD45. or hCD3 at 0, 6, 12, 24, 26, and 48 hours since treatment with saline or LVP.

[0096] Figure 38B is a flow cytometry dot plot showing gating for expression of CD69 and CD25 on CD3+ cells in human PBMC-engrafted OPM2 tumor bearing NSG mice.

[0097] Figure 38C is a set of graphs showing the percentage of CD3+ and CD69+ cells that are CD25- (left graph) or CD25+ (right graph) and the percentage of CD3+ and CD25+ cells that are CD69- (middle graph) in human PBMC-engrafted OPM2 tumor bearing NSG mice at 0, 6, 12, 24, 26, and 48 hours since treatment with saline or LVP.

[0098] Figures 39A-39C are a set of bioluminescence images of human PBMC-engrafted OPM2 tumor bearing NSG mice from Cohort A at day 0, 8. 14. 21. 29, 35, and 50 after being injected with saline or LVPs as labeled.

[0099] Figure 40 is a set of graphs showing the total flux as measured in photons per second at days 0, 10, 20, 30, 40, 50, and 60 post treatment saline or LVPs as labeled.

[0100] Figures 41 A-41B are a set of graphs showing the percentage of BCMA CAR+ cells in the hCD3+ cells, in the hCD8+ cells, and in the hCD4+ cells of human PBMC-engrafted OPM2 tumor bearing NSG mice at day 14, 21, and 60 post injection with saline or LVPs as labeled. The differences betw een the percentages of BCMA CAR+ cells in the hCD8+ cells and hCD4+ cell is also shown (FIG. 4 IB).Leydig 775537Vyriad P-63-00619

[0101] Figures 42A-42B are a set of representative flow cytometry dot plots showing the gating of BCMA CAR+ cells on CD45+ population in the blood of human PBMC-engrafted 0PM2 tumor bearing NSG mice at day 15 post injection with saline or LVPs as labeled.

[0102] Figures 43A-43B are a set of representative flow cytometry dot plots showing the gating of BCMA CAR+ cells on CD45+ population in the spleen of human PBMC-engrafted 0PM2 tumor bearing NSG mice at day 15 post injection with saline or LVPs as labeled.

[0103] Figures 44A-44B are a set of representative flow cytometry dot plots showing the gating of BCMA CAR+ cells on CD45+ population in the bone marrow' of human PBMC-engrafted 0PM2 tumor bearing NSG mice at day 15 post injection with saline or LVPs as labeled.

[0104] Figures 45A-45B are a set of representative flow' cytometry dot plots showing the gating of BCMA CAR+ cells on CD45+ population in the liver of human PBMC-engrafted 0PM2 tumor bearing NSG mice at day 15 post injection with saline or LVPs as labeled.

[0105] Figures 46A-46C are a set of graphs showing the BCMA CAR+ cells as a percentage of CD3+ T cells (FIG. 46 A), CD8+ T cells (FIG. 46B), and CD4+ T cells (FIG.46C) in the blood, spleen, bone marrow', and liver of human PBMC-engrafted 0PM2 tumor bearing NSG mice at days 15, 22, 36, and 60 post injection with saline or LVPs as labeled.

[0106] Figures 46D is a bar graph showing a comparison of the peak percentage of BCMA CAR+ cells within the CD8+ versus CD4+ T cell compartments in the blood, spleen, bone marrow; and liver of human PBMC-engrafted OPM2 tumor bearing NSG mice on Day 15 post inj ection with saline or LVPs as labeled.

[0107] Figure 47 is a representative flow cytometry dot plot showing the gating of BCMA CAR+ cells on Singlet / Live-Dead / hCD45+ / hCD3+ population in the bone marrow of human PBMC-engrafted OPM2 tumor bearing NSG mice at day 15 post injection with LVPs as labeled and a graph showing the percentage of BCMA CAR T cells in the Singlet / Live-Dead / hCD45+ / hCD3+ population of blood, spleen, bone marrow, and liver of human PBMC-engrafted OPM2 tumor bearing NSG mice at day 15.

[0108] Figure 48 is a set of graphs showing tissue lentivirus copy number analysis of spleen, liver, and bone marrow' of human PBMC-engrafted OPM2 tumor bearing NSG mice at days 15, 22, and 36 post injection with saline or LVPs, as measure by copies per diploid genomic DNA (top row graphs) or as copies per pg of genomic DNA (bottom row graphs).

[0109] Figure 49A is a set of flow cytometry dot plots showing CD 14+ versus CD3+ cells of PBMCs gated for CD45+ PBMCs.Leydig 775537Vyriad P-63-00620

[0110] Figure 49B is a set of bar graphs quantifying the levels of monocytes (CD14+). B cells (CD19+) and T cells (CD3+) as percentage of CD45+ PBMCs from each donor.

[0111] Figure 49C is a set of bar graphs quantifying the densify of CD3 and costimulatory molecules CD28 and CD2 on the surface of T cells from each donor based on geometric mean intensify (MFI) for each marker as labeled.

[0112] Figures 49D-49E are a set of flow cytometry dot plots showing surface expression of CCR7 and CD45RA in CD4+ (FIG. 49D) and CD8+ (FIG. 49E) PBMCs from each donor as labeled.

[0113] Figure 49F is a set of bar graphs showing the percent of CCR7+CD45RA+cells defined as naive T cells (Naive); CCR7+CD45RA cells defined as central memory (CM); CCR7 CD45R A cells defined as effector memory (EM); and CCR7 CD45RA+cells defined as terminally differentiated effector memory T cells (TEMRA) for each donor and the percent of CD4+ and CD8+ cells for each donor.

[0114] Figures 49G-49I are a set of bar graphs showing the levels of the cytokines IFNy. TNFa, GM-CSF, IL-6 and IL-2 in whole human blood samples 6 hours after mock treatment or treatment with VV169 at a dose of 5E8 VLPs or 2E9 VLPs, or with aCD3 / CD28 human T-activator beads (aCD3 / 28 beads).

[0115] Figures 49J-49K are a set of flow cytometry dot plots showing BCMA CAR expression vs. CD3 expression of PBMCs from each donor 8 days after mock treatment or treatment with VV 169 at a dose of 5E8 VLPs or 2E9 VLPs, or with aCD3 / 28 beads.

[0116] Figure 49L is a bar graph quantifying the percentage of CD3+cells positive for BCMA-CAR for each donor after mock treatment or treatment with VV169 at a dose of 5E8 VLPs or 2E9 VLPs, or with aCD3 / 28 beads as labeled.

[0117] Figure 49M is a set of flow cytometry histograms of CD25 expression levels in CD3+gated cells for each donor 8 days after mock treatment or treatment with VV169 at a dose of 5E8 VLPs or 2E9 VLPs, or with aCD3 / 28 beads as labeled.

[0118] Figure 49N is a set of bar graphs the percentages of CD25+in CD3+cells for each donor 8 days after mock treatment or treatment with VV169 at a dose of 5E8 VLPs or 2E9 VLPs, or with aCD3 / 28 beads as labeled.

[0119] Figures 49O-49P are a set of bar graphs showing the percentage of CD3+cells positive for CD4 (FIG. 490) and CD8 (FIG. 49P) and the percentage of CD4+ cells or CD8+ cells positive BCMA-CAR for each donor after mock treatment or treatment with VV169 at a dose of 5E8 VLPs or 2E9 VLPs, or with aCD3 / 28 beads as labeled.Leydig 775537Vyriad P-63-00621

[0120] Figure 50 is a schematic diagrams of transfer vectors comprising a chimeric 5’ long terminal repeat (5’ LTR) of a CMV enhancer and promoter or a RSV enhancer and promoter, a R, and a U5 sequence, a HIV 'P packaging signal, an expression cassette in reversion orientation to the transfer vector, a WPRE, and a 3’ LTR of a R region and U5 region, followed by a SV40 poly A tail. The expression cassettes comprise a CD2 enhancer or a CMV enhancer and a dLck 1.3 promoter, a BCMA-CAR transgene, and a bGH pA tail.

[0121] Figures 50B-50C are a set of flow cytometry dot plots showing BCMA-CAR levels vs. CD3 levels in CD45+ gated cells from donor 1 (FIG. 50B) and donor 2 (FIG. 50C).

[0122] Figures 50D-50E show the percent of CD3+cells positive for BCMA-CAR and fluorescence geometric mean (MFI) of the CAR+cells for PBMCs of each donor after mock treatment or treatment with CD2en-LCkl.3 or mCMVe-Lckl.3 containing viruses cultured with IL-2 (FIG. 50D) and without IL-2 (FIG. 50E).

[0123] Figure 50F is a set of bar graphs showing the vector integration copy number (VCN) for PBMCs of each donor after mock treatment or treatment with CD2en-LCkl.3 or mCMVe-Lckl.3 containing viruses cultured with IL-2 and without IL-2 (FIG. 50F).

[0124] Figure 50G is a set of bar graphs showing T cell activation as measured by the percent of CD3+ T cells expressing CD25 for PBMCs of each donor after mock treatment or treatment with CD2en-LCkl.3 or mCMVe-Lckl.3 containing viruses cultured with IL-2 and without IL-2 (FIG. 50G).

[0125] Figures 50H-50I are a set of bar graphs showing the levels of the cytokines IFNy, TNFa, and IL-6 in PBMCs of each donor after mock treatment or treatment with CD2en-LCkl.3 or mCMVe-Lckl.3 containing viruses cultured with IL-2 (FIG. 50H) and without IL-2 (FIG. 50I).

[0126] Figures 51 A-51 B are a set of flow cytometry dot plots showing CD69 expression vs. CD25 expression in CD3+ CD45+ gated PBMCs at 24, 48, and 72 hours after mock treatment or treatment with aCD3 / 28 beads, IL-7 and IL- 15, or VV169 as labeled.

[0127] Figures 51C-51E are a set of bar graphs showing the percent of CD69+cells and the percentage of CD25+cells within the CD3+T cell population, pre-gated on viable, CD45+and CD3+population after mock treatment or treatment with aCD3 / 28 beads, IL-7 and IL-15, or VV169 as labeled for donor 1 (FIG. 51C), donor 2 (FIG. 51D), and donor 3 (FIG.51E) as labeled.Leydig 775537Vyriad P-63-00622

[0128] Figure 51F is a set of flow cytometry- dot plots showing BCM A CAR expression on CD3+ T cells that were pre-gated on viable, CD45+ cells for each donor on day 7 after mock treatment or treatment with VV169 as labeled.

[0129] Figure 51G is a bar graph showing the percent of BCMA CAR+ cells within the CD3+ T cell population for each donor on day 7 after mock treatment or treatment with VV169 as labeled.

[0100] Figures 51H-51I are a set of bar graphs showing the results of a cell killing assay with effector (E) PBMCs transduced w ith VV169 or treated with aCD3 / 28 beads and cocultured with OPM2-Fluc multiple myeloma target (T) cells at the indicated E: T ratios (ranging from 0 to 8) and the viability of target cells (%) was evaluated after co-culture by luciferase assay.

[0130] Figure 52A is a set of bar graphs show ing the percent of BCMA CAR+ Jurkat WT, Jurkat-TCR-KO, Nalm6, and OPM2 cells untreated and after treatment with VSIV-G-WT or VV 169 as labeled.

[0131] Figure 52B is a set of bar graphs showing the vector integration copy number (VCN) for Jurkat WT, Jurkat-TCR-KO, Nalm6, and OPM2 cells that underw ent digital PCR (dPCR) at 7 days after no treatment or treatment with VSIV-G-WT or VV169 as labeled.

[0132] Figures 52C-52D are a set of line graphs showing the viable cell counts performed over the duration of the study for cells from each donor from the untransduced, control vector, and VV169 treatment groups in condition A.

[0133] Figures 52E-52F are a set of flow- cytometry- dot plots showing viable cells and BCMA CAR expression for cells from each donor from the untransduced, control vector, and VV169 treatment groups at days 7, 14, 29, and 43 after treatment in condition A.

[0134] Figures 52G-52H are a set of line graphs showing the viable cell counts performed over the duration of the study for cells from each donor from the untransduced, control vector, and VV169 treatment groups in condition B.

[0135] Figures 52I-52J are a set of flow cytometry dot plots showing viable cells and BCMA CAR expression for cells from each donor from the untransduced, control vector, and VV169 treatment groups at days 7, 14, and 29 after treatment in condition B.

[0136] Figures 53A-53B are a set of bar graphs showing the levels of the cytokines IFNy, TNFa, GM-CSF. IL- 10, IL-6 and IL-2 in peripheral blood samples of human PBMC-engrafted NSG mice beanng OPM2 tumors collected at 6 and 48 hours post injection of either a saline vehicle (control) or the VV169 vector at a dose of 3E9 LVPs.Leydig 775537Vyriad P-63-00623

[0137] Figures 53C-53D are a set of bar graphs showing the levels of the cytokines IFNy, TNFa, GM-CSF, IL-10, IL-6 and IL-2 in peripheral blood samples of human PBMC-engrafted NSG mice bearing 0PM2 tumors collected at days 15, 22, and 60 post injection of either a saline vehicle (control) or the VV169 vector at a dose of 3E9 LVPs.

[0138] Figures 54A-54B are a set of bar graphs showing T cell activation as quantified as shown by the percentage of CD69+ and CD25+ cells within the human CD3+ T cell population for human CD34+ engrafted NSG mice at 6, 24, and 48 hours post treatment with saline or 3E9 LVPs of VV169 for the male cohort (FIG. 54A) or treatment with saline or 1E8, 1E9, or 3E9 LVPs of VV169 for the female cohort (FIG. 54B).

[0139] Figures 54C-54D are a set of bar graphs showing the frequency of human CD45+ cells, mouse CD45+ cells, and human CD3+ T cells in peripheral blood of human CD34+ engrafted NSG mice at 6, 24, and 48 hours post treatment with saline or 3E9 LVPs of VV169 for the male cohort (FIG. 54C) or treatment with saline or 1E8, 1E9, or 3E9 LVPs of VV169 for the female cohort (FIG. 54D).

[0140] Figure 54E is a set of bar graphs showing the percent of BCMA C AR+ cells within the CD3+ T cell population of human CD34+ engrafted NSG mice at 4, 16, and 43 days post treatment with saline or 3E9 LVPs of VV169 for the male cohort or treatment with saline or 1E8, 1E9. or 3E9 LVPs of VV169 for the female cohort.

[0141] Figures 54F-54I are a set of bar graphs showing the levels of the cytokines IFNy, TNFa, GM-CSF, IL-10, IL-6 and IL-2 in peripheral blood samples of human CD34+ engrafted NSG mice at 6 and 48 hours post treatment with saline or 3E9 LVPs of VV169 for the male cohort (FIG. 54F and 54H) or treatment with saline or 1E8, 1E9, or 3E9 LVPs of VV169 for the female cohort (FIG. 54G and 541).

[0142] Figures 54J-54M are a set of bar graphs showing the levels of the cytokines IFNy, TNFa, GM-CSF, IL-10, IL-6 and IL-2 in peripheral blood samples of human CD34+ engrafted NSG mice at 16 days post treatment with saline or 3E9 LVPs of VV169 for the male cohort (FIG. 54J and 54L) or treatment with saline or 1E8, 1E9. or 3E9 LVPs of VV169 for the female cohort (FIG. 54K and 54M).DETAILED DESCRIPTION

[0143] In aspects, the present disclosure provides a retroviral vector expression system comprising a transfer vector, wherein the transfer vector comprises a nucleotide sequenceLeydig 775537Vyriad P-63-00624encoding an expression cassete, wherein the expression cassete comprises a transgene and one or more regulatory elements operably linked to the transgene, wherein the one or more regulatory elements reduce or ablate expression in a producer cell compared to expression in a target cell. In aspects, the nucleotide sequence encoding an expression cassete is in reverse orientation relative to the transcriptional direction of the transfer vector, wherein the reverse orientation reduces or ablates expression of the expression cassete when the transfer vector is in a producer cell compared to when the transfer vector is in a target cell. In aspects, the one or more regulatory elements are in reverse orientation relative to the transcriptional direction of the transfer vector, wherein the reverse orientation reduces or ablates expression of the expression cassete when the transfer vector is in a producer cell compared to when the transfer vector is in a target cell. Any combination of forward and reverse orientation of the expression cassete and the one or more regulatory elements are contemplated in the present disclosure. For example, the expression cassete itself as a whole can be in a reverse orientation relative to the transcriptional direction of the transfer vector while the one or more regulatory elements are in a forward orientation, or the one or more regulatory elements can be in a reverse orientation relative to the transcriptional direction of the transfer vector while the expression cassete is in a forward orientation, or both the expression cassete and the one or more regulatory elements can be in a reverse orientation relative to the transcriptional direction of the transfer vector, or the expression cassete and at least one of the one or more regulatory elements can be in a reverse orientation relative to the transcriptional direction of the transfer vector while at least one of the one or more regulatory7elements is in a forward orientation. In aspects, all features are in a forward orientation.

[0144] In aspects, the disclosure provides an expression cassete described herein comprising a nucleotide sequence encoding a tag for western detection or purification. In aspects, the tag is a tag for western detection. In aspects, the tag is a tag for purification. In aspects the tag is a FLAG tag, GFP, or others. In aspects, the nucleotide sequence encoding tag is located at the 3' terminus of the transgene, comprising a nucleotide sequence encoding a linker between the tag and the transgene. In aspects, the tag comprises a cleavage site.

[0145] In aspects, the one or more regulatory elements comprise one or more regulatory elements that are specific to the target cell. In aspects, the one or more specific regulatory elements comprise a promoter, an enhancer, a silencer, a poly A tail, or any combination thereof. In aspects, the one or more regulatory elements comprise a promoter, an enhancer, a silencer, an insulator, a chromatin-modulating element, or any combination thereof. InLeydig 775537Vyriad P-63-00625aspects, the one or more regulatory elements confer cell-type specificity, signal responsiveness, or combinatorial transcriptional control. In aspects, the one or more regulatory elements comprise a cHS4 insulator, ubiquitous chromatin opening element, MND promoter, SFFV promoter, NR4A-reponsive promoter, miRNA targeting and detargeting sequence, CD6 gene regulatory element, PGK promoter, or an element of a NF-kB signaling pathway, an AP-1 signaling pathway, or a NF AT signaling pathway.

[0146] In aspects, the transgene encodes a chimeric antigen receptor (CAR). In aspects, the transfer vector comprises one or more of the transgene, wherein the one or more transgenes encode two or more CARs. As used herein, "‘chimeric antigen receptor” or “CAR” refers to a protein engineered to equip immune cells, such as T cells, with the ability to recognize and / or bind specific antigens. In aspects, the CAR comprises an antigen-binding domain, such as an extracellular antigen-binding domain, a transmembrane domain, and a signaling domain, such as a T cell signaling domain. In aspects, the CAR comprises a spacer or hinge region between the antigen-binding domain and the transmembrane domain. In certain aspects, the CAR further comprises a selection marker, such as an antibiotic resistance gene or fluorescent protein.

[0147] In aspects, the target cell is a T lymphocyte. In aspects, the one or more regulatory7elements comprise a T cell-specific promoter. In aspects, the one or more regulatory elements comprise a T cell-specific enhancer. In aspects, the one or more regulatory elements comprise (a) a cytomegalovirus (CMV) enhancer, transcriptional element of RSV gene, or EFla promoter or (b) a T cell-specific transcriptional element of CD2, CD3s, LCK, or a functional variant thereof. In aspects, the producer cell is a HEK293 cell or a derivative of a HEK293 cell. In aspects, the producer cell is a HEK293-T, HEK293-E, HEK293-6E, HEK293-F, HEK293-SF, HEK293-Vec, or HEK293 viral production cell (HEK293-VPC). In aspects, the transgene is expressed following transduction of a target cell and not expressed in a producer cell.

[0148] A regulatory element (e.g., a promoter or an enhancer) that is specific for a cell (cell-specific) is active in a specific type of cell. A regulatory element (e.g., a promoter or an enhancer) that is specific for a tissue (tissue-specific) is active in a specific ty pe of tissue, which can include one or more cell types.

[0149] In aspects, one or more of the regulatory elements disclosed herein may comprise any functional variant thereof, including variants that differ in sequence, length, orientation,Leydig 775537Vyriad P-63-00626or composition. It is understood by those skilled in the art that lentiviral vector systems admit of numerous sequence variations and alternative configurations.

[0150] In aspects, the T cell-specific promoter is a portion of the distal Lek (dLck) promoter comprising a nucleotide sequence that has at least 80% sequence identity with SEQ ID NO: 33. In aspects, the T cell-specific promoter is a portion of the distal Lek (dLck) promoter comprising a nucleotide sequence that has at least 80% sequence identity with SEQ ID NO: 3. In aspects, the one or more regulatory elements comprise a promoter comprising the nucleotide sequence of SEQ ID NO: 3, 30, 31, 32, 33, or 34. In aspects, the promoter comprises a modification that increases T cell specific transcriptional activity. In aspects, the modification comprises an addition of splicing signals, insertion of a TATA box, insertion of an octamer motif, insertion of a consensus cap site sequence, deletion or replacement of endogenous putative promoter response elements (PRE) elements, endogenous transcription initiation sites, or any combination thereof.

[0151] In aspects, the CAR comprises an antigen binding domain that has antigenic specificity for B Cell Maturation Antigen (BCMA), CD22, CD20, or CD 19. In aspects, the antigen binding domain comprises a variable heavy domain of heavy chain (VHH) antibody comprising the amino acid sequence of SEQ ID NO: 1. In aspects, the retroviral expression system comprises a CAR nucleotide construct comprising: (a) a nucleotide sequence encoding a signal peptide comprising an amino acid sequence of a CD8a signal peptide comprising the amino acid sequence of SEQ ID NO: 5, (b) a nucleotide sequence encoding an antigen binding domain comprising an amino acid sequence of a BCM A- targeting VHH antibody comprising the amino acid sequence of SEQ ID NO: 1, (c) a nucleotide sequence encoding a hinge domain comprising an amino acid sequence of a CD28 hinge domain comprising the amino acid sequence of SEQ ID NO: 7, (d) a nucleotide sequence encoding a transmembrane domain comprising an amino acid sequence of a CD28 transmembrane domain comprising the amino acid sequence of SEQ ID NO: 17, (e) a nucleotide sequence encoding an intracellular signaling domain comprising an amino acid sequence of a costimulatory domain 4-1BB comprising the amino acid sequence of SEQ ID NO: 9, and (f) a nucleotide sequence encoding an activating domain comprising an amino acid sequence of a CD3 zeta activating domain comprising the amino acid sequence of SEQ ID NO: 11 or SEQ ID NO: 20.Leydig 775537Vyriad P-63-00627

[0152] In aspects, the CAR comprises a hinge domain, wherein the hinge domain is the hinge domain of CD28 or CD8a. In aspects having two or more CARs, the two or more CARs may comprise an identical or different hinge domain.

[0153] As used herein, “transmembrane domain” refers to a structural motif of a protein that spans the lipid bilayer of a cell membrane. In aspects, the transmembrane domain of the CAR is the transmembrane domain of CD28 or CD8. In aspects, the transmembrane domain provides stability', allows for enhanced CAR signaling, and / or supports enhanced T cell activation. In this manner, the transmembrane domain may play a role in anchoring the CAR to the cell membrane and facilitating intracellular signaling upon antigen binding. In aspects having two or more CARs, the two or more CARs may comprise an identical or different transmembrane domain.

[0154] In aspects, a CAR of the present disclosure may further comprise a spacer domain located between the antigen-binding domain and the transmembrane domain. In aspects, the spacer domain comprises a short peptide linker, such as a glycine-serine linker. In aspects, the spacer domain comprises a protein domain derived from a natural protein, such as a CD8a or a CD28 domain. In aspects having two or more CARs, the two or more CARs may comprise an identical or different spacer domains.

[0155] In aspects, the intracellular signaling domain of a CAR of the present disclosure comprises an amino acid sequence of a protein domain derived from a natural protein, such as a CD3^, CD3s, CD38, CD3y, CD 137 (4- IBB), CD28, ICOS, 0X40, or any combination thereof. In aspects, the intracellular signaling domain of the CAR comprises a primary' activating domain and at least one costimulatory domain. In aspects, the primary activating domain is CD3q. In aspects, the at least one costimulatory domain is 4-1BB or CD28. In aspects, the intracellular signaling domain comprises two costimulatory domains, wherein the costimulatory domains are 4-1BB and CD28. In aspects having two or more CARs, the two or more CARs may comprise an identical or different primary' activating domain and at least one costimulatory domain.

[0156] In aspects, the intracellular signaling domain comprises a T cell signaling domain. As used herein, “T cell signaling domain” refers to a component of a CAR or a T cell receptor (TCR) construct that transmits intracellular signals upon antigen recognition by a T cell. In aspects, the T cell signaling domain comprises signaling motifs derived from proteins involved in T cell activation and proliferation, such as CD28. In aspects, the T cell signaling domain facilitates downstream cellular responses such as cytokine release, cytotoxicity', andLeydig 775537Vyriad P-63-00628proliferation. In aspects, the transfer vector comprises, in a 5' to 3' orientation: (a) a chimeric 5' long terminal repeat (5'LTR) comprising enhancer and promoter nucleotide sequences in place of endogenous U3 enhancer and promoter sequences, positioned directly upstream of a 5' R - U5 region; (b) a Psi viral packaging signal nucleotide sequence; (c) a Rev response element (RRE) nucleotide sequence: (d) an expression cassette positioned in reverse orientation relative to the transcriptional direction of the transfer vector, the cassette comprising: i. a tissue specific regulatory element, and ii. a chimeric antigen receptor (CAR) transgene nucleotide sequence, wherein i and ii are operably linked; (e) optionally a woodchuck hepatitis virus post-transcriptional regulatory element (WPRE) nucleotide sequence or a functional variant thereof; (f) a 3' long terminal repeat (3'LTR) comprising a self-inactivating (SIN) U3 region; and (g) optionally an SV40 polyadenylation (pA) signal nucleotide sequence. In aspects, the expression cassette comprises iii. a polyadenylation (pA) signal nucleotide sequence. In aspects, the pA is a bGH polyadenylation signal nucleotide sequence, wherein i, ii, and iii are operably linked.

[0157] In aspects, the enhancer and promoter nucleotide sequences of the chimeric 5' LTR are of Rous sarcoma virus (RSV) or CMV. In aspects, the transfer vector comprises the WPRE nucleotide sequence or functional variant thereof. In aspects, the WPRE nucleotide sequence or functional variant thereof comprises a nucleotide sequence that has at least 80% sequence identity with SEQ ID NO: 26. In aspects, the transfer vector comprises the SV40 polyadenylation (pA) signal nucleotide sequence.

[0158] In aspects, the 5'LTR enhancer comprises SEQ ID NO: 21, the 5'LTR promoter nucleotide sequence comprises SEQ ID NO: 22, the 5' R - U5 region comprises SEQ ID NO: 23; the Psi viral packaging signal nucleotide sequence comprises SEQ ID NO: 24; the RRE nucleotide sequence comprises SEQ ID NO: 25; the CAR transgene nucleotide sequence has antigenic specificity for B Cell Maturation Antigen (BCMA), CD22, CD20, or CD19, the tissue specific regulatory element comprises two regulatory elements comprising a distal Lek promoter nucleotide sequence and an enhancer nucleotide sequence; the bGH polyadenylation (pA) signal nucleotide sequence comprises SEQ ID NO: 43; the WPRE nucleotide sequence or functional variant thereof comprises SEQ ID NO: 26 or SEQ ID NO: 58; the 3'LTR comprising the SIN U3 region comprises SEQ ID NO: 28; and the SV40 pA signal nucleotide sequence comprises SEQ ID NO: 27.

[0159] In aspects, the BCMA CAR transgene nucleotide sequence comprises SEQ ID NO: 42. In aspects, the enhancer nucleotide sequence comprises SEQ ID NO: 44 or SEQ IDLeydig 775537Vyriad P-63-00629NO: 4. In aspects, the distal Lek promoter nucleotide sequence comprises SEQ ID NO: 3. In aspects, the distal Lek promoter nucleotide sequence comprises SEQ ID NO: 30. In aspects, the distal Lek promoter nucleotide sequence comprises SEQ ID NO: 31. In aspects, the distal Lek promoter nucleotide sequence comprises SEQ ID NO: 32. In aspects, the distal Lek promoter nucleotide sequence comprises SEQ ID NO: 33. In aspects, the distal Lek promoter nucleotide sequence comprises SEQ ID NO: 34.

[0160] A “membrane-anchored glycoprotein” (MAG) is a glycoprotein associated with a lipid bilayer membrane. Association with a lipid bilayer can be covalently attached to the membrane. A MAG can be an integral protein, such as a transmembrane protein, or a peripheral protein associated with a surface of a membrane (inner surface or outer surface). In aspects, several peripheral MAGs can, e.g., coat a surface of a membrane. In aspects, several peripheral MAGs can coat a surface of a membrane with several separate MAGs coating the other surface of the membrane. A “viral membrane glycoprotein” (VMG) is a MAG that is from a virus or derived from a virus. A “fusogenic membrane glycoprotein” (FMG) is a MAG that comprises a glycoprotein capable of fusing lipid bilayers. A MAG can comprise an FMG, and a VMG can comprise an FMG. A MAG can comprise a cytoplasmic domain incapable of incorporation into certain membraned vesicles, e.g., enveloped delivery vehicles. A MAG comprising a cytoplasmic domain incapable of incorporation can, but does not necessarily, prevent a membraned vesicle from encapsulating cargo / payload, rendering the membraned vesicle incapable of delivery of cargo / payload. The VMGs may be any suitable glycoprotein. For example, the VMGs may be a Type 1 membrane glycoprotein (N-terminus opposite the lumen, C-terminus inside the lumen) or a Type 2 membrane glycoprotein (C-terminus opposite the lumen, N-terminus inside the lumen).

[0161] In aspects, the viral FMG or functional fragment or derivative thereof that has 99%, 98%, 97%, 96%, 95%, 94%, 93%, 92%, 91%, 90%, 85%, 80% 75%, 70%, 65%, or 60% sequence identity compared to a viral FMG or functional fragment or derivative thereof described herein. In aspects, the viral FMG or functional fragment or derivative thereof contains one or more conservative amino acid substitutions that do not interfere with the fusion function of the viral FMG or functional fragment or derivative thereof.

[0162] As used herein, “functional fragment” of a viral FMG means a viral FMG that is not a full length viral FMG but is a portion of a parent viral FMG (e.g., a truncated form of a full length viral FMG), where the portion retains the fusion function of the parent full length viral FMG. As used herein, “functional derivative” or “functional variant” of a viral FMGLeydig 775537Vyriad P-63-00630means a viral FMG that has been modified, e.g.. by conservative amino acid substitution, where the viral FMG retains the fusion function of the parent full length viral FMG. As used herein, “functional fragment or derivative” and “functional fragment or variant” encompass the meanings of both “functional fragment” and “functional derivative’7“functional variant”.

[0163] The “fusion function” of a viral FMG means that a viral FMG, when part of a virus, can initiate fusion of the virus with a target cell, e.g., such that the virus can infect the target cell. Such fusion can be due to the interaction of the viral FMG with a natural receptor or the interaction of the viral FMG with a different receptor (e.g., the viral FMG is blinded to a natural receptor, such that the viral FMG is engineered to reduce or abolish a natural receptor binding specificity, and the viral FMG is re-targeted to anew receptor). As used herein, the term “natural receptor” refers to an endogenously expressed receptor in an organism that a viral FMG is capable of binding. Any viral FMG may have more than one natural receptor. As used herein, the term “receptor blinded” refers to a viral FMG with reduced or abolished binding specificity for a natural receptor. A viral FMG or functional fragment or derivative thereof disclosed herein can have increased or decreased fusion efficiency compared to a wild type viral FMG. Increase in fusion efficiency specificity can be of any amount, e.g., increased by 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%. 19%. 20%. 21%. 22%. 23%. 24%. 25%. 26%. 27%. 28%.29%. 30%. 31%. 32%. 33%. 34%. 35%. 36%. 37%. 38%. 39%. 40%. 41%. 42%. 43%. 44%.45%, 46%, 47%, 48%, 49%, 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%. 90%. 91%. 92%.93%. 94%. 95%. 96%. 97%. 98%. 99%. 100%. 200%, 500%, 1000%, or any range between these percentages. Decrease in fusion efficiency can be of any amount, e.g., decreased by 99%, 98%, 99%, 98%, 97%, 96%, 95%, 94%, 93%, 92%, 91%, 90%, 89%, 88%, 87%, 86%, 85%, 84%, 83%, 82%, 81%, 80%, 79%, 78%, 77%, 76%, 75%, 74%, 73%, 72%, 71%, 70%, 69%, 68%, 67%. 66%, 65%. 64%. 63%. 62%. 61%. 60%. 59%. 58%. 57%. 56%. 55%. 54%.53%, 52%, 51%, 50%, 49%, 48%, 47%, 46%, 45%, 44%, 43%, 42%, 41%, 40%, 39%, 38%, 37%, 36%, 35%, 34%, 33%, 32%, 31%, 30%, 29%, 28%, 27%, 26%, 25%, 24%, 23%, 22%, 21%, 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, or any range between these percentages. A functional fragment and / or functional derivative / functional variant of a viral FMG can be within a recombinant VMG comprising a viral FMG.Leydig 775537Vyriad P-63-00631

[0164] In aspects, the viral FMG or functional fragment or derivative thereof is derived from a rhabdoviral G glycoprotein, a SARS-CoV-2 Spike (S) glycoprotein, a HIV-1 Envelope glycoprotein, an influenza hemagglutinin (HA) glycoprotein, an Ebola virus glycoprotein, a Hepatitis C virus (HCV) envelope 2 (E2) glycoprotein, a Machupo virus (MACV) spike glycoprotein (GP1), or a Sendai virus hemagglutinin-neuraminidase (HN) glycoprotein.

[0165] Rhabdoviruses are viruses within the family Rhabdoviridae. The viruses encode proteins denoted N (nucleoprotein), P (phosphoprotein), M (matrix protein), G (glycoprotein), and L (large protein, which is a polymerase), and the viruses appear to have a shape of a bullet when observed using electron microscopy. Dimensions of rhabdovirus virions can range from 100 nm to 430 nm in length and can range from 45 nm to 100 nm in diameter.

[0166] Rhabdoviral G glycoprotein mediates binding of rhabdovirus to a receptor on a cell, which binding then mediates entry of the rhabdovirus into the cell and infection of the cell. A rhabdoviral G glycoprotein or functional fragment or derivative thereof as described herein, including recombinant fusion proteins comprising the rhabdoviral G glycoprotein or functional fragment or derivative thereof, can be used to pseudotype a type of virus that is not the native / natural virus of the rhabdoviral G glycoprotein.

[0167] As used herein, a "pseudotype” of a virus, membraned vesicle, enveloped delivery vehicle, enveloped viral particle, or recombinant viral vector, etc. means a virus, membraned vesicle, enveloped delivery vehicle, enveloped viral particle, or recombinant viral vector, etc. comprising a molecule, e.g., a rhabdoviral G glycoprotein or functional fragment or derivative thereof (including a recombinant fusion protein comprising the rhabdoviral G glycoprotein or functional fragment or derivative thereof), that is not typically found in the virus, membraned vesicle, enveloped delivery vehicle, enveloped viral particle, or recombinant viral vector, etc. Such a molecule can have a mutation (e.g., a substitution or deletion) that impacts the tropism of the virus, membraned vesicle, enveloped delivery vehicle, enveloped viral particle, or recombinant viral vector, etc. The impact on tropism can be, e.g., to contribute to, direct, redirect, or completely change, or any combination thereof, the tropism of the virus, membraned vesicle, enveloped delivery vehicle, enveloped viral particle, or recombinant viral vector, etc. when compared to the virus, membraned vesicle, enveloped delivery vehicle, enveloped viral particle, or recombinant viral vector, etc. without the molecule and / or compared to the wild-ty pe virus, membraned vesicle, enveloped deliveryLeydig 775537Vyriad P-63-00632vehicle, enveloped viral particle, or recombinant viral vector, etc. The impact on tropism can be, e.g., to target a cell that is different from the cell normally targeted by the virus, membraned vesicle, enveloped delivery vehicle, enveloped viral particle, or recombinant viral vector, etc. and / or to not target a cell that is normally targeted by the virus, membraned vesicle, enveloped deliver)’ vehicle, enveloped viral particle, or recombinant viral vector, etc.

[0168] In aspects, the rhabdoviral G glycoprotein or functional fragment or derivative thereof is of a Flanders virus glycoprotein (FLAV-G), a Chandipura virus glycoprotein (CHPV-G), a Perinet virus glycoprotein (PERV-G), aPiry virus glycoprotein (PIRYV-G), a Fukuoka virus glycoprotein (FUKV-G), a Joinjakaka virus glycoprotein (JOIV-G). a Kumasi virus glycoprotein (KRV-G), a Keuraliba virus glycoprotein (KEUV-G), an Isfahan glycoprotein (ISFV-G), a Jurona glycoprotein (JURV-G), a Mediterranean Bat glycoprotein (MBV-G), a Malpais Spring glycoprotein (MSPV-G), a Radi glycoprotein (RADV-G), a Rhinolophus affinis-G, a Yug Bugdanavoc glycoprotein (YBV-G), a Yinshui Bat glycoprotein (YSBV-G). a Kimberley glycoprotein (KIMV-G). aKanyawara glycoprotein (KYAV-G), a La Joy a glycoprotein (LJV-G), a Mosquiero glycoprotein (MQOV-G), a Parry Creek glycoprotein (PCV-G), a Bas Congo glycoprotein (BASV-G), a Bovine Ephemeral fever glycoprotein (BEFV-G), a Curionopolis glycoprotein (CURV-G), a Drosophila melanogaster sigmavirus glycoprotein (DMelSV-G), a Niakha glycoprotein (NIAV-G), a Puerto almandras glycoprotein (PTAMV-G), or a Tupaia rhabdovirus (TUPTV-G). In aspects, the rhabdoviral G glycoprotein or functional fragment or derivative thereof is from any rhabdoviral G glycoprotein or functional fragment or derivative thereof as provided herein.

[0169] In aspects, the rhabdoviral G glycoprotein or functional fragment or derivative thereof is of Vesiculovirus glycoprotein or a functional fragment or derivative thereof. In aspects, the rhabdoviral G glycoprotein or functional fragment or derivative thereof is of Vesiculovirus Indiana (VSIV), Vesiculovirus newjersey (VSNJV), Vesiculovirus carajas (VSCV), or Vesiculovirus alagoas (VS AV). Vesiculovirus Indiana, also referred to as vesicular stomatitis virus (VSV) is a rhabdovirus, having a natural receptor of the low-density lipoprotein receptor (LDLR) or very low density lipoprotein receptor (VLDLR), which are expressed on the cell membrane of many types of cells. In aspects, the rhabdoviral G glycoprotein or functional fragment or derivative thereof is of Vesiculovirus Indiana. In aspects, the rhabdoviral G glycoprotein or functional fragment or derivative thereof is of Vesiculovirus newjersey.Leydig 775537Vyriad P-63-00633

[0170] In aspects, the rhabdoviral G glycoprotein is substantially intact. As used herein, a “substantially intact” rhabdoviral G glycoprotein means a rhabdoviral G glycoprotein that is a functional fragment of the rhabdoviral G glycoprotein, where the rhabdoviral G glycoprotein has each of the domains of a rhabdoviral G glycoprotein, the domains as defined in Roche et al., Cell. Mol. Life Sci., 65: 1716-1728 (2008), which is incorporated herein by reference in its entirety. In aspects, the rhabdoviral G glycoprotein is a functional fragment or derivative thereof.

[0171] In aspects, the rhabdoviral G glycoprotein is engineered to reduce or abolish its natural receptor binding specificity. In aspects, the rhabdoviral G glycoprotein is engineered to have a mutation to reduce or abolish its natural receptor binding specificity. In aspects, the rhabdoviral G glycoprotein comprises a mutation at one or more positions corresponding to H8, K47, Y209, and K354 on the Vesiculovirus Indiana glycoprotein. In aspects, the mutation is a substitution. In aspects, the substitution is with a Q. In aspects, the mutation is a substitution at three or more positions corresponding to H8. K47. Y209, and K354 on the Vesiculovirus Indiana glycoprotein. The US Patent Publication No. 2020 / 0216502 is incorporated herein by reference in its entirety. In aspects, the mutation is a deletion. In aspects, the mutation is a single deletion at the position corresponding to K47 on the Vesiculovirus Indiana glycoprotein.

[0172] It has been found that a Vesiculovirus Indiana rhabdoviral G glycoprotein having a deletion of K47 reduces or abolishes the natural receptor binding specificity of the rhabdoviral G glycoprotein while unexpectedly retaining full function of the G protein in other respects. In particular, this feature is seen when incorporated into alentiviral vector. However, when used in a VSIV vector, there is a second site mutation (F405I) generated in the VSIV-G protein during the virus amplification. This mutation leads to the loss of detargeting effect caused by the deletion on K47 residue. Without wishing to be bound by theory', this phenomenon may be due to VSIV being a replicating virus, whereas lentivirus is a non-replicating virus.

[0173] Vesiculovirus Indiana glycoprotein having H8 and / or K47 deletions, when incorporated into a lentiviral system, can support production of functional pseudotyped lentivirus and successful cell transduction. The H8 and / or K47 deletions, but not Y209 or R354 deletions or Y209 / R354 deletion combinations, demonstrated generation and rescue of pseudotyped lentivirus with low to no LDLR background binding.Leydig 775537Vyriad P-63-00634

[0174] Amino acid positions of other rhabdoviral G glycoproteins or functional fragments or derivatives thereof that are ‘'positions corresponding to” the amino acids discussed above can be determined using a global sequence alignment algorithm (see, e.g., Madeira et al., Nuc. Acids Res., 5O(W1): W276-W279 (2022), which is incorporated herein by reference in its entirety) comparing the base rhabdoviral G glycoprotein to another rhabdoviral G glycoprotein.

[0175] Viral FMG interactions with receptor proteins are important determinants of viral host range, tissue tropism, and pathogenicity. Table 1 shows viral FMG, receptor protein, and known oligomerization form or forms.Table 1

[0176] In aspects, the retroviral expression system comprises a nucleotide sequence encoding a recombinant fusion protein of a Vesiculovirus Indiana G glycoprotein (VSIV-G) engineered to have a mutation to reduce or abolish its natural receptor binding speci fici ty to low density’ lipoprotein receptor (LDL-R). In aspects, the VSIV-G mutation is a single deletion at K47 corresponding to the amino acid sequence of SEQ ID NO: 15.

[0177] In aspects, (a) the expression of the transgene in the producer cell and a lentiviral particle (LVP) produced by the producer cell is reduced or ablated compared to expression of the transgene in the target cell, or (b) wherein the expression of the transgene is increased in the target cell compared to the producer cell, or (c) wherein packaging efficiency of a transcript payload is improved in lentiviral particles produced by the producer cell compared to lentiviral particles produced by a producer cell wherein the expression cassette is in a forward orientation.Leydig 775537Vyriad P-63-00635

[0178] In aspects, the retroviral expression system comprises a second vector, wherein the second vector comprises a nucleotide sequence encoding an envelope protein in a forward orientation relative to the transcriptional direction of the second vector, wherein the envelope protein is optionally operably linked to one or more regulatory elements comprising a promoter or enhancer, the one or more regulatory elements able to drive expression of the envelope protein in a producer cell. In aspects, the envelope protein is engineered to have a mutation to reduce or abolish its natural receptor binding specificity.

[0179] In aspects, the retroviral expression system comprises a third vector, wherein the third vector comprises a nucleotide sequence encoding a recombinant fusion protein in a forward orientation relative to the transcriptional direction of the third vector, wherein the recombinant fusion protein is optionally operably linked to one or more regulatory elements comprising a promoter or enhancer, the one or more regulatory elements able to drive expression of the recombinant fusion protein in a producer cell, and wherein the recombinant fusion protein comprises a targeting molecule and an envelope protein engineered to have a mutation to reduce or abolish its natural receptor binding specificity.

[0180] In aspects, the retroviral expression system comprises a second vector encoding a chimeric G and a third vector encoding a nonchimeric G, that can be used to extend the lentiviral genome length to a size that can prevent incorporation into the cores of progeny lentiviral particles and thereby can prevent replication competence in second or third generation lentiviral packaging systems, which demonstrates improved safety compared to traditional lentiviral systems.

[0181] In aspects, the present disclosure provides a retroviral expression system as described herein, comprising a nucleotide sequence encoding a recombinant protein comprising (A) a targeting molecule, (B) an oligomerization peptide, and one or both of (C)(1) a binding domain of a receptor protein, wherein the binding domain of the receptor protein is capable of binding to or interacting with a wild-type rhabdo viral G glycoprotein or functional fragment or derivative thereof and (C)(2) an antigen binding domain, wherein the antigen binding domain specifically binds a rhabdoviral G glycoprotein or functional fragment or derivative thereof. In aspects, the recombinant protein comprises (C)(1), and wherein the binding domain of the receptor protein of the recombinant protein is of a cysteine rich region of a low-density lipoprotein receptor (LDLR). In aspects, the binding domain comprises (i) cysteine rich domain 2 (CR2) of LDLR (SEQ ID NO: 67), (ii) cysteine rich domain 3 (CR3) of LDLR (SEQ ID NO: 68), (iii) cysteine rich domain 4 (CR4) of LDLRLeydig 775537Vyriad P-63-00636(SEQ ID NO: 69), or (iv) any combination of (i)-(iii). In aspects, the binding domain comprises cysteine rich domain 1 (CR1) of LDLR (SEQ ID NO: 66), CR2 (SEQ ID NO: 67) of LDLR, and CR3 (SEQ ID NO: 68) of LDLR. In aspects, the recombinant protein comprises (C)(1), and wherein the binding domain of the receptor protein of the recombinant protein is N terminal to the oligomerization peptide, optionally wherein the oligomerization peptide is N terminal to the targeting molecule. In aspects, the recombinant protein comprises (C)(2). In aspects, the antigen binding domain is a single chain variable fragment (scFv). In aspects, binding of the antigen binding domain does not interfere with the fusion capability of the rhabdoviral G glycoprotein or functional fragment or derivative thereof.

[0182] In aspects, the present disclosure provides a method of delivering a payload to a T lymphocyte, the method comprising (a) transducing or transfecting a producer cell with the retroviral expression system as described herein, (b) recovering an enveloped delivery vehicle (EDV) produced by the transduced or transfected producer cell, and (c) contacting the T lymphocyte with the EDV.

[0183] As used herein, a “membraned vesicle” is a vesicle bound (delimited) by a lipid bilayer. In aspects, the membraned vesicle is either naturally-derived or engineered. A membraned vesicle can be cell-derived and thus be a cell-derived enveloped particle (CDEP). In aspects, the present disclosure provides a membraned vesicle comprising a retroviral expression system or transfer vector as descnbed herein.

[0184] In aspects, the vesicle is a gesicle or an exosome. A gesicle can be as described in Mangeot et al., Mol. Ther., 19: 1656-1666 (2011), which is incorporated herein by reference in its entirety, where overexpression of glycoprotein of VSIV-G in human cells induced release of fusogenic vesicles. As used herein, an '“exosome” refers to a lipid bilayer vesicle ranging in size from approximately 30 nm to 150 nm in diameter, secreted by eukaryotic cells via the endosomal pathway, and containing biologically active molecules such as proteins, lipids, RNA, or DNA. An exosome typically originates from multivesicular bodies (MVBs) and is released into the extracellular environment through exocytosis. Exosomes are known to serve as intercellular communication vehicles and may be utilized for diagnostic, therapeutic, or drug delivery applications. Examples of exosomes are provided in Li et al., European Journal of Medicinal Chemistry 207: 112784 (2020); Yang et al., Adv. Mater. 29: 1605604 (2017); U. S. Pat. No. 10,195,290; and U. S. Patent Application Publication No. 2018 / 0028600, each of which is incorporated herein by reference in its entirety.Leydig 775537Vyriad P-63-00637

[0185] In aspects, the disclosure provides an enveloped delivery vehicle comprising any retroviral expression system or transfer vector disclosed herein. Tn aspects, the enveloped delivery vehicle comprises any retroviral expression system or transfer vector disclosed herein.

[0186] As used herein, an "‘enveloped viral particle” is a vesicle bound (delimited) by a lipid bilayer and has the ability to infect a cell and produce additional enveloped viral particles. An enveloped viral particle can include one or more components of a virus, in addition to a rhabdoviral G glycoprotein or functional fragment or derivative thereof or recombinant fusion protein thereof. Exemplary components of a virus include, without limitation, the gag, pol, or env gene or gene product of lentivirus. In aspects, the present disclosure provides an enveloped viral particle comprising a retroviral expression system or transfer vector as described herein.

[0187] A “virus-like particle” as used herein means an enveloped viral particle that cannot produce additional virus-like particles (i.e., is replication-incompetent). Virus-like particles (VLPs) are non-infectious and mimic the conformation of their parental viruses but lack the viral genetic material for replication. A VLP can contain genetic material / nucleic acid not associated with self-replication. VLPs can preserve the high packaging efficiency and target-specificity of certain viruses while greatly minimizing the risk of host genome integration. Because VLPs do not replicate or integrate into the host genome, they are often associated with lower cytotoxicity and reduced immunogenic risk compared to replication-competent viral systems. In aspects, the present disclosure provides a virus-like particle comprising a retroviral expression system or transfer vector as described herein.

[0188] In aspects, membraned vesicles, cell-derived enveloped particles, enveloped viral particles, and virus-like particles can encapsulate proteins, lipids, nucleic acids, etc. for delivery, such that membraned vesicles, cell-derived enveloped particles, enveloped viral particles, and virus-like particles can be considered “enveloped delivery vehicles.”

[0189] An “enveloped delivery vehicle” (EDV) can encapsulate a cargo or payload. Any suitable cargo or payload of an EDV is contemplated herein, including, but not limited to, e.g., a protein, a lipid, a nucleic acid, a small molecule, a therapeutic agent, a gene editing system, such as CRISPR Cas, and any combination thereof.

[0190] In aspects, any method of making an enveloped delivery vehicle, lentivirus. retroviral vector expression system, recombinant viral vector, etc. as described herein can comprise transduction in a medium comprising a poloxamer-based chemical adjuvant. InLeydig 775537Vyriad P-63-00638aspects, the poloxamer-based chemical adjuvant is selected from vectofusin-1, poloxamer Fl 08, and Lentiboost™. In aspects, the method of making comprises aspinoculation step at the beginning of transduction.

[0191] In aspects, the present disclosure provides a method for reducing or ablating expression of a chimeric antigen receptor (CAR) in a producer cell compared to expression in a T lymphocyte, the method comprising: (a) preparing a transfer vector comprising a nucleotide sequence encoding the CAR and one or more tissue-specific transcriptional regulatory elements operably linked to the nucleotide sequence encoding the CAR, optionally in a reverse orientation relative to the transcriptional direction of the transfer vector, and (b) transducing or transfecting the transfer vector into the producer cell, (c) recovering an enveloped delivery vehicle (EDV) produced by the transduced or transfected producer cell, and (d) contacting the T lymphocyte with the EDV. In aspects, all features are in a forward orientation.

[0192] In aspects, the present disclosure provides a method for reducing or ablating expression of a chimeric antigen receptor (CAR) in an enveloped delivery vehicle (EDV) produced using lentivirus infection compared to expression in a T lymphocyte, the method comprising: (a) preparing a transfer vector comprising a nucleotide sequence encoding the CAR and one or more tissue-specific transcriptional regulatory elements operably linked to the nucleotide sequence encoding the CAR, optionally in a reverse orientation relative to the transcriptional direction of the transfer vector, and (b) transducing or transfecting the transfer vector into a producer cell, (c) recovering an EDV produced by the transduced or transfected producer cell, and (d) contacting the T lymphocyte cell with the EDV. In aspects, all features are in a forward orientation.

[0193] In aspects, the present disclosure provides a method of producing a virus-like particle (VLP) produced using retrovirus infection with ablated, not detectable, or low expression of a transgene on the viral envelope of the VLP, the method comprising transfecting or transducing a producer cell with a retroviral expression system as described herein.

[0194] In aspects, the present disclosure provides a method for reducing or ablating expression of a transgene in an enveloped delivery vehicle (EDV) produced using lentivirus infection compared to expression in a target cell, the method comprising: (a) preparing a transfer vector comprising a nucleotide sequence encoding the transgene and one or more tissue-specific transcriptional regulatory elements operably linked to the transgene, optionallyLeydig 775537Vyriad P-63-00639in a reverse orientation relative to the transcriptional direction of the transfer vector, (b) transducing or transfecting the transfer vector into a producer cell, (c) recovering an EDV produced by the transduced or transfected producer cell, and (d) contacting the target cell with the EDV. In aspects, all features are in a forward orientation.

[0195] In aspects, the present disclosure provides a method for reducing or ablating expression of a transgene payload in a producer cell compared to expression in a target cell, the method comprising: (a) preparing a transfer vector comprising a nucleotide sequence encoding the transgene payload and one or more tissue-specific transcriptional regulatory elements operably linked to the transgene payload, optionally in a reverse orientation relative to the transcriptional direction of the transfer vector, and (b) transducing or transfecting the transfer vector into the producer cell, (c) recovering an enveloped delivery vehicle (EDV) produced by the transduced or transfected producer cell, and (d) contacting the target cell with the EDV. In aspects, all features are in a forward orientation.

[0196] In aspects, a method as described herein has the contacting performed in vivo.

[0197] In aspects, the present disclosure provides a retroviral vector expression system comprising one or more nucleic acids encoding (i) a recombinant fusion protein, and (ii) a rhabdoviral G glycoprotein or functional fragment or derivative thereof that is not within a recombinant fusion protein. In aspects, ratio of (i) to (ii) is 1:3.

[0198] In aspects, the present disclosure provides a producer cell comprising a retroviral expression system as described herein.

[0199] In aspects, the present disclosure provides an enveloped delivery vehicle (EDV) produced using retrovirus infection, comprising: (a) a viral envelope comprising a recombinant protein or protein complex able to mediate delivery of the vehicle to a target cell; and (b) a transfer vector comprising a nucleotide sequence encoding an expression cassette, optionally in reverse orientation relative to the transcriptional direction of the transfer vector, wherein the expression cassette comprises a transgene operably linked to one or more regulatory elements comprising a tissue-specific promoter or enhancer, yvherein the enveloped delivery vehicle has ablated, low, or undetectable expression of the transgene on the viral envelope. In aspects, the present disclosure provides a enveloped delivery vehicle (EDV) produced in a producer cell transduced or transfected with a retroviral expression system as described herein. In aspects, all features are in a forward orientation.

[0200] In aspects, the present disclosure provides a pharmaceutical composition comprising an EDV as described herein.Leydig 775537Vyriad P-63-00640

[0201] In aspects, the present disclosure provides a method of delivering a payload transgene to a target cell, the method comprising contacting the target cell with a pharmaceutical composition as described herein.

[0202] In aspects, the present disclosure provides a recombinant promoter comprising the nucleotide sequence of SEQ ID NO: 33. In aspects, the present disclosure provides a recombinant promoter comprising a nucleotide sequence that has 90-99% sequence identity to SEQ ID NO: 33, wherein the promoter increases expression selectively in a target cell compared to expression in a producer cell. In aspects, the promoter increases expression selectively in a target cell compared to expression in a producer cell and the target cell is a T lymphocyte and the producer cell is a HEK293 cell or a derivative of a HEK293 cell. In aspects, the producer cell is a HEK293-T, HEK293-E, HEK293-6E, HEK293-F, HEK293-SF, HEK293-Vec, or HEK293 viral production cell (HEK293-VPC). In aspects, the present disclosure provides a recombinant promoter consisting of the nucleotide sequence of SEQ ID NO: 33.

[0203] In aspects, the present disclosure provides a recombinant promoter comprising the nucleotide sequence of SEQ ID NO: 3. In aspects, the present disclosure provides a recombinant promoter comprising the nucleotide sequence of SEQ ID NO: 30. In aspects, the present disclosure provides a recombinant promoter comprising the nucleotide sequence of SEQ ID NO: 31. In aspects, the present disclosure provides a recombinant promoter comprising the nucleotide sequence of SEQ ID NO: 32. In aspects, the present disclosure provides a recombinant promoter comprising the nucleotide sequence of SEQ ID NO: 34. In aspects, the present disclosure provides a recombinant promoter consisting of the nucleotide sequence of SEQ ID NO: 3. In aspects, the present disclosure provides a recombinant promoter consisting of the nucleotide sequence of SEQ ID NO: 30. In aspects, the present disclosure provides a recombinant promoter consisting of the nucleotide sequence of SEQ ID NO: 31. In aspects, the present disclosure provides a recombinant promoter consisting of the nucleotide sequence of SEQ ID NO: 32. In aspects, the present disclosure provides a recombinant promoter consisting of the nucleotide sequence of SEQ ID NO: 34.

[0204] In aspects, the present disclosure provides a method of increasing viral titers for lentiviral particles (LVPs) production in a retroviral vector expression system comprising: (a) preparing a transfer vector comprising an expression cassette, optionally in reverse orientation relative to the transcriptional direction of the transfer vector, wherein the expression cassette comprises a transgene operably linked to one or more tissue-specificLeydig 775537Vyriad P-63-00641transcriptional regulators- elements; (b) transducing or transfecting the transfer vector into a producer cell; and (c) recovering the LVPs produced by the transduced or transfected producer cell. In aspects, all features are in a forward orientation.

[0205] In aspects, viral vector yield is enhanced by engineering nucleotide sequences within the transfer vector to regulate RNA splicing, thereby increasing the availability and packaging efficiency of full-length genomic RNA. This includes introducing or removing splice donor and / or splice acceptor motifs, as well as associated splicing regulator}' elements, within coding or non-coding regions of the expression cassette, including when positioned in reverse orientation relative to the lentiviral genome, where cryptic splice sites may arise due to antisense sequence context. In aspects, synonymous or non-coding sequence modifications are used to disrupt cryptic splice sites that would otherwise lead to premature or aberrant splicing and loss of important cis-acting elements for packaging, including the signal, while optionally introducing or optimizing splice elements to improve RNA processing, stability, or nuclear export without compromising genomic integrity. These modifications increase the ratio of unspliced to spliced vector RNA during production, resulting in improved encapsidation of full-length genomes and increased viral titers.

[0206] In aspects, the present disclosure provides a retroviral transfer vector comprising a nucleotide sequence encoding an expression cassette, wherein the expression cassette comprises a transgene and one or more regulatory elements operably linked to the transgene, wherein the one or more regulatory elements reduce or ablate expression in a producer cell compared to expression in a target cell. In aspects, the nucleotide sequence encoding an expression cassette is in reverse orientation relative to the transcriptional direction of the transfer vector, wherein the reverse orientation reduces or ablates expression of the expression cassette when the transfer vector is in a producer cell compared to when the transfer vector is in a target cell. In aspects, the one or more regulator}- elements are in reverse orientation relative to the transcriptional direction of the transfer vector, wherein the reverse orientation reduces or ablates expression of the expression cassette when the transfer vector is in a producer cell compared to when the transfer vector is in a target cell. In aspects, all features are in a forward orientation.

[0207] In aspects, the one or more regulatory elements comprise one or more regulatory elements that are specific to the target cell. In aspects, the one or more specific regulatory elements comprise a promoter, an enhancer, a silencer, a poly A tail, or any combination thereof. In aspects, the transgene encodes a chimeric antigen receptor (CAR). In aspects, theLeydig 775537Vyriad P-63-00642target cell is a T lymphocyte. In aspects, the one or more regulatory elements comprise a T cell-specific promoter. In aspects, the one or more regulatory elements comprise a T cellspecific enhancer. In aspects, the one or more regulatory- elements comprise (a) a cytomegalovirus (CMV) enhancer, transcriptional element of RSV gene, or EFla promoter or (b) a T cell-specific transcriptional element of CD2, CD3e, LCK, or a functional variant thereof. In aspects, the producer cell is a HEK293 cell or a derivative of a HEK293 cell.

[0208] In aspects, the transgene is expressed following transduction of a target cell and not expressed in a producer cell.

[0209] In aspects, (a) the expression of the transgene in the producer cell and a lentiviral particle (LVP) produced by the producer cell is reduced or ablated compared to expression of the transgene in the target cell, or (b) wherein the expression of the transgene is increased in the target cell compared to the producer cell, or (c) wherein packaging efficiency of a transcript payload is improved in lentiviral particles produced by the producer cell compared to lentiviral particles produced by a producer cell wherein the expression cassette is in a forward orientation.

[0210] In aspects, the present disclosure provides a retroviral transfer vector as described herein, wherein the retroviral transfer vector is of a lentiviral vector.

[0211] In aspects, the disclosure provides a method of treating a disease in a mammal, comprising administering any one of the compositions disclosed herein or any one of the retroviral vector expression systems disclosed herein.

[0212] In aspects, the disease is a genetic disease. In aspects, the disease is a cancer. In aspects, the disease is beta-thalassemia, anemia, sickle cell disease. Gaucher disease.Parkinson disease, immunologic deficiency syndromes, mucopolysaccharidosis III, severe combined immunodeficiency disease, hepatitis C, chronic hepatitis C, pancytopenia, X-linked combined immunodeficiency diseases, epidermolysis bullosa, solid tumors, melanoma, Fanconi anemia, adenosine deaminase deficiency, granulomatous disease, chronic cystic fibrosis, HIV infections, HIV seropositivity, Hodgkin’s lymphoma, Bruton type agammaglobulinemia, Hemophilia A, arthritis, or choroidal neovascularization. In other aspects, the disease is any disease or condition that can be treated by delivery of a transgene. In other aspects, the disease is any disease or condition that can be treated by delivery of a gene editing system.

[0213] In aspects, the present disclosure provides a method of treating a hematological malignancy in a subject, the method comprising administering to the subject a therapeuticallyLeydig 775537Vyriad P-63-00643effective amount of a pharmaceutical composition as described herein. In aspects, the hematological malignancy is multiple myeloma.

[0214] In aspects, the present disclosure provides a method of treating systemic lupus erythematosus (SLE) in a subject, the method comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition as described herein.

[0215] In aspects, the present disclosure provides a method of treating a B Cell Maturation Antigen (BCMA)-expressing tumor in a subject, the method comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition as described herein.

[0216] The subject can be a mammal. The mammal may be any suitable mammal.Mammals include, but are not limited to, the order Rodentia, such as mice, and the order Lagomorpha, such as rabbits. The mammal can be from the order Carnivora, including Felines (cats) and Canines (dogs). The mammal can be from the order Artiodacty la, including Bovines (cows) and Swines (pigs) or of the order Perissodactyla, including Equines (horses). The mammal can be of the order Primates, Cebids, or Simioids (monkeys) or of the order Anthropoids (humans and apes). In aspects, the mammal is a human.

[0217] As used herein, “treatment'’ or “treat” refers to a therapeutic intervention that ameliorates a sign or symptom of a disease or pathological condition after it has begun to develop, and also includes addressing a medical condition or disease with the objective of improving or stabilizing an outcome in a mammal being treated. “Treating,” “treat,” and “treatment” have grammatically corresponding meanings. In the context of cancer, the terms “treat” or “treating” or “treatment'’ can, among other things, refer to inducing apoptosis of cancerous cells, reducing the size of a cancerous tumor, delaying the growth of tumors, or inducing or enhancing an immune response against one or more cancerous cells, where the immune response has the effect of inducing apoptosis, reducing the size of a tumor, or the like. The terms “treat,” “treating,” “treatment,” “therapeutically effective,” “prevention,” etc. used herein do not necessarily imply 100% or complete treatment / prevention / etc. Rather, there are varying degrees, which one of ordinary skill in the art recognizes as having a potential benefit or therapeutic effect. In this respect, the membraned vesicles, enveloped viral particles, recombinant viral vectors, etc. as described herein and methods as described herein can provide any amount of any level of treatment. Furthermore, the treatment provided by the disclosed method can include the treatment of one or more conditions or symptoms of the disease or condition being treated.Leydig 775537Vyriad P-63-00644

[0218] In aspects, a method of treating comprises administering a composition as described herein, for example a retroviral vector expression system as described herein, and subsequently administering a composition as described, for example a retroviral vector expression system as described herein, with each administration comprising a different viral FMG or functional fragment or derivative thereof or recombinant protein thereof. The subsequent administration may be within hours, days, months, or years of the first administration, with scheduling to be determined by patient needs. Multiple rounds of subsequent administrations may be performed, using the same or different viral FMGs as determined by the patient needs. Without wishing to be bound by theory, it is believed that administering a different viral FMG or functional fragment or derivative thereof reduces the likelihood of decreased effectiveness due to any immune response that is directed against the first viral FMG or functional fragment or derivative thereof. This sequence of events can be termed “re-dosing"’.

[0219] In aspects, the administration is intravenous. In aspects, the administration is intraperitoneal.

[0220] “Transfecting” and “transfection” as used herein means non-viral means of introducing nucleic acid into a cell. “Transducing"’ and “transduction” as used herein means use of viral means of introducing nucleic acid into a cell.

[0221] In aspects, the present disclosure provides provirus resulting from transfection or transduction using a retroviral vector expression system, transfer vector, etc. as described herein. In aspects, the provirus can be as described in Figure 28D.

[0222] In aspects, retroviral vector expression systems, membraned vesicles, compositions, etc. as described herein may be used with protein or peptide domains that are capable of spontaneously assembling into stable oligomers, which can also be fused to a heterologous functional moiety. These oligomerizing domains, which can be referred to as “CAPs.” provide a modular solution for enforcing oligomeric arrangements, e.g., a trimeric arrangement that is characteristic of many naturally occurring viral entry proteins. By¬ applying such CAPs to receptor-binding fragments, viral glycoprotein derivatives, or synthetic ligands, the caps can restore or replicate the precise geometry important for efficient receptor binding and subsequent membrane fusion events.

[0223] The CAPs are modular, meaning that a CAP may be paired with different receptor-binding domains or ligands. These may include viral receptor-binding fragments, single-chain variable fragments (scFvs) derived from antibodies, nanobodies or VariableLeydig 775537Vyriad P-63-00645Heavy domain of Heavy chain (VHH), peptides, or synthetic ligands engineered to recognize particular cellular receptors.

[0224] In aspects, a CAP comprises (a) a targeting domain and (b) an oligomerization domain. In aspects, a CAP comprises (c) a binding domain of a receptor protein, wherein the binding domain of the receptor protein is capable of binding to or interacting with a viral FMG or a functional fragment or derivative thereof. In aspects, the binding of the viral FMG or a functional fragment or derivative thereof is reduced or abolished for a binding domain of a receptor protein that is separate from the binding domain of the receptor protein of the CAP.

[0225] Commonly owned International Patent Application No., titled “OLIGOMERIZATION OF GLYCOPROTEINS AND USES THEREOF,” filed on May 7, 2026 and having Attorney Docket No. 775437, is incorporated herein by reference in its entirety.

[0226] The below are certain aspects of the disclosure.

[0227] 1. A retroviral vector expression system comprising a transfer vector, wherein the transfer vector comprises a nucleotide sequence encoding an expression cassette,wherein the expression cassette comprises a transgene and one or more regulatory elements operably linked to the transgene, wherein the one or more regulatory elements reduce or ablate expression in a producer cell compared to expression in a target cell.

[0228] 2. The retroviral vector expression system of aspect 1, wherein the nucleotide sequence encoding an expression cassette is in reverse orientation relative to the transcriptional direction of the transfer vector, wherein the reverse orientation reduces or ablates expression of the expression cassette when the transfer vector is in a producer cell compared to when the transfer vector is in a target cell.

[0229] 3. The retroviral vector expression system of aspect 1 or 2, wherein the one or more regulatory elements are in reverse orientation relative to the transcriptional direction of the transfer vector, wherein the reverse orientation reduces or ablates expression of the expression cassette when the transfer vector is in a producer cell compared to when the transfer vector is in a target cell.

[0230] 4. The retroviral vector expression system of any one of aspects 1-3, wherein the one or more regulatory elements comprise one or more regulatory elements that are specific to the target cell.Leydig 775537Vyriad P-63-00646

[0231] 5. The retroviral vector expression system of aspect 4, wherein the one or more specific regulatory elements comprise a promoter, an enhancer, a silencer, a poly A tail, or any combination thereof.

[0232] 6. The retroviral vector expression system of any one of aspects 1-5, wherein the transgene encodes a chimeric antigen receptor (CAR).

[0233] 7. The retroviral vector expression system of any one of aspects 1-6, wherein the transfer vector comprises one or more of the transgene, wherein the one or more transgenes encode two or more CARs.

[0234] 8. The retroviral vector expression system of any one of aspects 1-7, wherein the target cell is a T lymphocyte.

[0235] 9. The retroviral vector expression system of any one of aspects 1-8, wherein the one or more regulatory elements comprise a T cell-specific promoter.

[0236] 10. The retroviral vector expression system of any one of aspects 1-9, wherein the one or more regulatory elements comprise a T cell-specific enhancer.

[0237] 11. The retroviral vector expression system of any one of aspects 1-10, wherein the one or more regulatory elements comprise (a) a cytomegalovirus (CMV) enhancer, transcriptional element of RSV gene, or EFla promoter or (b) a T cell-specific transcriptional element of CD2, CD3s, LCK, or a functional variant thereof.

[0238] 12. The retroviral vector expression system of any one of aspects 1-11, wherein the producer cell is a HEK293 cell or a derivative of a HEK293 cell.

[0239] 13. The retroviral vector expression system of any one of aspects 1-12, wherein the transgene is expressed following transduction of a target cell and not expressed in a producer cell.

[0240] 14. The retroviral vector expression system of aspect 9, wherein the T cell-specific promoter is a portion of the distal Lek (dLck) promoter comprising a nucleotide sequence that has at least 80% sequence identity with SEQ ID NO: 33.

[0241] 15. The retroviral vector expression system of any one of aspects 1-14, wherein the one or more regulatory elements comprise a promoter comprising the nucleotide sequence of SEQ ID NO: 3, 30, 31, 32, 33, or 34.

[0242] 16. The retroviral vector expression system of any one of aspects 3-15, wherein the promoter comprises a modification that increases T cell specific transcriptional activity.

[0243] 17. The retroviral expression system of aspect 16, wherein the modification comprises an addition of splicing signals, insertion of a TATA box, insertion of an octamerLeydig 775537Vyriad P-63-00647motif, insertion of a consensus cap site sequence, deletion or replacement of endogenous putative promoter response elements (PRE) elements, endogenous transcription initiation sites, or any combination thereof.

[0244] 18. The retroviral expression system of aspect 6 or 7, wherein one or more CARs comprise an antigen binding domain that has antigenic specificity for B Cell Maturation Antigen (BCM A), CD22, CD20, or CD 19.

[0245] 19. The retroviral expression system of aspect 18, wherein the antigen binding domain comprises a variable heavy domain of heavy chain (VHH) antibody comprising the amino acid sequence of SEQ ID NO: 1.

[0246] 20. The retroviral expression system of any one of aspects 1-19. comprising a CAR nucleotide construct comprising:(a) a nucleotide sequence encoding a signal peptide comprising an amino acid sequence of a CD8a signal peptide comprising the amino acid sequence of SEQ ID NO: 5, (b) a nucleotide sequence encoding an antigen binding domain comprising an amino acid sequence of a BCMA-targeting VHH antibody comprising the amino acid sequence of SEQ ID NO: 1,(c) a nucleotide sequence encoding a hinge domain comprising an amino acid sequence of a CD28 hinge domain comprising the amino acid sequence of SEQ ID NO: 7, (d) a nucleotide sequence encoding a transmembrane domain comprising an amino acid sequence of a CD28 transmembrane domain comprising the amino acid sequence of SEQ ID NO: 17,(e) a nucleotide sequence encoding an intracellular signaling domain comprising an amino acid sequence of a costimulalorv domain 4- IBB comprising the amino acid sequence of SEQ ID NO: 9, and(1) a nucleotide sequence encoding an activating domain comprising an amino acid sequence of a CD3 zeta activating domain comprising the amino acid sequence of SEQ ID NO: 11 or SEQ ID NO: 20.

[0247] 21. The retroviral expression system of any one of aspects 1-20, wherein at least one transfer vector comprises, in a 5’ to 3’ orientation:(a) a chimeric 5’ long terminal repeat (5’LTR) comprising enhancer and promoter nucleotide sequences in place of endogenous U3 enhancer and promoter sequences, positioned directly upstream of a 5’ R - U5 region;(b) a Psi viral packaging signal nucleotide sequence;Leydig 775537Vyriad P-63-00648(c) a Rev response element (RRE) nucleotide sequence;(d) an expression cassette positioned in reverse orientation relative to the transcriptional direction of the transfer vector, the cassette comprising:i. a tissue specific regulatory element, andii. a chimeric antigen receptor (CAR) transgene nucleotide sequence, wherein i and ii are operably linked;(e) optionally a woodchuck hepatitis virus post-transcriptional regulatory element (WPRE) nucleotide sequence or a functional variant thereof;(f) a 3‘ long terminal repeat (3’LTR) comprising a self-inactivating (SIN) U3 region; and(g) optionally an SV40 polyadenylation (pA) signal nucleotide sequence.

[0248] 22. The retroviral expression system of aspect 21, wherein the expression cassette comprises iii. a poly adenylation (pA) signal nucleotide sequence.

[0249] 23. The retroviral expression system of aspect 22, wherein the pA is a bGH polyadenylation signal nucleotide sequence, and wherein i, ii, and iii are operably linked.

[0250] 24. The retroviral expression system of any one of aspects 21-23, wherein the enhancer and promoter nucleotide sequences of the chimeric 5’ LTR are of Rous sarcoma virus (RSV) or CMV.

[0251] 25. The retroviral expression system of any one of aspects 21-24, wherein the transfer vector comprises the WPRE nucleotide sequence or functional variant thereof.

[0252] 26. The retroviral expression system of aspect 25, wherein the WPRE nucleotide sequence or functional variant thereof comprises a nucleotide sequence that has at least 80% sequence identity with SEQ ID NO: 26.

[0253] 27. The retroviral expression system of any one of aspects 21-26, wherein the transfer vector comprises the SV40 poly adenylation (pA) signal nucleotide sequence.

[0254] 28. The retroviral expression system of any one of aspects 21-27, wherein the 5'LTR enhancer comprises SEQ ID NO: 21, the 5'LTR promoter nucleotide sequence comprises SEQ ID NO: 22, the 5’ R - U5 region comprises SEQ ID NO: 23; the Psi viral packaging signal nucleotide sequence comprises SEQ ID NO: 24; the RRE nucleotide sequence comprises SEQ ID NO: 25; the CAR transgene nucleotide sequence has antigenic specificity for B Cell Maturation Antigen (BCMA), the tissue specific regulatory element comprises two regulatory elements comprising a distal Lek promoter nucleotide sequence and an enhancer nucleotide sequence; the bGH polyadenylation (pA) signal nucleotide sequenceLeydig 775537Vyriad P-63-00649comprises SEQ ID NO: 43; the 3’LTR comprising the SIN U3 region comprises SEQ ID NO: 28; and the SV40 pA signal nucleotide sequence comprises SEQ ID NO: 27.

[0255] 29. The retroviral expression system of aspect 28, wherein the BCMA CAR transgene nucleotide sequence comprises SEQ ID NO: 42.

[0256] 30. The retroviral expression system of aspect 28 or 29, wherein the enhancer nucleotide sequence comprises SEQ ID NO: 44 or SEQ ID NO: 4.

[0257] 31. The retroviral expression system of any one of aspects 28-30, wherein the WPRE nucleotide sequence or functional variant thereof comprises SEQ ID NO: 26 or SEQ ID NO: 58

[0258] 32. The retroviral expression system of any one of aspects 28-31, wherein the distal Lek promoter nucleotide sequence comprises SEQ ID NO: 3.

[0259] 33. The retroviral expression system of any one of aspects 28-31, wherein the distal Lek promoter nucleotide sequence comprises SEQ ID NO: 30.

[0260] 34. The retroviral expression system of any one of aspects 28-31, wherein the distal Lek promoter nucleotide sequence comprises SEQ ID NO: 31.

[0261] 35. The retroviral expression system of any one of aspects 28-31, wherein the distal Lek promoter nucleotide sequence comprises SEQ ID NO: 32.

[0262] 36. The retroviral expression system of any one of aspects 28-31, wherein the distal Lek promoter nucleotide sequence comprises SEQ ID NO: 33.

[0263] 37. The retroviral expression system of any one of aspects 28-31, wherein the distal Lek promoter nucleotide sequence comprises SEQ ID NO: 34.

[0264] 38. The retroviral expression system of any one of aspects 1-37. comprising a nucleotide sequence encoding a recombinant fusion protein of a Vesiculovirus Indiana G glycoprotein (VSIV-G) engineered to have a mutation to reduce or abolish its natural receptor binding specificity to low density lipoprotein receptor (LDL-R).

[0265] 39. The retroviral expression system of aspect 38, wherein the VSIV-G mutation is a single deletion at K47 corresponding to the amino acid sequence of SEQ ID NO: 15.

[0266] 40. The retroviral vector expression system of any one of aspects 2-39, wherein (a) the expression of the transgene in the producer cell and a lentiviral particle (LVP) produced by the producer cell is reduced or ablated compared to expression of the transgene in the target cell, or(b) wherein the expression of the transgene is increased in the target cell compared to the producer cell, orLeydig 775537Vyriad P-63-00650(c) wherein packaging efficiency of a transcript payload is improved in lentiviral particles produced by the producer cell compared to lentiviral particles produced by a producer cell wherein the expression cassette is in a forward orientation.

[0267] 41. The retroviral expression system of any one of aspects 2-40. comprising a second vector, wherein the second vector comprises a nucleotide sequence encoding an envelope protein in a forward orientation relative to the transcriptional direction of the second vector, wherein the envelope protein is optionally operably linked to one or more regulatory elements comprising a promoter or enhancer, the one or more regulatory elements able to drive expression of the envelope protein in a producer cell.

[0268] 42. The retroviral expression system of aspect 41, wherein the envelope protein is engineered to have a mutation to reduce or abolish its natural receptor binding specificity.

[0269] 43. The retroviral expression system of aspect 41 or 42, comprising a third vector, wherein the third vector comprises a nucleotide sequence encoding a recombinant fusion protein in a forward orientation relative to the transcriptional direction of the third vector, wherein the recombinant fusion protein is optionally operably linked to one or more regulatory elements comprising a promoter or enhancer, the one or more regulatory elements able to drive expression of the recombinant fusion protein in a producer cell, and wherein the recombinant fusion protein comprises a targeting molecule and an envelope protein engineered to have a mutation to reduce or abolish its natural receptor binding specificity.

[0270] 44. The retroviral expression system of any one of aspects 1-43, comprising a nucleotide sequence encoding a recombinant protein comprising (A) a targeting molecule, (B) an oligomerization peptide, and one or both of (C)(1) a binding domain of a receptor protein, wherein the binding domain of the receptor protein is capable of binding to or interacting with a wild-type rhabdoviral G glycoprotein or functional fragment or derivative thereof and (C)(2) an antigen binding domain, wherein the antigen binding domain specifically binds a rhabdoviral G glycoprotein or functional fragment or derivative thereof.

[0271] 45. The retroviral expression system of aspect 44, wherein the recombinant protein comprises (C)(1), and wherein the binding domain of the receptor protein of the recombinant protein is of a cysteine rich region of a low-density lipoprotein receptor (LDLR).

[0272] 46. The retroviral expression system of aspect 45, wherein the binding domain comprises (i) cysteine rich domain 2 (CR2) of LDLR (SEQ ID NO: 67), (ii) cysteine rich domain 3 (CR3) of LDLR (SEQ ID NO: 68), (iii) cysteine rich domain 4 (CR4) of LDLR (SEQ ID NO: 69), or (iv) any combination of (i)-(iii).Leydig 775537Vyriad P-63-00651

[0273] 47. The retroviral expression system of aspect 45, wherein the binding domain comprises cysteine rich domain 1 (CR1) of LDLR (SEQ ID NO: 66), CR2 (SEQ ID NO: 67) of LDLR, and CR3 (SEQ ID NO: 68) of LDLR.

[0274] 48. The retroviral expression system of any one of aspects 44-47, wherein the recombinant protein comprises (C)(1). and wherein the binding domain of the receptor protein of the recombinant protein is N terminal to the oligomerization peptide, optionally wherein the oligomerization peptide is N terminal to the targeting molecule.

[0275] 49. The retroviral expression system of aspect 44, wherein the recombinant protein comprises (C)(2).

[0276] 50. The retroviral expression system of aspect 49, wherein the antigen binding domain is a single chain variable fragment (scFv) or nanobody.

[0277] 51. The retroviral expression system of aspect 49 or 50, wherein binding of the antigen binding domain does not interfere with the fusion capability of the rhabdoviral G glycoprotein or functional fragment or derivative thereof.

[0278] 52. A method of delivering a payload to a T lymphocyte, the method comprising (a) transducing or transfecting a producer cell with the retroviral expression system of any one of aspects 1-51,(b) recovering an enveloped delivery vehicle (EDV) produced by the transduced or transfected producer cell, and(c) contacting the T lymphocyte with the EDV.

[0279] 53. A method for reducing or ablating expression of a chimeric antigen receptor (CAR) in a producer cell compared to expression in a T lymphocyte, the method comprising:(a) preparing a transfer vector comprising a nucleotide sequence encoding the CAR and one or more tissue-specific transcriptional regulatory elements operably linked to the nucleotide sequence encoding the CAR, optionally in a reverse orientation relative to the transcriptional direction of the transfer vector, and(b) transducing or transfecting the transfer vector into the producer cell,(c) recovering an enveloped delivery vehicle (EDV) produced by the transduced or transfected producer cell, and(d) contacting the T lymphocyte with the EDV.

[0280] 54. A method for reducing or ablating expression of a chimeric antigen receptor (CAR) in an enveloped delivery vehicle (EDV) produced using lentivirus infection compared to expression in a T lymphocyte, the method comprising:Leydig 775537Vyriad P-63-00652(a) preparing a transfer vector comprising a nucleotide sequence encoding the CAR and one or more tissue-specific transcriptional regulatory elements operably linked to the nucleotide sequence encoding the CAR, optionally in a reverse orientation relative to the transcriptional direction of the transfer vector, and(b) transducing or transfecting the transfer vector into a producer cell,(c) recovering an EDV produced by the transduced or transfected producer cell, and(d) contacting the T lymphocyte cell with the EDV.

[0281] 55. A method of producing a virus-like particle (VLP) produced using retrovirus infection with ablated, not detectable, or low expression of a transgene on the viral envelope of the VLP, the method comprising transfecting or transducing a producer cell with the retroviral expression system of any one of aspects 1-51.

[0282] 56. A method for reducing or ablating expression of a transgene in an enveloped delivery vehicle (EDV) produced using lenti virus infection compared to expression in a target cell, the method comprising:(a) preparing a transfer vector comprising a nucleotide sequence encoding the transgene and one or more tissue-specific transcriptional regulatory elements operably linked to the transgene, optionally in a reverse orientation relative to the transcriptional direction of the transfer vector,(b) transducing or transfecting the transfer vector into a producer cell,(c) recovering an EDV produced by the transduced or transfected producer cell, and(d) contacting the target cell with the EDV.

[0283] 57. A method for reducing or ablating expression of a transgene payload in a producer cell compared to expression in a target cell, the method comprising:(a) preparing a transfer vector comprising a nucleotide sequence encoding the transgene payload and one or more tissue-specific transcriptional regulatory elements operably linked to the transgene payload, optionally in a reverse orientation relative to the transcriptional direction of the transfer vector, and(b) transducing or transfecting the transfer vector into the producer cell,(c) recovering an enveloped delivery vehicle (EDV) produced by the transduced or transfected producer cell, and(d) contacting the target cell with the EDV.Leydig 775537Vyriad P-63-00653

[0284] 58. The method of any one of aspects 52-57. wherein the contacting is performed in vivo.

[0285] 59. The method of any one of aspects 52-58, wherein the retroviral vector expression system comprises one or more nucleic acids encoding (i) a recombinant fusion protein, and (ii) a rhabdoviral G glycoprotein or functional fragment or derivative thereof that is not within a recombinant fusion protein.

[0286] 60. The method of aspect 59, wherein the ratio of (i) to (ii) is 1:3.

[0287] 61. A producer cell comprising the retroviral expression system of any one of aspects 1-51.

[0288] 62. An enveloped delivery vehicle (EDV) produced using retrovirus infection, comprising:(a) a viral envelope comprising a recombinant protein or protein complex able to mediate delivery of the vehicle to a target cell; and(b) a transfer vector comprising a nucleotide sequence encoding an expression cassette, optionally in reverse orientation relative to the transcriptional direction of the transfer vector, wherein the expression cassette comprises a transgene operably linked to one or more regulatory elements comprising a tissue-specific promoter or enhancer, wherein the enveloped delivery’ vehicle has ablated, low, or undetectable expression of the transgene on the viral envelope.

[0289] 63. An enveloped delivery vehicle (EDV) produced in a producer cell transduced or transfected with the retroviral expression system of any one of aspects 1-51.

[0290] 64. A pharmaceutical composition comprising the EDV of aspect 62 or 63.

[0291] 65. A method of delivering a payload transgene to a target cell, the method comprising contacting the target cell with the pharmaceutical composition of aspect 64.

[0292] 66. A recombinant promoter comprising the nucleotide sequence of SEQ ID NO: 33.

[0293] 67. A recombinant promoter comprising the nucleotide sequence of SEQ ID NO: 3.

[0294] 68. A recombinant promoter comprising the nucleotide sequence of SEQ ID NO: 30.

[0295] 69. A recombinant promoter comprising the nucleotide sequence of SEQ ID NO: 31.Leydig 775537Vyriad P-63-00654

[0296] 70. A recombinant promoter comprising the nucleotide sequence of SEQ ID NO: 32.

[0297] 71. A recombinant promoter comprising the nucleotide sequence of SEQ ID NO: 34.

[0298] 72. A recombinant promoter comprising a nucleotide sequence that has 90-99% sequence identity to SEQ ID NO: 33, wherein the promoter increases expression selectively in a target cell compared to expression in a producer cell.

[0299] 73. The recombinant promoter of any one of aspects 66-72, wherein the promoter increases expression selectively in a target cell compared to expression in a producer cell and the target cell is a T lymphocyte and the producer cell is a HEK293 cell or a derivative of a HEK293 cell.

[0300] 74. A recombinant promoter consisting of the nucleotide sequence of SEQ ID NO: 33.

[0301] 75. A recombinant promoter consisting of the nucleotide sequence of SEQ ID NO:3.

[0302] 76. A recombinant promoter consisting of the nucleotide sequence of SEQ ID NO:30.

[0303] 77. A recombinant promoter consisting of the nucleotide sequence of SEQ ID NO:31.

[0304] 78. A recombinant promoter consisting of the nucleotide sequence of SEQ ID NO:32.

[0305] 79. A recombinant promoter consisting of the nucleotide sequence of SEQ ID NO:34.

[0306] 80. A method of increasing viral titers for lentiviral particles (LVPs) production in a retroviral vector expression system comprising:(a) preparing a transfer vector comprising an expression cassete, optionally in reverse orientation relative to the transcriptional direction of the transfer vector, wherein the expression cassete comprises a transgene operably linked to one or more tissue-specific transcriptional regulatory elements;(b) transducing or transfecting the transfer vector into a producer cell; and (c) recovering the LVPs produced by the transduced or transfected producer cell.

[0307] 81. A retroviral transfer vector comprising a nucleotide sequence encoding an expression cassete.Leydig 775537Vyriad P-63-00655wherein the expression cassette comprises a transgene and one or more regulatory elements operably linked to the transgene, wherein the one or more regulatory elements reduce or ablate expression in a producer cell compared to expression in a target cell.

[0308] 82. The retroviral transfer vector of aspect 81, wherein the nucleotide sequence encoding an expression cassette is in reverse orientation relative to the transcriptional direction of the transfer vector,wherein the reverse orientation reduces or ablates expression of the expression cassette when the transfer vector is in a producer cell compared to when the transfer vector is in a target cell.

[0309] 83. The retroviral transfer vector of aspect 81 or aspect 82, wherein the one or more regulatory elements are in reverse orientation relative to the transcriptional direction of the transfer vector,wherein the reverse orientation reduces or ablates expression of the expression cassette when the transfer vector is in a producer cell compared to when the transfer vector is in a target cell.

[0310] 84. The retroviral transfer vector of any one of aspects 81-83, wherein the one or more regulatory elements comprise one or more regulatory elements that are specific to the target cell.

[0311] 85. The retroviral transfer vector of aspect 84, wherein the one or more specific regulatory elements comprise a promoter, an enhancer, a silencer, a poly A tail, or any combination thereof.

[0312] 86. The retroviral transfer vector of any one of aspects 81-85, wherein the transgene encodes a chimeric antigen receptor (CAR).

[0313] 87. The retroviral transfer vector of any one of aspects 81-86, wherein the target cell is a T lymphocyte.

[0314] 88. The retroviral transfer vector of any one of aspects 81-87, wherein the one or more regulatory elements comprise a T cell-specific promoter.

[0315] 89. The retroviral transfer vector of any one of aspects 81-88, wherein the one or more regulatory elements comprise a T cell-specific enhancer.

[0316] 90. The retroviral transfer vector of any one of aspects 81-89, wherein the one or more regulatory elements comprise (a) a cytomegalovirus (CMV) enhancer, transcriptional element of RSV gene, or EFla promoter or (b) a T cell-specific transcriptional element of CD2, CD3c, LCK, or a functional variant thereof.Leydig 775537Vyriad P-63-00656

[0317] 91. The retroviral transfer vector of any one of aspects 81-90, wherein the producer cell is a HEK293 cell or a derivative of a HEK293 cell.

[0318] 92. The retroviral transfer vector of any one of aspects 81-91, wherein the transgene is expressed following transduction of a target cell and not expressed in a producer cell.

[0319] 93. The retroviral transfer vector of aspect 88, wherein the T cell-specific promoter is a portion of the distal Lek (dLck) promoter comprising a nucleotide sequence that has at least 80% sequence identity with SEQ ID NO: 3.

[0320] 94. The retroviral transfer vector of any one of aspects 81-93, wherein the one or more regulatory elements comprise a promoter comprising the nucleotide sequence of SEQ ID NO: 3, 30, 31, 32, 33, or 34.

[0321] 95. The retroviral transfer vector of aspect 88, 93, or 94, wherein the promoter comprises a modification that increases T cell specific transcriptional activity.

[0322] 96. The retroviral transfer vector of aspect 95, wherein the modification comprises an addition of splicing signals, insertion of a TATA box, insertion of an octamer motif, insertion of a consensus cap site sequence, deletion or replacement of endogenous putative promoter response elements (PRE) elements, endogenous transcription initiation sites, or any combination thereof.

[0323] 97. The retroviral transfer vector of aspect 86, wherein the CAR comprises an antigen binding domain that has antigenic specificity for B Cell Maturation Antigen (BCMA), CD22, CD20, or CD19.

[0324] 98. The retroviral transfer vector of aspect 97, wherein the antigen binding domain comprises a variable heavv domain of heavy chain (VHH) antibody comprising the amino acid sequence of SEQ ID NO: 1.

[0325] 99. The retroviral transfer vector of any one of aspects 81-98, comprising a CAR nucleotide construct comprising:(a) a nucleotide sequence encoding a signal peptide comprising an amino acid sequence of a CD8a signal peptide comprising the amino acid sequence of SEQ ID NO: 5, (b) a nucleotide sequence encoding an antigen binding domain comprising an amino acid sequence of a BCMA-targeting VHH antibody comprising the amino acid sequence of SEQ ID NO: 1,(c) a nucleotide sequence encoding a hinge domain comprising an amino acid sequence of a CD28 hinge domain comprising the amino acid sequence of SEQ ID NO: 7,Leydig 775537Vyriad P-63-00657(d) a nucleotide sequence encoding a transmembrane domain comprising an amino acid sequence of a CD28 transmembrane domain comprising the amino acid sequence of SEQ ID NO: 17,(e) a nucleotide sequence encoding an intracellular signaling domain comprising an amino acid sequence of a costimulatory domain 4- IBB comprising the amino acid sequence of SEQ ID NO: 9, and(f) a nucleotide sequence encoding an activating domain comprising an amino acid sequence of a CD3 zeta activating domain comprising the amino acid sequence of SEQ ID NO: 11 or SEQ ID NO: 20.

[0326] 100. The retroviral transfer vector of any one of aspects 81-99, comprising, in a 5’ to 3’ orientation:(a) a chimeric 5’ long terminal repeat (5’LTR) comprising enhancer and promoter nucleotide sequences in place of endogenous U3 enhancer and promoter sequences, positioned directly upstream of a 5’ R - U5 region;(b) a Psi viral packaging signal nucleotide sequence:(c) a Rev response element (RRE) nucleotide sequence;(d) an expression cassette positioned in reverse orientation relative to the transcriptional direction of the transfer vector, the cassette comprising:i. a tissue specific regulatory element, andii. a chimeric antigen receptor (CAR) transgene nucleotide sequence; (e) optionally a woodchuck hepatitis virus post-transcriptional regulatory element (WPRE) nucleotide sequence or a functional variant thereof;(1) a 3’ long terminal repeat (3’LTR) comprising a self-inactivating (SIN) U3 region; and(g) optionally an SV40 polyadenylation (pA) signal nucleotide sequence.

[0327] 101. The retroviral transfer vector of aspect 100, wherein the expression cassette comprises iii. a polyadenylation (pA) signal nucleotide sequence.

[0328] 102. The retroviral transfer vector of aspect 101, wherein the pA is a bGH polyadenylation signal nucleotide sequence, and wherein i, ii, and iii are operably linked.

[0329] 103. The retroviral transfer vector of any one of aspects 100-102, wherein the enhancer and promoter nucleotide sequences of the chimeric 5‘ LTR are of Rous sarcoma virus (RSV) or CMV.Leydig 775537Vyriad P-63-00658

[0330] 104. The retroviral transfer vector of any one of aspects 100-103. wherein the transfer vector comprises the WPRE nucleotide sequence or functional variant thereof.

[0331] 105. The retroviral transfer vector of aspect 104, wherein the WPRE nucleotide sequence or functional variant thereof comprises a nucleotide sequence that has at least 80% sequence identity with SEQ ID NO: 26

[0332] 106. The retroviral transfer vector of any one of aspects 100-105, wherein the transfer vector comprises the SV40 polyadenylation (pA) signal nucleotide sequence.

[0333] 107. The retroviral transfer vector of aspect 100-106, wherein the 5’LTRenhancer comprises SEQ ID NO: 21, the 5'LTR promoter nucleotide sequence comprises SEQ ID NO: 22, the 5’ R - U5 region comprises SEQ ID NO: 23; the Psi viral packaging signal nucleotide sequence comprises SEQ ID NO: 24; the RRE nucleotide sequence comprises SEQ ID NO: 25; the CAR transgene nucleotide sequence has antigenic specificity for B Cell Maturation Antigen (BCMA), the tissue specific regulatory element comprises two regulatory elements comprising a distal Lek promoter nucleotide sequence and an enhancer nucleotide sequence; the bGH polyadenylation (pA) signal nucleotide sequence comprises SEQ ID NO: 43; the 3’LTR comprising the SIN U3 region comprises SEQ ID NO: 28; and the SV40 pA signal nucleotide sequence comprises SEQ ID NO: 27.

[0334] 108. The retroviral transfer vector of aspect 107, wherein the BCMA CAR transgene nucleotide sequence comprises SEQ ID NO: 42.

[0335] 109. The retroviral transfer vector of aspect 107 or 108, wherein the enhancer nucleotide sequence comprises SEQ ID NO: 44 or SEQ ID NO: 4.

[0336] 110. The retroviral transfer vector of any one of aspects 107-109, wherein the WPRE nucleotide sequence or functional variant thereof comprises SEQ ID NO: 26 or SEQ ID NO: 58.

[0337] 111. The retroviral transfer vector of any one of aspects 107-110, wherein the distal Lek promoter nucleotide sequence comprises SEQ ID NO: 3.

[0338] 112. The retroviral transfer vector of any one of aspects 107-110. wherein the distal Lek promoter nucleotide sequence comprises SEQ ID NO: 30.

[0339] 113. The retroviral transfer vector of any one of aspects 107-110, wherein the distal Lek promoter nucleotide sequence comprises SEQ ID NO: 31.

[0340] 114. The retroviral transfer vector of any one of aspects 107-110, wherein the distal Lek promoter nucleotide sequence comprises SEQ ID NO: 32.Leydig 775537Vyriad P-63-00659

[0341] 115. The retroviral transfer vector of any one of aspects 107-110. wherein the distal Lek promoter nucleotide sequence comprises SEQ ID NO: 33.

[0342] 116. The retroviral transfer vector of any one of aspects 107-110, wherein the distal Lek promoter nucleotide sequence comprises SEQ ID NO: 34.

[0343] 117. The retroviral transfer vector of any one of aspects 82-116, wherein (a) the expression of the transgene in the producer cell and a lentiviral particle (LVP) produced by the producer cell is reduced or ablated compared to expression of the transgene in the target cell, or(b) wherein the expression of the transgene is increased in the target cell compared to the producer cell, or(c) wherein packaging efficiency of a transcript payload is improved in lentiviral particles produced by the producer cell compared to lentiviral particles produced by a producer cell wherein the expression cassette is in a forward orientation.

[0344] 118. A retroviral transfer vector of any one of aspects 82-117, wherein the retroviral transfer vector is of a lentiviral vector.

[0345] 119. A pharmaceutical composition of aspect 64 for use in treating a hematological malignancy in a subject.

[0346] 120. The pharmaceutical composition of aspect 119, wherein the hematological malignancy is multiple myeloma.

[0347] 121. A pharmaceutical composition of aspect 64 for use in treating systemic lupus ery thematosus (SLE) in a subject.

[0348] 122. A pharmaceutical composition of aspect 64 for use in treating a B Cell Maturation Antigen (BCMA)-expressing tumor in a subject.

[0349] It shall be noted that the preceding are merely examples of aspects of the disclosure. Other exemplary aspects are apparent from the entirety of the description herein. It is understood by one of ordinary skill in the art that each of these aspects may be used in various combinations with the other aspects provided herein.

[0350] The following examples further illustrate aspects of the disclosure, but, of course, should not be construed as in any way limiting its scope.EXAMPLE 1

[0351] This example demonstrates that lentiviral particles (LVPs) produced using a transfer vector with an expression cassette comprising a transgene and cell specific regulatoryLeydig 775537Vyriad P-63-00660elements in a reverse orientation to the transfer vector have reduced or ablated expression of the transgene compared to LVPs produced using a transfer vector with an expression cassette comprising a transgene and universal regulatory elements in a forward orientation to the transfer vector.

[0352] During production of lentiviral particles (LVPs) containing a transgene payload, expression of transgene so as to turn on transcription only in target cells and not in the producer cells or the LVPs is desired. During LVP production, expression of transgene in producer cells can cause cell cytotoxicity and affect the health of the producer cells leading to lower titers and inefficient production of properly packaged LVPs. Expression of transgenes such as CAR on LVPs can be detrimental as it can cause off target transduction of the CAR pay load to the tumor cell expressing the antigen of interest. As FIG. 15 A illustrates, one challenge when producing LVPs containing a transgene payload arises from the use of universal promoters that tend to be strong and drive constitutive transgene payload expression at high level on the LVPs. To overcome such high transgene expressions in LVPs, one strategy is to use cell-specific or tissue-specific regulatory elements such as promoters that will not be active in producer cells. However, even with the use of specific regulatory elements it is possible that the promoter from the 5 ’ LTR of the transfer vector can drive transgene expression in the producer cells thus leading to leaky expression of the transgene at low levels on the LVPs (FIG. 15 A). The present application discloses a retroviral transfer vector for use in a retroviral vector expression system that can overcome both constitutive and leaky expression of the transgene in the producer cells and LVPs. The present application discloses retroviral transfer vectors with an expression cassette in reverse orientation to the transcriptional direction of the transfer vector with SIN 3 ’LTR. wherein the expression cassette contains a transgene payload with cell-specific or tissue-specific regulatory elements to drive the transgene payload expression (FIG. 15B).

[0353] The Lek gene encodes a lymphocyte-specific sre family tyrosine kinase which is transcribed from two developmentally regulated, independently functioning promoters. Both Lek promoters lack a TATAA element and they share little sequence similarity with each other. The proximal promoter is known to be used in thymocytes, but not in peripheral T lymphocytes. The distal promoter is known to operate in all stages of T cell development but predominates in more mature cells. To target expression of transgene in T cells, the distal Lek promoter was chosen for use in these studies. FIG. 16 shows the position of distal Lek (dLck) promoter relative to the proximal (pLck) promoter in the endogenous Lek promoter locus andLeydig 775537Vyriad P-63-00661the relative length and position of the short version of dLck promoter in relation to the endogenous long dLck promoter in the transfer vector design.

[0354] To examine the transcriptional activity of the dLck promoter, a T cell specific promoter, to drive the transcription of a BCMA binder (SEQ ID NO: 1) disclosed as SEQ ID NO: 25 in International Patent Publication WO 2024 / 097979 Al in a CAR transgene, plasmids containing EFla promoter and dLck promoter were packaged in LVPs pseudotyped with VSIV-G-WT using a second generation lentiviral system. To determine if the placement of an expression cassette in reverse orientation would prevent premature transgene expression in producer cells and LVPs, plasmid constructs for transfer vectors were designed with an expression cassette containing BCMA-CAR transgene (SEQ ID NO: 1) and its transcriptional regulatory elements placed in reverse orientation to the transfer vector (FIG. 1 and FIGS. 2A-2L). Transfer vectors used as a control were designed with an expression cassette of BCMA-CAR with EFl promoter in the same orientation as the transcriptional direction of the transfer vector.

[0355] LVPs containing plasmid constructs were produced in producer cells (HEK-293T) and harvested to evaluate transgene expression on surface of LVPs using western blot (FIG.2N). LVPs were harvested and normalized to 5x107LVP per well as calculated using p24. Membranes were blotted with specific antibodies to CD3^ or p24.

[0356] These results showed that while LVPs produced using a transfer vector with an expression cassette comprising a transgene and a universal promoter in a forward orientation to the transfer vector showed premature expression of the transgene on the LVP, LVPs produced using a transfer vector with an expression cassette comprising a transgene and cell specific regulatory elements in a reverse orientation to the transfer vector have reduced or ablated expression of the transgene (FIG. 2N-2O). These results suggest that the use of transfer vectors with expression cassettes in reverse orientation and with specific regulatory elements can produce better targeted and more efficiently packaged LVPs.EXAMPLE 2

[0357] This example demonstrates that LVPs pseudotyped with 1:3 ratio of a recombinant protein of anti-CD3 scFv UCHT1 comprising a VH of SEQ ID NO: 70 and a VL of SEQ ID NO: 71 fused N terminal to VSIV-G with a deletion at residue K47(SEQ ID NO: 13) (UCHTl-VSIV-G-dK47) to VSIV-G-dK47 (SEQ ID NO: 13) containing a BCMA-CAR transgene can successfully transduce T cells ex vivo.Leydig 775537Vyriad P-63-00662

[0358] To test the efficacy of different BCMAs in a CAR constructs were designed as shown in FIG. 3A. LVPs pseudotyped with VSIV-G-WT (SEQ ID NO: 72) or a 1:3 ratio of UCHTl-VSIV-G-dK47 (SEQ ID NOS: 70, 71, and 13) to VSIV-G-dK47 (SEQ ID NO: 13) and containing a BCMA3-CAR or BCMA1-CAR transgene were produced in producer cells (HEK-293T) and harvested.

[0359] To test the efficacy of the LVPs for use in CAR-T experiments were carried out as shown in FIG. 3B. Frozen human PBMC from healthy volunteers were thawed in media w ith the cytokine interleukin 2 (IL-2) for T cell maintenance overnight. The PBMCs were then transduced with LVPs pseudotyped with VSIV-G-WT (SEQ ID NO: 72) or a 1:3 ratio of UCHTl-VSIV-G-dK47 to VSIV-G-dK47 and containing a BCMA3-CAR or BCMA1-CAR transgene at a concentration of 1000 LVPs / cell or 500 LVPs / cell. 7 days post infection the PBMCs underwent How analysis for CD3 vs. GFP (FIG. 3C) and for BCMA vs. GFP (FIG 3D) and the results were quantified.

[0360] The results of the flow analysis showed that the cells transduced with LVPs containing BCMA-CAR transgene had increased GFP+ and CD3+ cells compared to mock controls and showed that the LVPs can transduce CD4 and CD8 T cells in PBMC ex vivo even at lower LVP per cells of 500.EXAMPLE 3

[0361] This example demonstrates that LVPs pseudotyped with 1:3 ratio of a UCHT1-VSIV-G-dK47 (SEQ ID NOS: 70. 71, and 13) to VSIV-G-dK47 (SEQ ID NO: 13) containing a BCMA-CAR transgene can successfully transduce T cells in vivo and generate CAR-T cells capable of reducing tumor burden.

[0362] To test the efficacy of LVPs pseudotyped with 1:3 ratio of a UCHT1-VSIV-G-dK47 (SEQ ID NOS: 70, 71. and 13) to VSIV-G-dK47 (SEQ ID NO: 13) containing a BCMA-CAR transgene to generate CAR-T cells in vivo, NSG MHC I / II DKO mice from Jackson Labs were intravenously implanted with OPM-2 cells (human multiple myeloma) expressing firefly luciferase (Flue). NSG MHC I / II DKO mice combine the features of the severe combined immune deficiency mutation (scid), IL2 receptor gamma chain deficiency, MHC class I molecule deficiency (H2-K and D), MHC class II molecule deficiency (IA), and exhibit a significant delay in the onset of graft versus host disease (GVHD).

[0363] Four groups of mice w ere prepared receiving either a saline injection (Group 1) or an injection of LVPs pseudoty ped with VSIV-G-WT (SEQ ID NO: 72) and containing aLeydig 775537Vyriad P-63-00663BCMA3-CAR transgene (Group 2), LVPs pseudotyped with a 1:3 ratio of UCHT1-VSIV-G-dK47 (SEQ ID NOS: 70, 71, and 13) to VSIV-G-dK47 (SEQ ID NO: 13) and containing a BCMA3-CAR transgene (Group 3), or LVPs containing a BCMA1-CAR transgene (Group 4) as shown in FIG. 4 A.

[0364] NSG MHC I / II DKO mice were implanted with a tumor by IV injection of 1E6 OPM-2 cells expressing (Flue) in the tail vein. Mice were humanized by injection of 1E7 human PBMCs via IP injection on day 13 post tumor implantation. 8 days after PBMC injection mice were infected with LVPs as shown in Table 1. Mice underwent clinical observation for any moribund signs, weekly IVIS imaging, body weight was monitored, blood was collected in EDTA tubes for flow cytometry, tissue was collected at day 15 and day 29 from corresponding groups.Table 1

[0365] A random mouse BLI assay showed that the injection was 95% accurate (FIG. 4B), using a protocol adapted from Lin et al. (“IFN-y-dependent NK cell activation isLeydig 775537Vyriad P-63-00664essential to metastasis suppression by engineered Salmonella / ’ NATURE COMMUNICATIONS, 12: 2537 (2021)).

[0366] Samples of blood, bone marrow, and spleen underwent flow cytometry analysis as shown in FIG. 4C using combinations of the cell markers shown in Table 2. The flow cytometry was quantified as flow cytometry dot plots for samples taken 15 days after LVP treatment showing intensity of forward scatter height (FSC-H) vs. side scatter height (SSC-H), FSC-H vs. forward scatter area (FSC-A), and FSC-H vs. LD780, a dye for cell viability (FIG. 5A), mouse CD45 (mCD45) vs. human CD45 (hCD45), mCD45 vs. human CD3 (hCD3), and human CD8 (hCD8) vs. human CD4 (hCD4) (FIG. 5B). Further flow cytometry analysis is shown of flow cytometry dot plots showing intensity of GFP vs. CD3 in blood (FIG. 5C), bone marrow (FIG. 5D), and spleen (FIG. 5E) cells. These results demonstrate successful in vivo generation of CAR T cells in blood, bone marrow and spleen (GFP+ CD3+) by LVPs pseudotyped with a 1:3 ratio of UCHTl-VSIV-G-dK47 to VSIV-G-dK47 and containing a BCMA-CAR transgene, but not by LVPs pseudotyped with VSIV-G-WT. Additional flow cytometry analysis was performed showing intensity of GFP vs. CD3 in blood (FIG. 6A), bone marrow (FIG. 6B), and spleen (FIG. 6C) cells of OPM2-Fluc injected mice 29 days after LVP injection. These results showed a detectable but reduced presence of CAR T cells after 29 days. Further flow cytometry’ analysis was showing intensity of GFP vs. TIM3, an exhaustion marker, GFP vs. CD39, and GFP vs. PD1 in human CD4+ cells, human TCR5 / y+ cells, and human CD8+ cells from the spleen of OPM2-Fluc injected mice 15 days after injection with saline (FIG. 7A), LVPs pseudotyped with VSIV-G-WT containing BCMA3-CAR (FIG. 7B), or LVPs pseudotyped with a 1:3 ratio of UCHTl-VSIV-G-dK47 to VSIV-G-dK47 containing BCMA3- CAR (FIG. 7C) or BCMA1-CAR (FIG. 7D). This data was quantified in a bar graph showing the percentage of GFP+ / CD8+ and GFP+ / CD4+ cells of OPM2-Fluc injected mice 15 days after injection with saline or LVPs pseudotyped with VSIV-G-WT containing BCMA3-CAR or LVPs pseudotyped with a 1:3 ratio of UCHT1-VSIV-G-dK47 to VSIV-G-dK47 containing BCMA1-CAR or BCMA3-CAR (FIG. 7E). These results showed CD8+ T cell express higher GFP+CAR T cells than CD4+ T cells, but both CD4+ and CD8+ CAR T cell express high Tim3, an activation / exhaustion market for T cells.Leydig 775537Vyriad P-63-00665Table 2. T cell phenotype and functional markers for flow cytometry

[0367] IVIS imaging was performed on NSG-MHC I / II DKO mice 1 day before (-1) being injected with OPM2-Fluc and 7, 14, 21. 28, 35, 42, and 49 after OPM2-Fluc injection and injected with saline (Group 1), 1E6 TU LVP pseudotyped with VSIV-G-WT containing BCMA3-CAR (Group 2), 1E6 TU LVP pseudotyped with a 1:3 ratio of UCHT1-VSIV-G-dK47 to VSIV-G-dK47 containing BCMA3-CAR (Group 3), 1E6 TU (Group 4) or 5E5 TU (Group 5) LVP pseudotyped with a 1:3 ratio of UCHTl-VSIV-G-dK47 to VSIV-G-dK47 containing BCMA1-CAR, or 5E5 TU (Group 6), 1.5E5 TU (Group 7), or 1E4 TU (Group 8) LVP pseudotyped with PD-UCHTl-VSIV-G-dK47 containing BCMA1-CAR (FIGS. 8A-8C). These results showed that while Group 2 mice and mouse #70 from Group 8 did have PBMCs they did not generate CAR-T cells, while the mice from Groups 3, 4, 5, 6, 7. and 8 (except mouse #70) did generate CAR-T cells and reduced or eliminated tumors.

[0368] The number of hCD45+ (FIG. 9A) and CD3+GFP+ (FIG. 9B) cells per pL of blood at 15, 22, 29, and 36 days post treatment with saline (Group 1), 1E6 TU LVP pseudotyped with VSIV-G-WT containing BCMA3-CAR (Group 2), 1E6 TU LVP pseudotyped with a 1:3 ratio of UCHTl-VSIV-G-dK47 to VSIV-G-dK47 containingLeydig 775537Vyriad P-63-00666BCMA3-CAR (Group 3), 1E6 TU (Group 4) or 5E5 TU (Group 5) LVP pseudotyped with a 1:3 ratio of UCHTl-VSIV-G-dK47 to VSIV-G-dK47 containing BCMA1-CAR, or 5E5 TU (Group 6), 1.5E5 TU (Group 7), or 1E4 TU (Group 8) LVP pseudotyped with PD-UCHT1-VSIV-G-dK47 containing BCMA1-CAR was also quantified (FIGS. 9A-9B).

[0369] These results showed that based on the presence of PBMC, CAR T cells and BLI assay result the most effective minimum dose for this study was 5E5 for the group 6 BCMA1 where all the mice survived 5E5 TU / mouse. These results also showed that BCMA CAR T cell number significantly increase with high tumor burden and decreased when mice were free from tumor cells. This suggests that BCMA CAR T cells remained longer in the blood in the low doses of LVP treated group to ensure the clearance of tumor from mice. These results also showed that blood CAR T cells start depleting earlier than spleen and bone marrow after elimination of OPM-2 cells.EXAMPLE 4

[0370] This example demonstrates that LVPs pseudotyped with 1:3 ratio of a UCHT1-VSIV-G-dK47 (SEQ ID NOS: 70, 71, and 13) to VSIV-G-dK47 (SEQ ID NO: 13) containing a BCMA-CAR transgene can successfully transduce T cells in vivo and generate CAR-T cells capable of reducing tumor burden even in a relapse model.

[0371] BCMA CAR T-cell therapy has demonstrated impressive overall response rates, ranging from 73% to 100% in clinical trials. Despite these encouraging results, a subset of patients experience relapse or disease progression, with some studies suggesting that up to 30-60% of patients could relapse. So to further investigate the early immunological changes cured mice were rechallenged with OPM-2 tumor, which mimics a relapse tumor.

[0372] OPM-2 Flue injected NSG MHC I / II DKO mice were prepared as in Example 3. Five groups of mice were prepared receiving either a saline injection (Group 1) or an injection of LVPs pseudotyped a 1:3 ratio of UCHTl-VSIV-G-dK47 (SEQ ID NOS: 70. 71. and 13) to VSIV-G-dK47 (SEQ ID NO: 13) and containing a BCMA33-CAR transgene (Group 2), BCMA03-CAR transgene (Group 3), BCMA1-CAR transgene (Group 4), or BCMA2-CAR transgene (Group 5) as shown in FIG. 10A.

[0373] IVIS imaging of NSG-MHC I / II DKO mice injected with OPM2-Fluc before being rechallenged at 56 days after LVP injection, 2 hours after being rechallenged at 68 days after LVP injection, and 21 days after being rechallenged at day 89 after injection with the LVPs containing BCMA33, BCMA003, BCMA022, or BCMA2 constructs was performedLeydig 775537Vyriad P-63-00667(FIG. 10B). These results showed the clearance of tumor cells upon rechallenge by Day 21 post rechallenge in groups 2-5, which suggests a robust memory response by CAR T cells.

[0374] A human IFNg ELISPOT assay was performed on the splenocytes of mice after the end of the rechallenging study and showed rechallenged CAR T cells are functional and can produce cytotoxic cytokines such as IFNg (FIGS. 10C-10E).

[0375] These results show that BCMA CAR LVP treated mice effectively eliminate rechallenged OPM-2 tumor, which mimics as relapse tumor, and keeps mice tumor free until the end of the experiment, 42 days after OPM-2 rechallenge and a total 110 days after LVP treatments. This results also show that most BCMA-CAR LVP mice retain IFNg producing memory cells 42 days after OPM-2 rechallenge as measured by IFNg ELISPOT assay.

[0376] To further study the efficacy of the BCMA containing LVPs at generating CAR-T cells in vivo and reducing tumor burden additional experiments were performed as shown in FIG. 11A.

[0377] OPM-2 Flue injected NSG MHC I / II DKO mice were prepared as in Example 3. Four groups of mice were prepared receiving either a saline injection (Group 1) or an injection of LVPs pseudotyped a 1:3 ratio of UCHTl-VSIV-G-dK47 to VSIV-G-dK47 and containing a BCMA33-CAR transgene that were not rechallenged with OPM-2 (Group 4), or were rechallenged with 1E6 OPM-2 tumor cells at day 56 (Groups 5 and 6) as shown in FIG.11A. 3 days after rechallenge, one mouse from group 1, 2 mice from group 4, and three mice from group 6 were sacrificed and blood, bone marrow, and spleen samples w ere collected. 7 days after rechallenge, one mouse from group 1, 2 mice from group 4, and three mice from group 6 were sacrificed and blood, bone marrow and spleen samples were collected.

[0378] IVIS imaging was performed on NSG-MHC I / II DKO mice injected with OPM2-Fluc before being rechallenged, 2 hours after being rechallenged at 56 days after LVP injection, and 7 days after being rechallenged at day 63 after LVP injection with the LVPs containing BCMA1 CAR constructs (FIG. 11B). The clearance of tumor cells upon rechallenge by Day 7 post rechallenge indicates a robust memory response by CAR T cells.

[0379] Samples of blood, bone marrow, and spleen underwent flow cytometry analysis as shown in FIG. 4C using combinations of the cell markers shown in Table 2 and Table 3.Leydig 775537Vyriad P-63-00668Table 3. Extracellular Cell Markers and Intracellular Transcription Factor Staining

[0380] The flow cytometry was quantified as flow cytometry dot plots showing intensity of GFP vs. CD3 in blood (FIG. 12A), bone marrow (FIG. 12B), and spleen (FIG. 12C) cells from OPM2-Fluc injected mice 59 days after injection with saline or LVP containing BCMA1-CAR and cells from OPM2-Fluc injected mice 3 days after rechallenge with OPM2 and 59 days after injection with LVP containing BCMA1-CAR. These results showed a lower percent of rechallenged CAR-T cells as measured as GFP+ and CD3+ cells at day 3 after rechallenge. The same flow cytometry analysis of GFP vs. CD3 was performed in blood (FIG. 13A), bone marrow (FIG. 13B), and spleen (FIG. 13C) cells from OPM2-Fluc injected mice 63 days after injection with saline or LVP containing BCMA1-CAR and cells from OPM2-Fluc injected mice 7 days after rechallenge with OPM2 and 63 days after injection with LVP containing BCMA1-CAR. These results also showed a lower percent of rechallenged CAR-T cells at day 7 after rechallenge in mice previously injected with 5E5 LVPs containing BCMA1-CAR compared to no rechallenge in mice previously injected with 1E6 LVPs containing BCMA1-CAR. This suggests that lower number of LVPs treated mice generated lower frequency of CAR T cells..Leydig 775537Vyriad P-63-00669

[0381] Further flow cytometry analysis was performed showing intensity of CD3 vs. CD39 in bone marrow cells from OPM2-Fluc injected mice that are injected with saline or LVP containing BCMA1-CAR at 15 days post LVP injection (FIG. 14A) and at 59 and 63 days post LVP injection (FIG. 14B) for mice that were not rechallenged or rechallenged with OPM2 at day 56 post LVP injection. These results showed rechallenged CAR-T cells expressed exhaustion related marked CD39. Previous studies have shown that CD39 plays an important role in balancing immune activation and suppression in cancer immunology, that CD39 is expressed on T regulatory cells (Treg), which can suppress the activity of other immune cells, and that CD39 is involved in attenuating inflammatory responses through the conversion of ATP to adenosine (Xu et al., ' CD39 transforming cancer therapy by modulating tumor microenvironment,” Cancer Letters 597: 217072 (2024)).

[0382] Additional flow cytometry analysis was performed showing intensity of CD3 vs. PD1 in bone marrow cells from OPM2-Fluc injected mice that are injected with saline or LVP containing BCMA1-CAR at 15 days post LVP injection (FIG. 14C) and at 59 and 63 days post LVP injection (FIG. 14D) for mice that were not rechallenged or rechallenged with OPM2 at day 56 post LVP injection. These results showed rechallenged CAR-T cells expressed exhaustion related marked PD-1. Programmed cell death protein 1 (PD-1) is a known immune checkpoint molecule that plays a role in regulating immune responses.

[0383] In summary these results demonstrate that in vivo generated BCMA CAR T cell successfully cleared BCMA+ OPM-2 tumor. These results also show CAR-T cell generation was detected at 15 days post LVP treatment. BCMA CAR T cells increased in the presence of OPM-2 tumor and declined in the absence of tumor with successfully generated memory cells. These memory CAR T cells eliminated rechallenged OPM-2 tumor suggesting BCMA CAR T cells maintain IFNg producing memory cell pool to protect future relapse of same tumor. Additionally, these data showed minimal or almost no treatment associated toxicities in this OPM-2-NSG-DKO mouse tumor model.EXAMPLE 5

[0384] This example demonstrates that lentiviral particles (LVPs) produced using a transfer vector with an expression cassette comprising a transgene and cell specific regulatory elements in a reverse orientation to the transfer vector have reduced or ablated expression of the transgene compared to LVPs produced using a transfer vector with an expression cassetteLeydig 775537Vyriad P-63-00670comprising a transgene and universal regulatory elements in a forward orientation to the transfer vector.

[0385] To examine the transcriptional activity of dLck promoter with or without mCMV enhancer to drive the transcription of CAR transgene (CD19-CAR eGFP), plasmids containing mCMV enhancer (SEQ ID NO: 4) and EFla promoter (SEQ ID NO: 29, mCMV enhancer and dLck promoter, or dLck promoter alone were packaged in LVPs pseudotyped with VSIV-G-WT (SEQ ID NO: 72) using a second generation lentiviral system. CAR transgene incorporation into lentiviral particles is known to occur when packaging cells express CAR transgene. To determine if the placement of an expression cassette in reverse orientation would prevent premature transgene expression in producer cells and LVPs, plasmid constructs for transfer vectors were designed with an expression cassette containing CD19-CAR (SEQ ID NO: 55) eGFP and its transcriptional regulatory elements placed in reverse orientation to the transfer vector. Transfer vectors used as a control were designed with an expression cassette of CD19-CAR eGFP with mCMV enhancer and EFla promoter in same orientation as the transcriptional direction of the transfer vector (FIG. 17A).

[0386] LVPs containing plasmid constructs were produced in producer cells (HEK-293T) and harvested to evaluate transgene expression on surface of LVPs using western blot (FIG.17C). The day before transfection HEK-293T cells were plated in 10% FBS-DMEM on a 150 mm culture dish. The following day, cells were transfected with a mixture containing transfer plasmid and packaging helper plasmids. Transfection mixture contained two to three helper plasmids and one transfer plasmid; (1) a packaging plasmid containing HIV Gag / Rev / Pol elements, (2) VSIV-G envelope, and (3) transfer plasmid with expression cassette containing transgene under its specific transcriptional regulatory elements (mCMV enhancer and EFla promoter, mCMV enhancer and dLck promoter, or dLck promoter alone). A total of 15 µg of DNA was added per plate, containing a mixture of transfection reagent PEIPro (GenClone, cat no 55-311) and serum-free Opti-MEM I media according to manufacturer instructions. The media was replaced 16-20 hours after transfection with 15 mL of Opti-MEM I.Supernatant was collected 48-72 hours post-transfection, clarified from cell debris, filtered through a 0.45 pm filter, and concentrated 20-100x of original volume by PEG or high-speed centrifugation (4 hours at 12,000xg, 4°C). PBMC and lentiviral particles were lysed with RIPA lysis buffer (Thermo Scientific cat no J63306. AP) containing protease cocktail (Sigma Aldrich cat no Pl 860). For cell lysates analysis samples were loaded on gel as 5 pg of protein and for LV prep analysis the lysates from 5E+7 LVP particles per sample were used. SamplesLeydig 775537Vyriad P-63-00671were separated by NuPAGE 4 to 12%, Bis-Tris Gels (Thermo Scientific cat no NP0336BOX) and transferred to a PVDF membrane by iBlot 3 transfer system (Thermo Scientific).Membranes were blotted with specific antibodies to CD3(^ (BD Biosciences cat no 51-6527GR), p24 (Sino Biological cat no 11695-R002), or GAPDH (Millipore Sigma cat no G8795) and appropriate secondary antibodies conjugated with HRP. Membranes were developed with ECL substrate (Clarity7Western ECL Cat No 1705061) and signals were recorded by ChemiDoc MP (Bio-Rad) (FIGS. 17C-17D).

[0387] Harvested LVPs were used to transduce PMBCs and 6 days post-transduction and expression of GFP and CD3 was examined using flow cytometry (FIG. 17B). While transduction frequencies were similar between the samples, the density of CAR on the cell surface (GFP MFI) was significantly higher when CAR transgene was expressed under EFla. Moreover, the density of CAR transgene expressed under mCMV enhancer and dLck promoter was higher than in PBMCs transduced with LVPs containing control dLck promoter alone (FIG. 17B). This suggests that adding the mCMV enhancer to the dLck promoter increased dLck promoter transcriptional activity and CAR surface density on target cells. Figure 17C shows the absence of CAR transgene (anti-CD3^ staining) on the surface of LVPs packaged with plasmids containing the expression cassette with mCMV enhancer and dLck promoter, or dLck promoter alone in reverse orientation relative to the 5' LTR of the transfer vector. While surface transgene expression is detected in LVPs packaged with control plasmid containing expression cassette with mCMV enhancer and constitutive EFla promoter positioned in forward orientation relative to the 5‘ LTR of the transfer vector.

[0388] To further examine transcriptional activity in T cells by dLck promoter with or without mCMV enhancer placed in reverse orientation relative to 5’ LTR of transfer vector, LVPs containing CAR transgene (CD19-CAR eGFP) driven by mCMV enhancer and EFl a promoter, mCMV enhancer and dLck promoter, or dLck promoter alone w ere used to transduce PBMC cells. 72 hours after transduction, cell lysates were prepared from PBMCs and expression of CAR transgene was examined using western blot with an anti-CD3ij antibody and an anti-GAPDH antibody as a control. Western blot shows the presence of CAR transgene (anti-CD3Q in all samples that were transduced with LVPs containing CAR transgene indicating generation of CAR T cells by LVPs containing dLck promoter in reverse direction (FIG. 17D). These results suggest that although premature expression of CAR transgene is prevented in producer cells and LVPs, the expression cassette containing dLckLeydig 775537Vyriad P-63-00672promoter and transgene is transduced and activated in target cells and retains transcriptional activity in T cells even when oriented in reverse orientation in a transfer vector.EXAMPLE 6

[0389] This example demonstrates transcriptional activity' and targeting specificity by LVPs containing modified distal Lek promoters driving BCMA CAR transgene, pseudotyped with VSV-G WT.

[0390] To increase targeting specificity and transcriptional activity of distal Lek promoter, several modifications comprising addition or deletion of splicing signals, introduction of additional exogenous cis-regulatory elements, removal of endogenous promoter regulatory elements, or any combination thereof were made. To examine if splicing activity would enhance gene transcription, in Lck_l, a splice acceptor site was introduced in between the 3’ end of the intron and the first five nucleotides of the coding exon because of an endogenous splice donor in the 3’ end of exon (FIG. 18 A). Additionally, in Lck_2, the intron with its associated splicing signal was deleted resulting in the non-coding exon being directly upstream of the first coding exon similarly to splicing activity (FIG. 18A).

[0391] To determine if additional exogenous cis-regulatory elements would enhance transcriptional activity of distal Lek promoter, in Lck_3, similar to Lck_2, the intron with its associated splicing signal was cleaved; additionally, a TATA box and an octamer motif were introduced directly upstream of the putative promoter responsive element (PRE) of the distal Lek promoter (FIG. 18B). Furthermore, to determine if replacement of endogenous promoter regulatory elements with exogenous cis-regulatory elements would enhance distal Lek promoter transcription activity, in Lck4, like Lck_ 2, intron with its associated splicing signal was removed; additionally the endogenous PRE and the transcription initiation site was replaced with the addition of a TATA box, an octamer motif and a consensus cap site sequence, 5’ PyPyCAPyPyPyPyPy-3’ (FIG. I8B).

[0392] To determine if in the presence of splicing activity' with the addition of exogenous cis-regulatory elements or replacement of endogenous promoter regulatory elements with exogenous cis-regulatory elements would enhance distal Lek promoter transcription activity, such modifications were made on Lek 1.3 and Lek 1.4. In Lek 1.3. similar to Lek 1. a splice acceptor site was introduced in between the intron and the first five nucleotides of the coding exon; additionally, a TATA box and an octamer motifs were added directly upstream of the putative PRE (FIG. 18C). In Lck_ 1.4, similar to Lck l, a splice acceptor site wasLeydig 775537Vyriad P-63-00673introduced in between the intron and the first five nucleotides of the coding exon; additionally, the endogenous PRE and the transcription initiation site was replaced by TATA box, octamer motif and a consensus cap site sequence, 5’ PyPyCAPyPyPyPyPy-3’ (FIG. 18C).

[0393] To examine if LVPs containing plasmid constructs with modified dLck promoters, as shown in Table 4, can be produced while preventing premature transgene expression on producer cells using second generation lentiviral expression system as described in Example 5, HEK293 producer cells were transfected with helper plasmid, envelope plasmid encoding VSIV-G-WT (SEQ ID NO: 72) protein and transfer vectors containing dLck promoters with modifications as listed in Table 4 and shown in FIGS. 19A-19B.Table 4

[0394] 72 hours post transfection, LVPs were harvested and subjected to western blot analysis for CAR expression on the surface of LVPs using anti-CD3^ antibody. FIG. 19C shows that only LVPs packaged with transfer vector containing mCMV enhancer and EFla promoter, had surface protein expression of CAR transgene indicating constitutive transcriptional activity by EFla in HEK293 cells. LVPs packaged with transfer vector containing modified dLck promoters in reverse orientation relative to 5’ LTR of transfer vector had undetectable CAR transgene expression, indicating dLck promoter was not active in HEK293 producer cells (FIG. I9C). Moreover, using anti-p24 antibody and anti-VSV-G antibody as controls, Figure 19C also shows that although CAR transgene was not prematurely expressed in LVPs containing modified Lek promoter in reverse orientation, the LVPs were able to successfully display similar levels of VSIV-G glycoprotein compared to LVPs containing EFla promoter in appropriate constructs. This western blot data suggests that reversing the expression cassette containing modified dLck promoter, relative to the 5’Leydig 775537Vyriad P-63-00674LTR of transfer vector, was able to prevent premature protein expression of transgene in produce cells and LVPs.

[0395] To test the transcriptional activity of modified Lek promoters and infectivity of the LVPs packaged w ith expression cassette containing modified dLck promoters, LVPs containing a BCMA CAR trans gene driven by a CMV enhancer with an EFla promoter in forward orientation relative to the transfer vector, or a BCMA CAR transgene driven by a CMV enhancer with modified Lek promoters (LCK 1, LCK 2, LCK 3, LCK 1.3, LCK 4, LCK_1.4) in reverse orientation relative to the transfer vector, pseudotyped with VSIV-G-WT (SEQ ID NO: 72). were used to transduce PBMCs.

[0396] Primary human T cells were activated and expanded from peripheral blood mononuclear cells (PBMC) by either CD3 / CD28 Dynabeads (Thermo Scientific, cat no 11131D) or CD3-targeted activation by LVP. For T cells that underwent activation by CD3 / CD28 beads, activation occurred 2 days prior to transduction. The PBMCs were maintained in 10% FBS-ATCC RPMI with 25 ng / mL of hIL-2. The amount of virus added was based upon either p24 MOI (LVP per cell) or TU MOI (transducing units per cell). When indicated, cells underw ent spin-infection by centrifuging the plate at 800xg for 90 minutes after adding virus. Culture media underwent 50% media replacement 4-16 hours posttransduction. After 3 days post infection, PBMCs were examined for recombinant BCMA expression using flow cytometry. FIG. 20 shows flow cytometry dot plots with expression of CD3 versus recombinant BCMA. The expression of BCMA-CAR was robust in all groups, PBMCs transduced with LVPs containing dLck_3 promoter, dLck_1.3 promoter, dLck_4 promoter, or dLck 1.4 promoter achieving transduction efficiency and GFP MFI comparable to PBMCs transduced with LVPs containing EF 1 a promoter. PBMCs treated with mock (no infection) used as negative control showed no expression of recBCMA. This suggests that LVPs packaged with expression cassettes containing modified dLck promoter in reverse orientation can infect PBMCs and induce targeted CAR transgene expression.

[0397] To further test the infectivity and transcriptional activity of the modified dLck promoters in the reverse oriented expression cassettes, LVPs were used to transduce Jurkat cells and PBMCs as shown in Table 5.Leydig 775537Vyriad P-63-00675Table 5

[0398] Jurkat cells and PBMCs were collected four days post infection and cell lysates made for western blot analysis (FIG. 21). CAR expression was examined using anti-CD3^ antibody while anti-GAPDH antibody was used as control. As shown in FIG. 21, CAR protein expression was higher in Jurkat cell lysates than PBMC lysates with cells transduced with LVPs packaged with dLck l promoter and dLck_2 promoter, which showed lower levels of CAR expression compared to the other modified dLck promoter. Cells transduced with LVPs containing EFla promoter had the strongest CAR trans gene expression.Moreover, expression of control protein (anti-GAPDH) w as similar across all LVPs indicating lower levels of BCMA CAR protein in cells transduced with LVPs containing dLck_l promoter and dLck_2 promoter, w as not due to inequal loading of cell lysates. Image #2 of Fig. 21 was overexposed relative to #1, showing distinct differences in PBMC lysates with dLck_l promoter and dLck_2 promoter compared to other cell lysates. Altogether these data suggests that LVPs can successfully package plasmids containing modified distal LekLeydig 775537Vyriad P-63-00676promoters while preventing premature CAR transgene expression in producer cells and LVPs. It also suggests that T cell specific transcriptional activity is maintained by modified distal Lek promoters in expression cassette placed in reverse orientation relative to 5’ LTR of transfer vector.EXAMPLE 7

[0399] This example demonstrates the tissue specificity and transduction efficiency by LVPs containing modified distal Lek promoters pseudotyped with VSIV-G-WT (SEQ ID NO: 72).

[0400] To examine the tissue specificity by LVPs containing the modified dLck promoters driving BCMA CAR transgene, Jurkat, a T cell specific cell line that expresses Lek, HEK293, a producer cell line with no Lek activity, and off-target cell lines (OPM2, A549, and NALM6 cells) were transduced with LVPs packaged with constructs containing reverse oriented expression cassette with modified dLck promoters, forward oriented expression cassette with EFla promoter as control and mock treatment was used as negative control. After 72 hours of transduction, cells were subjected to flow cytometry analysis for surface level recBCMA expression and quantified as bar graphs (FIG. 22A). Constitutive promoter EFla induced BCMA-CAR expression in off target cell lines (HEK293, OPM2, A594, NALM6) indicating lack of cell-specificity7. None of the LVPs containing modified Lek promoters had expression in producer cell line HEK293 cells indicating lack of premature CAR transgene expression in producer cells due to inactivity of distal Lek promoter in HEK293 producer cells. The Lck l construct showed the least off-target expression while Lck_4 and Lck_1.4 had the most off-target expression with the highest off target expression in OPM2 cells.

[0401] Together these results suggest that reverse orientation of modified distal Lek promoters prevent premature CAR transgene expression in HEK293 producer cells and has lower off target activities in A594 and NALM6 cells. The results also show Lck_l having the least off target expression effect and Lck_1.3 having the highest T cell specific expression. Furthermore, these data show that the combination of reverse orientation of expression cassette containing CAR transgene with the tissue-specific transcriptional regulatory elements such as modified Lek promoter, driving the CAR transgene are able to prevent premature CAR expression in producer cells and LVPs while maintaining expression of CAR in target cells.Leydig 775537Vyriad P-63-00677

[0402] To further test the tissue specificity of LVPs containing the modified dLck promoters driving BCMA CAR transgene, human PBMCs were transduced with the retargeted lentivirus and analyzed via flow cytometry at 7 days post infection (FIG. 22B). These results showed the LVPs with the modified dLck were able to successfully transduce human PBMCs.

[0403] To measure CAR activity levels in the PBMCs, a bioluminescence-based cytotoxicity assay for in vitro cytolytic activity of effector (E) PBMCs co-cultured with 0PM2 multiple myeloma, K562-BCMA+, and K562-CD19+ target (T) cells was performed. The PBMCs transduced with LVPs with Lckl, Lckl.3, Lckl.4, or EFla were incubated with target cells at the indicated E: T ratios (ranging from 0 to 4) and the viability of target cells (%) was evaluated after co-culture by luciferase assay (FIG. 22C). These results showed that for effector cells treated with a BCMA-CAR containing LVP and the BCMA expressing target cells (OPM2 and K562-BCMA+) as the E: T ratio increased, target cell viability progressively declined, reaching approximately 25% viability at the highest E: T ratio of 4. The effector cells did not appear to reduce viability in the K562-CD19+ effector cells at any E: T ratio, suggesting the cytotoxicity was targeted to cells expressing BCMA.EXAMPLE 8

[0404] This example demonstrates the benefit of combining CD3-retargeting with T cell specific promoter to enhance T cell specific activity and infectivity by CD3 -retargeted LVPs containing modified Lek promoter.

[0405] To examine tissue infectivity and BCMA-CAR generation by LVPs packaged with modified distal Lek promoters driving BCMA-CAR transgene in reverse orientation and EFla promoter driving BCMA-CAR transgene in forward orientation, pseudotyped with either VSIV-G-WT (SEQ ID NO: 72) only (FIG. 23 A) or mixed blinded VSIV-G-dK47 (SEQ ID NO: 13) non-chimeric (non-targeted) and VSIV-G-dK47 chimeric (CD3-targeted) (FIG. 23B), expression of recombinant BCMA was examined in Jurkat and 0PM2 tumor cells using flow7cytometry. Using second generation lentiviral expression system as described in Example 5, the day before transfection HEK-293T cells were plated in 10% FBS-DMEM on a 150 mm culture dish. The following day, cells were transfected with a mixture containing transfer plasmid and packaging helper plasmids. Transfection mixture contained tw o to three helper plasmids and one transfer plasmid; (1) a packaging plasmid containingLeydig 775537Vyriad P-63-00678HIV Gag / Rev / Pol elements, (2) either VSIV-G-WT (SEQ ID NO: 72) envelope or chimeric CD3-targeting UCHT1 -VSIV-G-dK47 (SEQ ID NOS: 70, 71, and 13) and VSIV-G-dK47 (SEQ ID NO: 13), and (3) transfer plasmid containing expression cassette (BCMA transgene driven by EFla promoter or Lck_1.3 promoter). A total of 15 pg of DNA was added per plate, containing a mixture of transfection reagent PEIPro (GenClone, cat no 55-311) and serum-free Opti-MEM I media according to manufacturer instructions. The media was replaced 16-20 hours after transfection with 15 mL of Opti-MEM I. Supernatant was collected 48-72 hours post-transfection, clarified from cell debris, filtered through a 0.45 pm filter, and concentrated 20-1 OOx of original volume by PEG or high-speed centrifugation (4 hours at 12,000xg, 4°C). HEK-293T producer cells underwent fluorescent imaging, showing no GFP expression in the cells with the reverse oriented Lek 1.3 expression cassette (FIG. 23C). The cell lysate of the HEK-293T packaging cells were analyzed by western blot using vinculin and anti-CD3^ antibodies (FIG. 23D). The western blot analysis of the packaging cell lysate showed that there was no expression of the CAR using the reverse oriented expression cassette with modified Lek promoter, while there was CAR expression in both the forward oriented expression cassettes. These results suggest that reverse orientation of the expression cassette with tissue specific promoters can prevent undesired expression of a trans gene in a packaging cell.

[0406] Harvested LVPs were used to infect Jurkat and OPM2 cells and BCMA CAR generation was examined by expression of recombinant BCMA at 3 - 4 days post infection using flow cytometry. Harvested LVPs were analyzed by western blot using 5E7 LVPs per well and anti-VSIV-G, anti-p24, and anti-CD3^ antibodies (FIG. 23E). The western blot analysis showed that BCMA-CAR was not expressed on the surface of the LVPs pseudotyped with a 1:3 ratio of UCHTl-VSIV-GdK47 to VSIV-GdK47 containing dLck_l or dLck_1.3 Lek promoters driving BCMA-CAR transgene in reverse orientation but it was expressed on the surface of the LVPs containing EFla promoter driving BCMA-CAR transgene in forward orientation.

[0407] FIGS. 23A-23B shows generation of BCMA CAR in Jurkat cells transduced with LVPs containing either EFla promoter or the modified distal Lek promoters while mock untreated used as a negative control had no BCMA CAR expression. Additionally, UCHT1-LVPs containing EFla promoter also induced BCMA CAR transgene expression in OPM2 cells, while UCHTl-LVPs containing Lck_mod_1.3 had no BCMA transgene expression in OMP2 cells. This suggests that retargeted LVPs (UCHTl-LVPs) with tissue-specificLeydig 775537Vyriad P-63-00679modified Lek promoter eliminates CAR expression in off target cells such as 0PM2 cells, demonstrating increased targeting specificity and decreased off-target expression.EXAMPLE 9

[0408] This example demonstrates the increase in tissue specificity and transcriptional activity by modified distal Lek promoter combined with T cell specific CD2 enhancer as tissue specific regulatory elements driving transgene expression.

[0409] To optimize and increase tissue specificity with tissue specific transcriptional activity by the modified distal Lek promoter, the broad range CMV enhancer was replaced with a T cell specific CD2 enhancer. To examine the transcriptional activity and tissue specificity7by regulatory elements containing EFla promoter or Lck_3 promoter with CMV enhancer, Lck_3 promoter with CD2 enhancer, or Lck_3 promoter alone to drive transgene expression, plasmids containing luciferase reporter (Luciferase - P2A - GFP) under these regulatory elements (Lck_3 promoter with CMV enhancer, Lck_3 promoter with CD2 enhancer, or Lck_3 promoter alone) were generated and packaged in to LVPs pseudoty ped with VSIV-G-WT (SEQ ID NO: 72) (FIG. 24A). Harvested LVPs were used to transduce Jurkat cells, a T cell specific cell line, HEK293. a producer cell line, other off-target cell lines: A549, an epithelial cell line, OPM2, a myeloma cell line, and THP-1, a macrophage cell line, at 500 LVPs per cell. The luciferase activity7was measured and for comparison purpose the luciferase activity by Lck_3 with CMV enhancer was normalized to 100%. Data were additionally normalized based on vector copy number (VCN) as determined by digital PCR (dPCR). FIGS. 24B-24C shows the percentage of luciferase activity driven by the specific regulatory elements in each cell line at day 4 (FIG. 24B) and day 10 (FIG. 24C) post transduction. Lck_3 promoter with CD2 enhancer had the highest percentage of luciferase activity in Jurkat cells while luciferase reporter gene expression was significantly reduced in all non-T cell lines, even in OPM2 cells where previously some level of off-target activity was observed (FIG. 22A).

[0410] The transcriptional activity. and tissue specificity7by regulatory7elements containing EFla promoter or Lck3 promoter with CMV enhancer, Lck3 promoter with CD2 enhancer, or Lck3 promoter alone to drive transgene expression, LVPs containing luciferase reporter (Luciferase - P2A - GFP) under these regulatory elements (CMV enhancer-EFla promoter, CMV enhancer-Lck3 promoter, CD2 enhancer-Lck3 promoter, or Lck3 promoter alone) was used to transduce PBMC and PBMC derived macrophages. PBMCs wereLeydig 775537Vyriad P-63-00680activated by aCD3 / aCD28 beads for 3 days before being transduced with 500 lentiviral particles per cell containing Luciferase-P2A-GFP reporter transgene driven by the different promoters in forward orientation. PBMCs were then examined for luciferase activity by addition of Bio-Gio luciferase substrate and luminesce was measured (FIG. 25) and expression of GFP transgene was examined using flow cytometry (FIG. 26).

[0411] Monocytes were purified from PBMC by magnetic beads (negative selection) and cultured in the presence of 25 ng / ml GM-CSF to generate macrophages. On the 5th day of culturing, they were transduced with LVs at MOI-IOOO LVP / cells and an additional five days later luciferase activity was examined by addition of Bio-Gio substrate and luminescence was measured (FIG. 25). The percent luciferase activity by CD2 enhancer - Lck3 promoter was comparable to CMV enhancer - Lck3 promoter in PBMCs however CD2 enhancer-Lck 3 promoter had higher tissue specificity compared to CMV enhancer-Lck3 promoter with no luciferase activity observed in macrophages derived from PBMC. Additionally, the frequency of GFP expressing CD3 T cells in PBMCs transduced with LVPs containing CD2 enhancer-Lck 3 promoter was the highest compared to PBMCs transduced with LVPs containing CMV enhancer - Lck3 promoter, CMV enhancer - EFl a promoter, or Lck3 promoter alone while the GFP MFI was reduced in PBMCs transduced with LVPs containing CD2 enhancer-Lck 3 promoter (FIG. 26). These data suggest that replacing the broad range CMV enhancer with T cell specific CD2 enhancer improved tissue specificity and transcriptional activity of Lck3 promoter.EXAMPLE 10

[0412] This example demonstrates the specificity and transcriptional activity of VLPS produced using transfer vectors with an expression cassette in reverse orientation to the transfer vector with modified distal Lek promoter combined with T cell specific CD2 enhancer.

[0413] To test the cell specificity and infectivity7of the LVPs produced using a transfer vector with an expression cassette in reverse orientation to the transfer vector, containing modified dLck promoters and the T cell specific enhancer CD2 and a BCMA-CAR transgene constructs are produced as shown in FIGS. 28A-28C. The transfer vectors comprise a chimeric 5’ long terminal repeat (5’ LTR) of a CMV enhancer and promoter, a R, and a U5 sequence, a HIV packaging signal and RRE, an expression cassette in reverse orientation to the transfer vector, a WPRE, and a 3’ LTR of a SIN U3 region (AU3), R region, and U5Leydig 775537Vyriad P-63-00681region followed by a SV40 poly A tail. The expression cassetes comprise a T cell specific enhancer CD2 and a dLck promoter, LCK 1, LCK 2, LCK 3, LCK 4, LCK 1.3, and LCK 1.4, respectively, a BCMA-CAR transgene, and a bGH pA.

[0414] To test the efficacy of the transfer vectors shown in FIGS. 28B-28C at preventing premature transgene expression in producer cells, a second-generation lentiviral expression system is used as described in Example 5. LVPs containing plasmid constructs are produced in producer cells (HEK-293T) and cell lysates of the producer cells and the LVPs are harvested to evaluate transgene expression on surface of producer cells and LVPs using western blot.

[0415] To examine the tissue specificity of LVPs produced using the transfer vectors shown in FIGS. 28B-28C, Jurkat, HEK293, OPM2, A549, and NALM6 cells are transduced with LVPs or mock treatment as a negative control. After 72 hours of transduction, cells are subjected to flow cytometry analysis for surface level recBCMA expression and quantified as bar graphs (FIG. 22A).EXAMPLE 11

[0416] This example demonstrates the increased viral titers during LVP production mediated by changes in components of the transfer vector, including (1) the use of CMV or RSV promoters in the 5' LTR; (2) the replacement of the SV40 poly(A) tail with a bGH poly (A) tail in the expression cassette; and (3) the repositioning of the WPRE to the 3' end of the reverse-oriented expression cassete (FIG. 29).

[0417] To assess viral titers, LVPs were produced by packaging plasmid constructs as shown in Tables 6-9. Harvested LVPs ere analyzed for viral titer as measured by three independent methods: p24 ELISA, digital transfection unit (dTU) values determined by qPCR, and functional transfection unit (fTU) values determined by flow cytometry.

[0418] Table 6 shows fold changes in p24 and dTU values relative to a reference construct in which the expression cassete is in reverse orientation and contains the transgene under the CD2 enhancer and modified Lckl.3 promoter. Changes in each construct compared to the prior construct in the table are highlighted in bold. Replacement of the RSV promoter with the CMV promoter in the 5’ LTR, together with repositioning of the WPRE to the 3' end of the expression cassette, resulted in a greater than 16-fold increase in transfection units.Leydig 775537Vyriad P-63-00682Table 6. Titer value comparison with transgene under CD2en / Lckl.3 in reverse orientation

[0419] Table 7 compares titer values of LVPs containing a reverse-oriented expression cassette with the transgene under the CMV enhancer and modified Lckl.3 promoter.Replacement of the SV40 poly(A) signal with bGHpA and repositioning of the WPRE to the 3' end of the expression cassette led to a >303-fold increase in functional transfection units (fTU) relative to the reference construct 5'RSV-SV40pA-WPRE-BCMA1046- CMVen / Lckl.3-3'.Table 7. Titer value comparison with transgene under CMVen / Lckl.3 in reverse orientation

[0420] Table 8 compares titer values of LVPs containing a reverse-oriented expression cassette with the transgene under the CMV enhancer and modified Lckl promoter. Similar to Table 7, replacement of the SV40 pA with bGHpA and repositioning of the WPRE to the 3' end of the expression cassette led to a > 169-fold increase in fTU relative to the reference construct 5'RSV-SV40pA-WPRE-BCMA1046-CMVen / Lckl-3'. These data highlight the improvement in viral titer during LVP production when plasmids containing reverse-orientedLeydig 775537Vyriad P-63-00683expression cassettes with the transgene under the CMV enhancer and modified Lek promoter include bGHpA in the expression cassette and the WPRE repositioned at the 3' end.Table 8. Comparison of titer values with transgene under CMVen / Lckl in reverse orientation

[0421] Table 9 compares viral titer values of LVPs containing reverse-oriented expression cassettes with the transgene under either the CD2 or CMV enhancer and either the modified Lckl or Lckl.3 promoter (SEQ ID NOS: 47-49 and 54). The data show that pairing the CD2 enhancer with the modified Lckl or Lckl.3 promoter (SEQ ID NOS: 47-48) yields approximately 5-fold and 10-fold increases in viral titer, respectively.Table 9. Comparison of titer values with transgene under CD2en / Lck vs CMVen / Lck

[0422] Altogether, these data demonstrate that, during production of LVPs containing reverse-oriented expression cassettes with a CD2 or CMV enhancer paired with Lckl or Lckl.3 promoters, improvements in viral titers are achieved by (i) replacing the SV40 poly(A) signal with a bGH poly(A) signal in the expression cassette and (ii) repositioning theLeydig 775537Vyriad P-63-00684WPRE to the 3' end of the expression cassette. These modifications effectively address the low-titer challenge observed when producing LVPs with reverse-oriented expression cassettes.EXAMPLE 12

[0423] This example demonstrates that LVPs pseudotyped with 1:3 ratio of a UCHT1-VSIV-G-dK47 (SEQ ID NOS: 70, 71, and 13) to VSIV-G-dK47 (SEQ ID NO: 13) produced using a retroviral transfer vector with an expression cassette in reverse orientation to the transfer vector and containing a BCMA-CAR transgene driven by T cell specific regulatory elements can successfully transduce T cells in vivo and generate CAR-T cells capable of reducing tumor burden in a multiple my eloma mouse model.

[0424] To test the efficacy of LVPs pseudotyped with 1:3 ratio of a UCHT1-VSIV-G-dK47 (SEQ ID NOS: 70, 71. and 13) to VSlV-G-dK47 (SEQ ID NO: 13) produced using a retroviral transfer vector with an expression cassette in reverse orientation to the transfer vector and containing a BCMA-CAR (SEQ ID NO: 42) transgene driven by T cell specific regulatory elements to generate CAR-T cells in vivo, NSG MHC I / II DKO mice were implanted with a tumor by IV injection of 2E6 OPM-2 cells expressing (Flue) in the tail vein. Mice were humanized by injection of human PBMCs via IP injection on day 13 post tumor implantation. 8 days after PBMC injection mice were injected with saline or LVPs.

[0425] Four groups of mice were prepared receiving either a saline injection (Group 1) or an injection of LVPs produced using a transfer vector with an expression cassette in forward orientation containing a BCMA-CAR transgene driven by an EFla promoter (Group 2), LVPs pseudotyped with a 1:3 ratio of UCHTl-VSIV-G-dK47 to VSIV-G-dK47 produced and 54) using a transfer vector with expression cassette in reverse orientation containing a BCMA-CAR transgene (SEQ ID NO: 42) driven by an dLck l promoter (SEQ ID NO: 56) (Group 3) or a dLck_1.3 promoter (SEQ ID NO: 57) (Group 4) as shown in FIG. 30A.

[0426] Mice underwent weekly IVIS imaging. IVIS imaging was performed on OPM2-Fluc injected NSG-MHC I / II DKO mice 1 day before (-1) being injected with saline or LVPs pseudotyped with a 1:3 ratio of UCHTl-VSIV-G-dK47 to VSIV-G-dK47 and containing the BCMA-CAR transgene driven either by an EFla promoter in forward orientation relative to the transfer vector, or by a modified Lek promoter Lck_l or Lck_1.3 in reverse orientation to the transfer vector and 7, 14, 21, 28, 35, 42, 49, 64, and 77 days after injection with saline orLeydig 775537Vyriad P-63-00685LVPs (FIG. 30B). These results showed that the LVPs were able to generate CAR-T cells and reduce or eliminate tumors by day 14 in the OPM-2 Flue injected NSG-MHC I / II DKO mice.EXAMPLE 13

[0427] This example demonstrates that LVPs pseudotyped with 1:3 ratio of a UCHT1-VSIV-G-dK47 (SEQ ID NOS: 70, 71, and 13) to VSIV-G-dK47 (SEQ ID NO: 13) containing a BCMA-CAR transgene driven either by a -modified Lek promoter Lck l or Lck_1.3 with a CMV or CD2 enhancer (SEQ ID NOS: 47-49 and 54) can successfully transduce T cells in vivo and generate CAR-T cells capable of reducing tumor burden even in a relapse model of human PBMC -engrafted OPM2 tumor bearing NSG mice.

[0428] OPM-2 Flue injected NSG MHC I / II DKO mice were prepared as in Example 3, with an experimental design as shown in FIG. 32. Six groups of mice (n=5) were prepared receiving either a saline injection (Group 1) or an injection of LVPs pseudotyped at a 1:3 ratio of UCHTl-VSIV-G-dK47 (SEQ ID NOS: 70, 71, and 13) to VSIV-G-dK47 (SEQ ID NO: 13) and containing a BCMA-CAR transgene driven either by a modified Lek promoter Lck_l or Lck_1.3 with a CMV enhancer or CD2 enhancer as shown in Table 10. At day 21 and again at 28, group 4 and 5 mice were rechallenged with 2e6 OPM2 cells. Mice underwent clinical observation for any moribund signs, weekly IVIS imaging, body weight was monitored, tumor grow th was monitored, and blood was collected in EDTA tubes for flow cytometry.Table 10

[0429] IVIS imaging of the mice was performed at day 1 before injection with saline or LVP, and at days 7, 21, 28, 35, 43, 50, and 56 after injection (FIGS. 33A-33B). These results showed that mice injected with LVP containing a BCMA-CAR transgene driven by a CMV enhancer and modified Lek promoter Lck l (group 4) or Lck_1.3 (group 5) cleared theLeydig 775537Vyriad P-63-00686tumors and showed the clearance of tumor cells upon rechallenge, which suggests a robust memory response by CAR T cells (FIG. 34). None of the LVP injected mice showed reduction in body weight to less than 70% of day 0 body weight suggesting the LVPs did not have any moribund effects (FIGS. 35A-35C).

[0430] Peripheral blood was collected from the mice at day 14 post injection and underwent flow cytometry analysis for BCMA CAR T cells in CD3+ cells. FIGS. 36A-36B show flow plots of 3 representative mice from each group. Overall these results suggest that LVPs pseudotyped at a 1:3 ratio of UCHTl-VSIV-G-dK47 to VSIV-G-dK47 and containing a BCMA-CAR transgene driven by a modified Lek promoter Lck_1.3 with a CMV enhancer at suboptimal dose are able to effectively generate persistent CAR T cells in vivo that reduce tumor burden upon rechallenge.EXAMPLE 14

[0431] This example demonstrates the efficacy of LVPs pseudotyped with a 1:3 ratio of a UCHTl-VSIV-G-dK47 (SEQ ID NOS: 70, 71, and 13) to VSIV-G-dK47 (SEQ ID NO: 13) containing a BCMA-CAR transgene driven by a modified Lek promoter Lck_1.3 with a CMV enhancer (referred to as VV169) (SEQ ID NO: 57) can successfully transduce T cells in vivo and generate CAR-T cells capable of reducing tumor burden in human PBMC-engrafted OPM2 tumor bearing NSG mice.

[0432] OPM-2 Flue injected NSG MHC I / II DKO mice were prepared as in Example 3, with an experimental design as shown in FIG. 37. For cohort A five groups of mice (n=15) were prepared receiving either a saline injection (Group 1) or an injection of LVPs pseudotyped at a 1:3 ratio of UCHTl-VSIV-G-dK47 (SEQ ID NOS: 70, 71, and 13) to VSIV-G-dK47 (SEQ ID NO: 13) and containing a BCMA-CAR transgene driven by a modified Lek promoter Lck_1.3 with a CMV enhancer at a dose of le8(Group 2), 3e8(Group 3), le9(Group 4), and 3e9(Group 5). The cohort was divided into two subsets for different analyses. A subset of five mice was designated for longitudinal monitoring of CAR-T cell kinetics, with peripheral blood samples collected on Days 14, 21, and 60 post-injections. A second, separate subset of ten mice was used exclusively to evaluate the primary efficacy endpoint of tumor burden reduction. To minimize the potential impact of repeated sampling on the efficacy outcome, these mice underwent a single blood draw on Day 21 solely to confirm the presence of circulating BCMA-CAR-T cells.Leydig 775537Vyriad P-63-00687

[0433] For cohort B six groups of mice (n=5) were prepared receiving either a saline injection (Groups 1, 3, and 5) or an injection of LVPs pseudotyped at a 1:3 ratio of UCHT1-VSIV-G-dK47 (SEQ ID NOS: 70, 71, and 13) to VSIV-G-dK47 (SEQ ID NO: 13) and containing a BCMA-CAR transgene driven by a modified Lek promoter Lck_1.3 with a CMV enhancer at a dose of 3e8(Groups 2, 4, and 6). CAR-T cell kinetics in cohort B were evaluated at pre-defined time points aligned with their anticipated dynamics: such as Day 15-Day 22 (expansion and peak), Day 36 (contraction), and Day 60 (long-term persistence). At each scheduled harvest, peripheral blood samples were analyzed for T-cell activation via CD25 and CD69 surface marker profiling and for CAR-T cell expression and bone marrow, spleen, and liver were harvested to determine CAR-T cell expression levels.

[0434] Peripheral blood was collected on days 1, 2, and 3 post-injection for flow cytometric analysis in cohort B. Flow cytometry analysis was performed on major leukocyte populations and showed the frequency of human CD45+ cells, mouse CD45+ cells, and human CD3+ T cells in peripheral blood, with data presented as mean ± SEM (n =5 per group) (FIG. 38A). Flow cytometry gating for expression of CD69 and CD25 on CD3+ cells was shown using a representative flow cytometry dot plot (FIG. 38B). T cell activation was quantified showing the percentage of CD69+ and CD25+ cells within the human CD3+ T cell population (FIG. 38C). These results suggest that the LVPs were able to induce transient T cell activation without impacting major host or human immune cell populations.

[0435] Tumor burden was measured in cohort A by bioluminescent imaging (BLI) of mice under anesthesia using an XENOGEN IVIS SPECTRUM™. Ten minutes before imaging, mice were intraperitoneally administered with 150 mg / kg of luciferin substrate dissolved in saline. Images were captured with an exposure time of 0.5 seconds with a F-stop setting of 2. If the image photon counts were lower than 1x106photons / sec / cm3, the setting was changed to auto exposure with a F-stop setting of 2 for maximum sensitivity. For quantitation, region of interest (ROI) sizes were kept consistent across all groups, and consisted of an oval that encompassed the area from the tip of the head to the base of the tail. ROI and associated luminescence values (flux; photos / sec / cm3) were measured using the LIVING IMAGE™ software (FIGS. 39A-39C). Additional data analysis was carried out using MICROSOFT EXCEL™. The total flux in tumor burden showed that in all surviving mice treated with LVPs tumor burden was reduced (FIG. 40).

[0436] Peripheral blood samples were collected at 14. 21 and 60 days for cohort A mice to perform flow cytometry analysis to assess BCMA CAR+ cells expression in blood. FIGS.Leydig 775537Vyriad P-63-0068841A-41B shows the percentage of BCMA CAR+ cells in the hCD3+ cells, hCD8+ cells, and hCD4+ cells and the differences between the percentage of BCMA CAR+ cells in the hCD8+ cells and hCD4+ cells, show n as mean ± SEM (n = 5 per group). These results suggest that LVPs exhibited dose-dependent expansion and kinetics of peripheral BCMA CAR T cells.

[0437] Analysis of in vivo expansion kinetics showed that CAR-T cell levels increased substantially between Days 14 and 21 following vector administration, indicating active in vivo generation and expansion of CAR-modified T cells. This expansion phase was follow ed by a contraction phase by Day 60, consistent with the physiological dynamics of activated T cells following antigen engagement and tumor clearance. The preferential enrichment of CAR-T cells within the CD8+ subset is consistent with their established role as primary mediators of tumor cytotoxicity in CAR-T therapy.

[0438] Importantly, the magnitude of peripheral CAR-T cell expansion correlated with antitumor activity observed in treated mice, with higher vector doses generating greater CAR-T cell frequencies and stronger tumor control. These findings suggest the ability of VV169 to efficiently generate functional anti BCMA-directed CAR-T cells in vivo in a dosedependent manner, with expansion kinetics consistent with antigen-driven activation and subsequent immune contraction following tumor burden reduction.

[0439] To analyze the in vivo biodistribution and persistence of LVP generated BCMA CAR T cells on days 15, 22, 36, and 60 post-injection, mice were euthanized, and blood, spleen, bone marrow- (BM), and liver were harvested for flow' cytometric analysis. Gating for BCMA CAR+ cells on CD45+ population were shown using representative flow cytometry plots from day 15 for samples from the blood (FIGS. 42A-42B), spleen (FIGS. 43A-43B), bone marrow (FIGS. 44A-44B), and liver (FIGS. 45A-45B). These data were quantified in blood, spleen, bone marrow (BM), and liver cells from cohort B at days 15, 22, 36, and 60 and the kinetics of BCMA CAR+ cells as a percentage of CD3+ T cells (FIG. 46A), CD8+ T cells (FIG. 46B), and CD4+ T cells (FIG. 46C) and quantified as a comparison of the peak percentage of BCMA CAR+ cells within the CD8+ versus CD4+ T cell compartments across all tissues on Day 15 (FIG. 46D), with data presented as mean ± SEM (n = 5 per group).

[0440] These dynamics suggest that CAR-T cell expansion was largely antigen-driven, where the presence of a high tumor burden promoted robust CAR-T cell proliferation, and subsequent tumor elimination led to contraction of the CAR-T cell population. Phenotypic analysis further demonstrated that the CAR-T cell compartment was predominantly composed of CD8+ T cells and peak CD8+ CAR T cell expression w'as on Day 15 andLeydig 775537Pvriad P-63-00689subsequently declined to detectable levels at Day 60, consistent with the cytotoxic role of this subset in mediating tumor cell killing. A CD4+ CAR-T cell population was also detected; however, its frequency was substantially lower compared with the CD8+subset.

[0441] The expansion kinetics of the dominant CD8+ CAR-T cell population mirrored the overall CAR-T dynamics, reaching maximal levels at Day 15 before gradually declining over time (FIG. 46B). Despite this contraction, low but detectable levels of CAR-T cells persisted in peripheral blood, spleen, and bone marrow at Day 60 in a subset of animals, suggesting the establishment of a durable CAR-T cell population following tumor clearance.

[0442] The gating of BCMA CAR+ cells on Singlet / Live-Dead / hCD45+ / hCD3+ population in the bone marrow of human PBMC-engrafted OPM2 tumor bearing NSG mice at day 15 post injection with LVPs was shown using a representative flow cytometry dot plot and the percentage of as labeled and a graph showing the percentage of BCMA CAR T cells of CD3+ cells in each tissue at day 15, with data presented as mean ± SEM (n = 5 per group) was quantified (FIG. 47).

[0443] Analysis of lentivirus copy number was performed for spleen, liver, and bone marrow of human PBMC-engrafted OPM2 tumor bearing NSG mice at days 15, 22, and 36 post injection with saline or LVPs was performed as measured by copies per diploid genomic DNA or as copies per pg of genomic DNA (FIG. 48).

[0444] Overall these results suggest that LVPs pseudotyped at a 1:3 ratio of UCHT1-VSIV-G-dK47 to VSIV-G-dK47 and containing a BCMA-CAR transgene driven by a modified Lek promoter Lck_1.3 with a CMV enhancer at a dose of 3e8are able to effectively generate CAR T cells in vivo that reduce tumor burden with minimal or almost no treatment associated toxicities.EXAMPLE 15

[0445] This example demonstrates LVPs pseudotyped with a 1:3 ratio of UCHT1-VSIV-G-dK47 (SEQ ID NOS: 70, 71, and 13) to VSIV-G-dK47 (SEQ ID NO: 13) produced using a transfer vector with expression cassette in reverse orientation containing a BCMA-CAR driven by a modified dLck_1.3 promoter (referred to as VV169) (SEQ ID NO: 57) were able to successfully transduce CD3+ T cells in whole human blood.

[0446] T o test the targeting efficacy of LVPs pseudotyped with a 1: 3 ratio of UCHT1 - VSIV-G-dK47 (SEQ ID NOS: 70, 71, and 13) to VSIV-G-dK47 (SEQ ID NO: 13) produced using a transfer vector with expression cassette in reverse orientation containing a BCMA-Leydig 775537Vyriad P-63-00690CAR driven by a modified dLck_1.3 promoter (SEQ ID NO: 57) the LVPs encoding aBCMA-CAR were directly contacted to whole human blood collected in heparin Vacutainer tubes from 3 donors and incubated for 6 hours. After 6 hours, plasma samples were collected for cytokine analysis and PBMCs were isolated into cell cultures in culture media supplemented with IL-2. Flow cytometry analysis for T-cell markers and CAR expression was performed on the PBMCs on day 8 post transduction.

[0447] To characterize the starting PBMC component of the whole blood used for transduction, PBMCs were isolated from aliquots of whole blood collected from each of the three donors and analyzed by flow cytometry. Flow cytometry analysis was performed measuring CD14+ versus CD3+ cells of PBMCs gated for CD45+ cells (FIG. 49 A). The levels of monocytes (CD14+), B cells (CD 19+) and T cells (CD3+) as percentage of CD45+ immune cells were determined (FIG. 49B). The density of CD3 and co-stimulatory molecules CD28 and CD2 on the surface of T cells was estimated based on geometric mean intensity (MFI) for each marker (FIG. 49C). The measured parameters for the three donors were comparable without any outliers.

[0448] The initial composition of T cell memory subsets based on expression of CCR7 and CD45RA markers was characterized using flow cytometry analysis (FIGS. 49D-49E). T cell subsets were identified by flow cytometry based on surface expression of CCR7 and CD45RA, with CCR7+CD45RA+cells defined as naive T cells (Naive); CCR7+CD45RA cells as central memory (CM); CCR7 CD45RA cells as effector memory (EM); and CCR7 CD45RA+cells as terminally differentiated effector memory T cells (TEMRA). The distribution of CD4 and CD8 T cell population subsets across the three donors used in this study were quantified and the percent of CD4 and CD8 cells in each donor was quantified as well (FIG. 49F). These results showed that donors IM#1 and IM#3 had more CD4+ than CD8+ T cells and that donor IM#3 had the highest percentage of naive T cells, both CD4+ and CD8+. Donor IM#4 had slightly more CD8+ T cells than CD4+ T cells and also more effector than naive CD8+ T cells.

[0449] To evaluate the effect of VV 169 interaction with blood on production of cytokines, plasma was isolated from a portion of VV169 treated whole blood after 6 hours and used for analysis of human cytokines IFNy, TNFa, GM-CSF, IL-6 and IL-2 with a customized, pre-mixed multiplex discovery kit. Cytokine levels were also increased in blood treated with aCD3 / CD28 human T-activator beads (aCD3 / 28 beads), which not only activate T-cells through CD3 and CD28, but may also non-specifically bind to Fc receptors on non-TLeydig 775537Vyriad P-63-00691cell subpopulations, leading to additional elevation in blood cytokine levels. In all donors, both doses of VV1 9 induced upregulation of all analyzed cytokines compared to mock treatment (FIGS. 49G-49I). Among all measured cytokines, IL-2 is the only one which is produced exclusively by T cells. Activator beads induced significantly higher levels of IL-2 compared to VV169 in all three donors, implying that the beads were much stronger activators of T cells in the blood compared to VV169 at the doses tested. In contrast, VV169 induced comparable or higher levels of the other cytokines compared to activator beads. In particular, IFNy levels were much higher following incubation with VV169 compared to activator beads. While TNFa, GM-CSF and IL-6 levels were also elevated after treatment, the degree of elevation was more variable between donors and treatments. Together, these data demonstrated that adding VV 169 to blood induced immediate (within 6 hours) cytokine release that likely involves several types of immune cells.

[0450] To determine the efficacy of VV169 targeting T cells, T cells transduction was estimated by flow cytometry on PBMCs day 8 post VV169 treatment. PBMCs were gated for CD45+ cells to show BCMA-CAR+ versus CD3+ cells (FIGS. 49J-49K). The percentage of CD3+cells positive for BCMA-CAR was quantified for each treatment group (FIG. 49L). BCMA 1046-C AR+T cells were detected in all three donors following transduction w ith either the low dose of VV169 (3E5 LVPs) or the high dose of VV169 (2E9 LVPs).

[0451] Flow cytometry histograms of CD25 expression levels in CD3+gated cells at 8 days post treatment were generated (FIG. 49M) and the percentages of CD25+in CD3+cells was quantified (FIG. 49N). These results show ed that VV169 induced CD25 activation on the surface of the majority of CD3+ T cells, ith levels of activation similar to those induced by activator beads.

[0452] Further analysis demonstrated that both the CD4+(FIG. 490) and CD8+(FIG. 49P) T-cell subpopulations contained BCMA1046-CAR+T cells. Slightly higher levels of BCMA-CAR+T cells in the CD8+subpopulation were observed and corresponded to an overall shift towards a CD8+ dominant population following VV169 treatment relative to mock or activator beads in two of the three donors.

[0453] These results demonstrated that VV169 successfully generated both CD4 and CD8+aBCMA-CAR+T cells when directly added to fresh human blood ex vivo and induced accumulation of inflammatory cytokines at 6 hours after VV169 addition in blood from all three donors.Leydig 775537Vyriad P-63-00692EXAMPLE 16

[0454] This example demonstrates LVPs pseudotyped with a 1:3 ratio of UCHT1-VSIV-G-dK47 (SEQ ID NOS: 70, 71, and 13) to VSIV-G-dK47 (SEQ ID NO: 13) produced using a transfer vector with driven by an RSV or CMV promoter and an expression cassette in reverse orientation containing a BCMA-CAR driven by a modified dLck_1.3 promoter with a CD2 or CMV enhancer were able to express BCMA CAR, to induce CAR-T cell activation, and to induce CAR activity in CAR-T cells generated in vitro by transduction of PBMCs.

[0455] LVPs were prepared using the constructs shown in FIG. 50A and titered as shown in Table 11.Table 11

[0456] PBMCs from 2 donors were seeded into 96-well suspension culture plates at 2 x 105cells / well in 50 pL of 10% FBS-RPMI (ATCC modification) media with or without 25 ng / mL human IL-2. The lentiviral vectors with the BCMA CAR transgene were added at a dose of 2000 lentiviral particles (LVP) (based on p24 titer) per cell, and the total volume was adjusted to 100 pL per well with culture medium. Following gentle mixing, spinoculation was performed at 900 xg for 30 minutes at 32°C. The plates were incubated overnight, and 100 pL of fresh medium with or without IL-2 was added to each well the following day. The cultures were maintained through half-medium changes performed every other day. As a negative control, cells were mock transduced and for a positive control (for cytokine assays), PBMCs were treated with aCD3 / aCD28 activation beads.

[0457] PBMCs from two healthy donors were transduced with both VV169 vectors and cultured with or without IL-2. Cytokine release in response to VV169 was measured 48 hours post-transduction, while vector copy number analysis for integrated lentiviral genomes and flow cytometry analysis for T-cell markers and CAR expression was performed on day 7 post transduction

[0458] For BCMA-CAR expression analysis, 80 pL of PBMCs were collected 7 days posttransduction and two-step staining was performed. In brief, cells were washed with DPBS, incubated with Ghost Dye LD510 to discriminate live and dead cells for 20 minutes at ambient temperature in the dark, and washed twice. Cells were incubated with FcR Blocking buffer forLeydig 775537Vyriad P-63-0069315 minutes, followed by incubation with 0.2 pL / sample of unconjugated human BCMA-llama-Fc-Tag protein (ACROBiosystem, BC A-H5259) for 20 minutes. Cells were washed twice then stained with 0.4 pL / sample of secondary' AF647-Goat anti-Llama IgG H& L antibody (Abeam, abl 12784 labeled with AF647 in house) and antibodies against human cell markers CD45 (FITC), CD3 (BV605), CD4 (PerCP / Cy5.5), CD8 (PE / Cy7), CD25 (BV421). To reduce background and increase specificity, staining was done in the presence of Tandem Signal Enhancer, human (Miltenyi Biotec, 130-099-887). After staining, cells were washed, fixed in Fixation Buffer for 20 minutes, and data was acquired using a Cytoflex LX. Analysis was performed using FlowJo Software.

[0459] Flow cytometry analysis was performed showing BCMA-CAR levels vs. CD3 levels in CD45+ gated cells from donor 1 (FIG. 50B) and donor 2 (FIG. 50C). The percentage of CD3+cells positive for BCMA-CAR and fluorescence geometric mean (MFI) of the CAR+cells was calculated for PBMCs cultured with IL-2 (FIG. 50D) and without IL-2 (FIG. 50E).

[0460] Genomic DNA was isolated from PBMCs on day 10 post transduction using a DNeasy Blood & Tissue Kit (QIAGEN). Vector DNA levels were quantified using a qualified dPCR assay incorporating two primer-probe sets targeting human reference gene RPP25 (ribonuclease P / MRP subunit p25) and vector-specific long terminal repeat (LTR) sequence (Pro) generated only after reverse transcription of vector in target cells. Vector integration copy number (VCN) was calculated by normalizing the total Pro copy number to half the copy number of RPP25 (RPP25 / 2), reflecting diploid genomic content per cell. This was quantified for PBMCs cultured with IL-2 and without IL-2 (FIG. 50F). These results showed that LVPs with both the CD2en-Lckl.3 and mCMVen-Lckl.3 BCMA-CAR constructs were able to integrate into the genome of PBMCs.

[0461] T cell activation was measured by flow cytometry analysis showing the percentage of CD3+ T cells expressing CD25 (FIG. 50G). These results show ed increased CD25 levels on CD3+cells following transduction with either LVP preparation relative to mock-treated PBMCs, regardless of whether media contained IL-2 or not.

[0462] To measure cytokine levels cell culture media w as collected from PBMCs 48 hours post - transduction and stored at -80°C until the day of analysis, when human cytokines IFNy, TNFa, IL-6 and IL-2 were measured with a customized pre-mixed multiplex discovery’ kit from RnD systems and quantified (FIGS. 50H-50I). LVPs with both the CD2en-Lckl.3 andLeydig 775537Vyriad P-63-00694mCMVen-Lckl.3 BCMA-CAR constructs induced an increase in cytokines IFNy. TNFa and IL-6 to similar levels regardless of whether media contained IL-2 or not.

[0463] These results demonstrated that LVPs pseudotyped with a 1:3 ratio of UCHT1-VSIV-G-dK47 to VSIV-G-dK47 produced using a transfer vector of CD2en-Lckl.3 or mCMVen-Lckl.3 successfully integrated into the genome of human PBMCs in vitro and generated BCMA-CAR T cells and induced T cell activation and cytokine release.EXAMPLE 17

[0464] This example demonstrates LVPs pseudotyped with a 1:3 ratio of UCHT1-VSIV-G-dK47 (SEQ ID NOS: 70, 71, and 13) to VSIV-G-dK47 (SEQ ID NO: 13) produced using a transfer vector with expression cassette in reverse orientation containing a BCMA-CAR driven by a modified dLck_1.3 promoter (referred to as VV169) (SEQ ID NO: 57) were able to successfully transduce CD3+ T cells in human PBMCs and induce CAR T cell activation, induce CAR expression, and induce CAR activity in generated CAR T cells.

[0465] PBMCs from three independent donors were transduced with VV169 (1,000 LVPs / cell), stimulated with Dynabeads® Human T-Activator CD3 / CD28 or an IL-7 / IL-15 cytokine cocktail, or left untreated as a control. Following gentle mixing, spinoculation was performed at 900 x g for 30 minutes at 32°C for each sample. To monitor T-cell activation in the absence of lentivirus, Dynabeads® Human T-Activator CD3 / CD28 or a cytokine cocktail (25 ng / mL IL-7 and IL-15) were added to wells without VV169 to serve as positive controls. Cells were incubated overnight, and 1 mL of fresh medium was added to each well the following day. Culture maintenance was achieved via half-medium exchanges every other day.

[0466] To determine CAR T cell activation flow cytometry analysis for CD69 expression and CD25 expression was measured at 24, 48. and 72 hours post-treatment in CD3+ CD45+ gated PBMCs (FIGS. 51A-51B). The percentage of CD69+cells and the percentage of CD25+cells within the CD3+T cell population, pre-gated on viable, CD45+and CD3+population was quantified (FIGS. 51C-51E). These results showed robust upregulation of the early activation marker CD69 on T cells was observed at 24 hours in VV 169-transduced, Dynabeads-activated, and IL-7 / IL-15 cytokine cocktail-activated PBMCs relative to untreated control PBMCs and CD69 levels declined progressively through 72 hours. The late activation marker CD25 was also upregulated at 24 hours in VV 169-transduced, Dynabeads-activated, and IL-7 / IL-15 cytokine cocktail-activated PBMCs relative to untreated controlLeydig 775537Vyriad P-63-00695PBMCs with surface levels of CD25 moderately increasing through 72 hours. Thus, VV169 transduction of PBMCs was characterized by rapid CD69 upregulation followed by subsequent CD25 induction.

[0467] To measure expression of CAR on T cells flow cytometry analysis was performed on day 7 after transduction to measure BCMA CAR expression on CD3+ T cells that were pre-gated on viable, CD45+ cells (FIG. 5 IF). The percentage of BCMA CAR+cells within the CD3+T cell population for each donor was quantified (FIG. 51G).

[0468] To measure CAR activity levels, a bioluminescence-based cytotoxicity7assay for in vitro cytolytic activity of effector (E) PBMCs co-cultured with OPM2-Fluc multiple myeloma target (T) cells was performed. VV169-transduced PBMCs or aCD3 / CD28-activated mock PBMCs were incubated with target cells at the indicated E: T ratios (ranging from 0 to 8) and the viability7of target cells (%) was evaluated after co-culture by luciferase assay (FIGS. 51H-51I). Dashed lines indicate reference baselines for minimum target cell viability following co-culture with VV 169-transduced PBMCs or aCD3 / CD28-activated mock PBMCs. Across all three PBMC donors, VV169-transduced PBMCs demonstrated dose-dependent cytotoxicity7against OPM2-Fluc cells. As the E: T ratio increased, target cell viability7progressively declined, reaching 20% to 40% viability at the highest E: T ratio of 8. In contrast. aCD3 / CD28-activated mock PBMCs exerted minimal cytotoxic effects, with target cell viability remaining high across all evaluated ratios. These results indicate that VV169-transduced CAR T-cells are functionally active and capable of eradicating BCMA-expressing tumor cells.EXAMPLE 18

[0469] This example demonstrates that LVPs pseudotyped with a 1:3 ratio of UCHT1-VSIV-G-dK47 (SEQ ID NOS: 70, 71, and 13) to VSIV-G-dK47 (SEQ ID NO: 13) produced using a transfer vector with expression cassette in reverse orientation containing a BCMA-CAR driven by a modified dLck_1.3 promoter (referred to as VV169) (SEQ ID NO: 57) did not exhibit tumorgenicity in human PBMCs and show minimal off target effects in B cells and T cells not expressing CD3.

[0470] To assess the off-target effects of VV169, a lentiviral vector (LV) with a CD3-targeted glycoprotein envelope packaging an aBCMA-CAR transfer vector. To this end, several T and B-cell lines, Jurkat WT (CD3 / LDLR7BCMA ), Jurkat-TCR-KO (CD3‘ / LDLR / BCMA ), Nalm6 (CD37LDLR / BCMA), and the BCMA+multiple myeloma cellLeydig 775537Vyriad P-63-00696line 0PM2 (CD37LDLR / BCMA ) were transduced with VV169 or LVV encoding the same aBCMA-CAR transfer plasmid but pseudotyped with wild-type VSIV-G glycoprotein (G-WT).

[0471] Cells were analyzed 5 days post-transduction by flow cytometry to measure BCMA-CAR expression levels (FIG 52A). The VSIV-G- WT (SEQ ID NO: 72) LV efficiently transduced all cell lines, resulting in aBCMA-CAR expression in both T-cell and B-cell lines, while the CD3-targeted VV169 selectively transduced Jurkat cells, with aBCMA-CAR expression in Nalm6 and 0PM2 B-cell lines indistinguishable from mock-transduced controls. Additionally, VV169 transduction was reduced in Jurkat-TCR-KO cells relative to Jurkat WT, indicating that VV169-tropism is highly linked to the presence of the TCR (CD3) on the T-cell surface.

[0472] Jurkat WT, Jurkat-TCR-KO, Nalm6 (CD37LDLR / BCMA ), and OPM2 cells underwent digital PCR (dPCR) at 7 days post-transduction to evaluate the off-target integration of the vector, and vector copy number (VCN) analysis was performed (FIG. 52B). The VSIV-G- WT LV exhibited high-frequency genome integration (> 2 copies / cell) in both T- and B-cell lines, while integrated VV169 genomes were only detected in Jurkat cells, and not the B-cell lines, and integrated VV169 genome copies were also reduced in Jurkat-TCR-KO cells relative to Jurkat WT cells.

[0473] These results suggest that VV169 specifically targets CD3+ T cells and has minimal off-target effects.

[0474] To evaluate the tumorigenic potential of VV169, human PBMCs were transduced with the CD3 -retargeted lenti viral vector at 2,000 LVPs / cell and monitored longitudinally every week for viable cell counts, viability, and aBCMA-CAR expression. LV-SFFV-eGFP was included as a comparator vector containing a strong viral promoter. PBMCs were split into two groups Condition A and Condition B.

[0475] In Condition A, VV169-transduced PBMCs were maintained in IL-2-containing medium for 14 days prior to cytokine withdrawal. Viable cell counts were performed over the duration of the study and quantified (FIGS. 52C-52D). Flow cytometry analysis was performed to measure viable cells (FIGS. 52E-52F). aBCMA-CAR expression was detectable by Day 7 in all donors. During the initial culture period in the presence of IL-2, an increase in viable cell counts was observed in VV 169-treated cells. This transient increase is consistent with activation and proliferative effects associated with CD3-directed engagement in the presence of exogenous cytokine support. However, following IL-2 withdrawal, viableLeydig 775537Vyriad P-63-00697cell counts declined over time in all donors. By Days 47 to 50, viable cell counts in all Cohort A donors had declined below the limit of detection. No sustained cellular outgrowth was observed following removal of cytokine support.

[0476] To assess cellular persistence independent of IL-2 support from study initiation, Condition B was established in which VV169-transduced PBMCs were cultured without exogenous cytokines throughout the study. Viable cell counts were performed over the duration of the study and quantified (FIGS. 52G-52H). Flow cytometry analysis was performed to measure viable cells (FIGS. 52I-52J). Under these conditions, viable cell counts declined progressively from the start of the study, with all donors falling below the limit of detection by Day 28. This condition therefore did not demonstrate evidence of cytokineindependent survival or proliferative expansion following VV 169 transduction.

[0477] These results suggest that under the in vitro conditions evaluated in this study, VV 169- transduced human PBMCs did not demonstrate evidence of tumorigenic transformation or transformation-associated outgrowth.EXAMPLE 19

[0478] This example demonstrates that VV169 safely mediates in vivo CAR T cell generation without triggering severe or prolonged systemic cytokine toxicity.

[0479] To analyze the safety of LVPs pseudotyped with a 1:3 ratio of a UCHT1-VSIV-G-dK47 (SEQ ID NOS: 70, 71. and 13) to VSIV-G-dK47 (SEQ ID NO: 13) containing a BCMA-CAR transgene driven by a modified Lek promoter Lck_1.3 with a CMV enhancer (referred to as VV169) (SEQ ID NO: 57) as used in Example 14, cytokine levels were measured to assess risk of chronic systemic hypercytokinemia and cytokine release syndrome.

[0480] To evaluate the acute systemic cytokine response human PBMC-engrafted NSG mice bearing OPM2 tumors received a single intravenous (i.v.) injection of either a saline vehicle (control) or the VV169 vector (LVP / mouse). Peripheral blood was collected at 6 and 48 hours post-infection, and plasma was isolated for cytokine profiling via Luminex multiplex assay. The plasma concentrations (pg / mL) of human TNFot, IL-2, and IL-6 (FIG.53 A) and human IL- 10, GM-CSF. and IFNy (FIG. 53B) were quantified with data presented as mean ± SEM, with individual dots representing individual mice (n = 3-4 per group). Horizontal dashed lines indicate the assay's limit of detection (LOD) for each respective cytokine.Leydig 775537Vyriad P-63-00698

[0481] At 6 hours post-infection, mice treated with VV169 exhibited a rapid elevation in TNFa, IL-2, IFNy, IL- 10, and GM-CSF circulating human cytokines compared to the saline-treated controls. However, the secretion levels of these cytokines were mild and did not cause adverse effects on mouse health. IL-6 levels remained mostly below' the limit of detection in both 6 and 48 hours postinfection. Notably, the systemic cytokine release induced by VV169 as highly transient. By 48 hours post-infection, plasma concentrations of TNFa, IL-2, IL-10, GM-CSF, and IFNy had markedly contracted, returning to near-baseline levels that were largely indistinguishable from those of the saline vehicle group. Together, these data indicate that systemic delivery of VV169 successfully engages the engrafted human immune compartment, driving a mild and self-limiting cytokine response without causing prolonged systemic hypercytokinemia.

[0482] To evaluate the systemic immune activation elicited by VV169, human PBMC-engrafted, OPM2 tumor-bearing NSG mice were administered a single intravenous injection of the VV169 vector (3xl09LVP / mouse) or a saline vehicle. Peripheral blood was collected at days 15, 22, and 60 post-VV169 or saline infusion, and plasma was analyzed via Luminex multiplex assay to assess late-stage circulating human cytokine levels. The plasma concentrations (pg / mL) of human TNFa, IL-2, and IL-6 (FIG. 53C) and human IL-10, GM-CSF, and IFNy (FIG. 53D) were quantified with data presented as mean ± SEM, (n = 3-5 per group), with individual dots representing individual mice. Horizontal dashed lines indicate the limit of detection (LOD) for each respective cytokine assay.

[0483] These results demonstrate that compared to the early cytokine release observed at 6 hours post-injection, there was no sustained vector-specific elevation of systemic cytokines at later time points. Notably, circulating levels of IL-6, a primary driver of cytokine release syndrome (CRS) remained entirely below the limit of detection in both cohorts throughout the 60-day observation period. Similarly, IL-2 and the immunomodulatory cytokine IL- 10 were predominantly undetectable in both saline and VV169-treated mice. While high levels of IFNy, along with moderate levels of TNFa and GM-CSF, were detected in the plasma, these cytokines were present at comparable levels in both the VV169-treated and saline-treated control groups and the upward trend of TNFa and GM-CSF observed by day 60 occurred independent of treatment group. Taken together, these data indicate that w hile VV169 drives an initial acute immune response, the long-term persistence and anti-tumor activity of the resulting in vzvo-generated CAR T cells are well-tolerated and do not trigger chronic systemic cytokine toxicity.Leydig 775537Vyriad P-63-00699EXAMPLE 20

[0484] This example demonstrates that VV169 (SEQ ID NO: 57) does not induce severe or prolonged systemic cytokine toxicity in vivo.

[0485] To assess the safety of lentiviral vector infusion human CD34+ engrafted NSG mice were intravenously (i.v.) injected IxlO8, IxlO9, and 3xl09LVP / mouse of VV169-LV vector or saline vehicle. Mice were split into a male cohort that received a fixed dose of 3.0 x 109lentiviral particles (LVP)Zmouse, while the female cohort was treated with three escalating doses (1.0 x |()\ 1.0 x |()9. and 3.0 x 109LVP / mouse). Peripheral blood was collected on 6, 24 and 48 hours post-injection for flow cytometric analysis. T cell activation was quantified as shown by the percentage of CD69+ and CD25+ cells within the human CD3+ T cell population for the male cohort (FIG. 54A) and the female cohort (FIG. 54B). Leukocyte populations were analyzed and the frequency of human CD45+ cells, mouse CD45+ cells, and human CD3+ T cells in peripheral blood was quantified for the male cohort (FIG. 54C) and the female cohort (FIG. 54D). Data are presented as mean ± SEM (n =5 per group).

[0486] Flow cytometric analysis demonstrated a rapid but transient increase in the early activation marker CD69, which peaked at the 6-hour time point and returned to near-baseline levels by 24 hours. A similar temporal pattern was observed for CD25 expression, which peaked at 6 hours and declined over subsequent time points. Collectively, these kinetics indicate a brief and self-resolving vector-associated T-cell activation event. Furthermore, in the female cohort, the upregulation of both CD69 and CD25 occurred in a dose-dependent manner, with expression levels scaling proportionally with the administered dose of VV169.

[0487] To assess whether vector exposure affected circulating leukocyte populations, human CD45+ leukocytes, mouse CD45+ cells, and human CD3+ T cells were quantified in peripheral blood over the same time course. The absolute numbers of these populations remained within normal ranges and exhibited comparable temporal trends in both VV 169-injected and saline-injected control. Importantly, no sustained depletion, abnormal expansion, or other changes indicative of hematologic or immune toxicity were observed. Overall, these findings indicate that VV169 administration induces a transient early T-cell activation without evidence of adverse effects on circulating immune cell populations during the acute post-injection period.

[0488] To monitor the generation, expansion, and contraction of anti-BCMA CAR-T cells, peripheral blood samples were collected from the male and female cohort at days 4, 16,Leydig 775537Vyriad P-63-006100and 43 post-injection and subjected to flow cytometric analysis showing the frequency of BCMA-CAR+ cells expressed as a percentage of CD3+ T cells for the male and female cohorts (FIG. 54E). Data are presented as mean ± SEM (n =4-5).

[0489] No detectable BCMA CAR-T cell expression was observed in the peripheral blood across all three time points examined in both male and female cohort mice, suggesting insufficient expansion below the limit of detection. Without wishing to be bound by theory the lack of measurable CAR-T cell expansion may be primarily attributable to the absence of the BCMA-expressing target cells within the standard CD34+ humanized NSG mouse model.

[0490] To evaluate the acute systemic cytokine response peripheral blood was collected at 6 and 48 hours post-infection, and plasma was isolated for cytokine profiling via Luminex multiplex assay. The plasma concentrations (pg / mL) of human TNFa, IL-2, and IL-6 (FIGS.54F-54G) and human IL-10, GM-CSF, and IFNy (FIG. 54H-54I) for both male and female cohorts were quantified with data presented as mean ± SEM, with individual dots representing individual mice (n = 3 -5 per group). Horizontal dashed lines indicate the assay's limit of detection (LOD) for each respective cytokine.

[0491] At 6 hours post-infection, mice treated with VV169 exhibited a rapid elevation in TNFa and IL-2, circulating human cytokines compared to the saline-treated controls. IL-6 levels remained mostly below the limit of detection in both 6 and 48 hours postinfection. Notably, the systemic cytokine release induced by VV169 was highly transient. By 48 hours post-infection, plasma concentrations of TNFa and IL-2 had markedly contracted, returning to near-baseline levels that were largely indistinguishable from those of the saline vehicle group. Together, these data indicate that systemic delivery- ofVV169 successfully engages the engrafted human immune compartment, driving a mild and self-limiting cytokine response without causing prolonged systemic hypercytokinemia.

[0492] To evaluate the systemic immune activation elicited by VV169, peripheral blood was collected at day 16 post-VV169 or saline infusion, and plasma was analyzed via Luminex multiplex assay to assess late-stage circulating human cytokine levels. The plasma concentrations (pg / mL) of human TNFa, IL-2, and IL-6 (FIG. 54J-54K) and human IL-10, GM-CSF, and IFNy (FIG. 54L-54M) were quantified with data presented as mean ± SEM, (n = 3-5 per group), with individual dots representing individual mice. Horizontal dashed lines indicate the limit of detection (LOD) for each respective cytokine assay.

[0493] These results demonstrate that compared to the early cytokine release observed at 6 hours post-injection, there was no sustained vector-specific elevation of systemic cytokinesLeydig 775537Vyriad P-63-006101at later time points. Taken together, these data indicate that VV169 drives a transient and mild initial acute immune response but does not trigger chronic systemic cytokine toxicity.

[0494] All references, including publications, patent applications, and patents, cited herein are hereby incorporated by reference to the same extent as if each reference were individually and specifically indicated to be incorporated by reference and were set forth in its entirety herein.

[0495] The use of the terms “a” and “an” and “the” and “at least one” and similar referents in the context of describing the invention (especially in the context of the follow ing claims) are to be construed to cover both the singular and the plural, unless otherwise indicated herein or clearly contradicted by context. The use of the term “at least one” followed by a list of one or more items (for example, “at least one of A and B”) is to be construed to mean one item selected from the listed items (A or B) or any combination of two or more of the listed items (A and B), unless otherwise indicated herein or clearly contradicted by context. The terms "comprising,” “having,” “including,” and “containing” are to be construed as open-ended terms (i.e., meaning “including, but not limited to,”) unless otherwise noted. Recitation of ranges of values herein are merely intended to serve as a shorthand method of referring individually to each separate value falling within the range, unless otherwise indicated herein, and each separate value is incorporated into the specification as if it were individually recited herein. All methods described herein can be performed in any suitable order unless otherwise indicated herein or otherwise clearly contradicted by context. The use of any and all examples, or exemplary' language (e.g., “such as”) provided herein, is intended merely to better illuminate the invention and does not pose a limitation on the scope of the invention unless otherwise claimed. No language in the specification should be construed as indicating any non-claimed element as essential to the practice of the invention.

[0496] Preferred embodiments of this invention are described herein, including the best mode known to the inventors for carrying out the invention. Variations of those preferred embodiments may become apparent to those of ordinary skill in the art upon reading the foregoing description. The inventors expect skilled artisans to employ such variations as appropriate, and the inventors intend for the invention to be practiced otherwise than as specifically described herein. Accordingly, this invention includes all modifications and equivalents of the subject matter recited in the claims appended hereto as permitted by applicable law. Moreover, any combination of the above-described elements in all possibleLeydig 775537Vyriad P-63-006102variations thereof is encompassed by the invention unless otherwise indicated herein or otherwise clearly contradicted by context.References (each incorporated by reference herein):• International Patent Publication No. WO 2023 / 023467 Al• International Patent Publication No. WO 2023 / 201238 Al• International Patent Publication No. WO 2024 / 097979 Al• International Patent Publication No. WO 2024 / 216227 Al• International Patent Publication No. WO 2024 / 159071• Chinese Patent Publication NO. CN 114502591 B• International Patent Publication No. WO 2021 / 063349 Al• Ruella et al., “Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell,” Nat Med, 24: 1499- 1503 (2018).• Lin et al., “IFN-y-dependent NK cell activation is essential to metastasis suppression by engineered Salmonella,” NATURE COMMUNICATIONS, 12: 2537 (2021)• Xu et al., “CD39 transforming cancer therapy by modulating tumor microenvironment,” Cancer Leiters, 597: 217072 (2024)SEQUENCESLeydig 775537Vyriad P-63-006103Leydig 775537Vyriad P-63-006104Leydig 775537Vyriad P-63-006105Leydig 775537Vyriad P-63-006106Leydig 775537Vyriad P-63-006107Leydig 775537Vyriad P-63-006108Leydig 775537Vyriad P-63-006109Leydig 775537Vyriad P-63-006110Leydig 775537Vyriad P-63-006I l lLeydig 775537Vyriad P-63-006112Leydig 775537 Vyriad P-63-006Leydig 775537Vyriad P-63-006114Leydig 775537Vyriad P-63-006115Leydig 775537Vyriad P-63-006116Leydig 775537Vyriad P-63-006117Leydig 775537Vyriad P-63-006118Leydig 775537Vyriad P-63-006119Leydig 775537Vyriad P-63-006120Leydig 775537Vyriad P-63-006121Leydig 775537Vyriad P-63-006122Leydig 775537Vyriad P-63-006123Leydig 775537Vyriad P-63-006124Leydig 775537Vyriad P-63-006125Leydig 775537Vyriad P-63-006126Leydig 775537Vyriad P-63-006127Leydig 775537Vyriad P-63-006128Leydig 775537Vyriad P-63-006129Leydig 775537Vyriad P-63-006130Leydig 775537Vyriad P-63-006131Leydig 775537Vyriad P-63-006132Leydig 775537Vyriad P-63-006133Leydig 775537Vyriad P-63-006134Leydig 775537Vyriad P-63-006135Leydig 775537Vyriad P-63-006136Leydig 775537Vyriad P-63-006137Leydig 775537Vyriad P-63-006138Leydig 775537Vyriad P-63-006139Leydig 775537Vyriad P-63-006140Leydig 775537Vyriad P-63-006141Leydig 775537Vyriad P-63-006142Leydig 775537Vyriad P-63-006143Leydig 775537Vyriad P-63-006144Leydig 775537Vyriad P-63-006145Leydig 775537Vyriad P-63-006146

Claims

Leydig 775537Vyriad P-63-006147CLAIMS:

1. A retroviral vector expression system comprising a transfer vector, wherein the transfer vector comprises a nucleotide sequence encoding an expression cassette,wherein the expression cassette comprises a transgene and one or more regulatory elements operably linked to the transgene, wherein the one or more regulatory elements reduce or ablate expression in a producer cell compared to expression in a target cell.

2. The retroviral vector expression system of claim 1, wherein the nucleotide sequence encoding an expression cassette is in reverse orientation relative to the transcriptional direction of the transfer vector, wherein the reverse orientation reduces or ablates expression of the expression cassette when the transfer vector is in a producer cell compared to when the transfer vector is in a target cell.

3. The retroviral vector expression system of claim 1 or 2, wherein the one or more regulatory elements are in reverse orientation relative to the transcriptional direction of the transfer vector, wherein the reverse orientation reduces or ablates expression of the expression cassette when the transfer vector is in a producer cell compared to when the transfer vector is in a target cell.

4. The retroviral vector expression system of any one of claims 1-3, wherein the one or more regulatory elements comprise one or more regulatory elements that are specific to the target cell.

5. The retroviral vector expression system of claim 4, wherein the one or more specific regulatory elements comprise a promoter, an enhancer, a silencer, a poly A tail, or any combination thereof.

6. The retroviral vector expression system of any one of claims 1-5, wherein the transgene encodes a chimeric antigen receptor (CAR).

7. The retroviral vector expression system of any one of claims 1-6, wherein the transfer vector comprises one or more of the transgene, wherein the one or more transgenes encode two or more CARs.Leydig 775537Vyriad P-63-0061488. The retroviral vector expression system of any one of claims 1-7, wherein the target cell is a T lymphocyte.

9. The retroviral vector expression system of any one of claims 1-8, wherein the one or more regulatory elements comprise a T cell-specific promoter.

10. The retroviral vector expression system of any one of claims 1-9, wherein the one or more regulatory elements comprise a T cell-specific enhancer.

11. The retroviral vector expression system of any one of claims 1-10, wherein the one or more regulatory elements comprise (a) a cytomegalovirus (CMV) enhancer, transcriptional element of RSV gene, or EFla promoter or (b) a T cell-specific transcriptional element of CD2, CD3e, LCK, or a functional variant thereof.

12. The retroviral vector expression system of any one of claims 1-11, wherein the producer cell is a HEK293 cell or a derivative of a HEK293 cell.

13. The retroviral vector expression system of any one of claims 1-12, wherein the transgene is expressed following transduction of a target cell and not expressed in a producer cell.

14. The retroviral vector expression system of claim 9, wherein the T cellspecific promoter is a portion of the distal Lek (dLck) promoter comprising a nucleotide sequence that has at least 80% sequence identity with SEQ ID NO: 33.

15. The retroviral vector expression system of any one of claims 1-14, wherein the one or more regulatory elements comprise a promoter comprising the nucleotide sequence of SEQ ID NO: 3, 30, 31, 32, 33, or 34.

16. The retroviral vector expression system of any one of claims 3-15, wherein the promoter comprises a modification that increases T cell specific transcriptional activity..Leydig 775537Vyriad P-63-00614917. The retroviral expression system of claim 16, wherein the modification comprises an addition of splicing signals, insertion of a TATA box, insertion of an octamer motif, insertion of a consensus cap site sequence, deletion or replacement of endogenous putative promoter response elements (PRE) elements, endogenous transcription initiation sites, or any combination thereof.

18. The retroviral expression system of claim 6 or 7, wherein one or more CARs comprise an antigen binding domain that has antigenic specificity for B Cell Maturation Antigen (BCMA), CD22, CD20, or CD 19.

19. The retroviral expression system of claim 18, wherein the antigen binding domain comprises a variable heavy domain of heavy chain (VHH) antibody comprising the amino acid sequence of SEQ ID NO: 1.

20. The retroviral expression system of any one of claims 1-19, comprising a CAR nucleotide construct comprising:(a) a nucleotide sequence encoding a signal peptide comprising an amino acid sequence of a CD8a signal peptide comprising the amino acid sequence of SEQ ID NO: 5,(b) a nucleotide sequence encoding an antigen binding domain comprising an amino acid sequence of a BCMA-targeting VHH antibody comprising the amino acid sequence of SEQ ID NO: 1,(c) a nucleotide sequence encoding a hinge domain comprising an amino acid sequence of a CD28 hinge domain comprising the amino acid sequence of SEQ ID NO: 7,(d) a nucleotide sequence encoding a transmembrane domain comprising an amino acid sequence of a CD28 transmembrane domain comprising the amino acid sequence of SEQ ID NO: 17,(e) a nucleotide sequence encoding an intracellular signaling domain comprising an amino acid sequence of a costimulatory domain 4- IBB comprising the amino acid sequence of SEQ ID NO: 9, and(f) a nucleotide sequence encoding an activating domain comprising an amino acid sequence of a CD3 zeta activating domain comprising the amino acid sequence of SEQ ID NO: 11 or SEQ ID NO: 20.Leydig 775537Vyriad P-63-00615021. The retroviral expression system of any one of claims 1-20, wherein at least one transfer vector comprises, in a 5’ to 3’ orientation:(a) a chimeric 5’ long terminal repeat (5’LTR) comprising enhancer and promoter nucleotide sequences in place of endogenous U3 enhancer and promoter sequences, positioned directly upstream of a 5' R - U5 region;(b) a Psi viral packaging signal nucleotide sequence;(c) a Rev response element (RRE) nucleotide sequence;(d) an expression cassette positioned in reverse orientation relative to the transcriptional direction of the transfer vector, the cassette comprising:i. a tissue specific regulatory element, andii. a chimeric antigen receptor (CAR) transgene nucleotide sequence, wherein i and ii are operably linked;(e) optionally a woodchuck hepatitis virus post-transcriptional regulatory element (WPRE) nucleotide sequence or a functional variant thereof;(f) a 3’ long terminal repeat (3’LTR) comprising a self-inactivating (SIN) U3 region; and(g) optionally an SV40 poly adenylation (pA) signal nucleotide sequence.

22. The retroviral expression system of claim 21, wherein the expression cassette comprises iii. a polyadenylation (pA) signal nucleotide sequence.

23. The retroviral expression system of claim 22, wherein the pA is a bGH polyadenylation signal nucleotide sequence, and wherein i, ii, and iii are operably linked.

24. The retroviral expression system of any one of claims 21-23, wherein the enhancer and promoter nucleotide sequences of the chimeric 5’ LTR are of Rous sarcoma virus (RSV) or CMV.

25. The retroviral expression system of any one of claims 21-24, wherein the transfer vector comprises the WPRE nucleotide sequence or functional variant thereof.

26. The retroviral expression system of claim 25, wherein the WPRE nucleotide sequence or functional variant thereof comprises a nucleotide sequence that has at least 80% sequence identity with SEQ ID NO: 26.Leydig 775537Vyriad P-63-00615127. The retroviral expression system of any one of claims 21-26, wherein the transfer vector comprises the SV40 polyadenylation (pA) signal nucleotide sequence.

28. The retroviral expression system of any one of claims 21-27, wherein the 5'LTR enhancer comprises SEQ ID NO: 21, the 5'LTR promoter nucleotide sequence comprises SEQ ID NO: 22, the 5’ R - U5 region comprises SEQ ID NO: 23; the Psi viral packaging signal nucleotide sequence comprises SEQ ID NO: 24; the RRE nucleotide sequence comprises SEQ ID NO: 25; the CAR transgene nucleotide sequence has antigenic specificity for B Cell Maturation Antigen (BCMA). the tissue specific regulatory element comprises two regulatory elements comprising a distal Lek promoter nucleotide sequence and an enhancer nucleotide sequence; the bGH polyadenylation (pA) signal nucleotide sequence comprises SEQ ID NO: 43; the 3’LTR comprising the SIN U3 region comprises SEQ ID NO: 28; and the SV40 pA signal nucleotide sequence comprises SEQ ID NO: 27.

29. The retroviral expression system of claim 28, wherein the BCMA CAR transgene nucleotide sequence comprises SEQ ID NO: 42.

30. The retroviral expression system of claim 28 or 29, wherein the enhancer nucleotide sequence comprises SEQ ID NO: 44 or SEQ ID NO: 4.

31. The retroviral expression system of any one of claims 28-30, wherein the WPRE nucleotide sequence or functional variant thereof comprises SEQ ID NO: 26 or SEQ ID NO: 5832. The retroviral expression system of any one of claims 28-31, wherein the distal Lek promoter nucleotide sequence comprises SEQ ID NO: 3.

33. The retroviral expression system of any one of claims 28-31, wherein the distal Lek promoter nucleotide sequence comprises SEQ ID NO: 30.

34. The retroviral expression system of any one of claims 28-31, wherein the distal Lek promoter nucleotide sequence comprises SEQ ID NO: 31.

35. The retroviral expression system of any one of claims 28-31, wherein the distal Lek promoter nucleotide sequence comprises SEQ ID NO: 32.Leydig 775537Vyriad P-63-00615236. The retroviral expression system of any one of claims 28-31, wherein the distal Lek promoter nucleotide sequence comprises SEQ ID NO: 33.

37. The retroviral expression system of any one of claims 28-31, wherein the distal Lek promoter nucleotide sequence comprises SEQ ID NO: 34.

38. The retroviral expression system of any one of claims 1-37, comprising a nucleotide sequence encoding a recombinant fusion protein of a Vesiculovirus Indiana G glycoprotein (VSIV-G) engineered to have a mutation to reduce or abolish its natural receptor binding specificity to low density lipoprotein receptor (LDL-R).

39. The retroviral expression system of claim 38, wherein the VSIV-G mutation is a single deletion at K47 corresponding to the amino acid sequence of SEQ ID NO: 15.

40. The retroviral vector expression system of any one of claims 2-39, wherein(a) the expression of the transgene in the producer cell and a lentiviral particle (LVP) produced by the producer cell is reduced or ablated compared to expression of the transgene in the target cell, or(b) wherein the expression of the transgene is increased in the target cell compared to the producer cell, or(c) wherein packaging efficiency of a transcript payload is improved in lentiviral particles produced by the producer cell compared to lentiviral particles produced by a producer cell wherein the expression cassette is in a forward orientation.

41. The retroviral expression system of any one of claims 2-40, comprising a second vector, wherein the second vector comprises a nucleotide sequence encoding an envelope protein in a forward orientation relative to the transcriptional direction of the second vector, wherein the envelope protein is optionally operably linked to one or more regulatory elements comprising a promoter or enhancer, the one or more regulatory elements able to drive expression of the envelope protein in a producer cell.Leydig 775537Vyriad P-63-00615342. The retroviral expression system of claim 41, wherein the envelope protein is engineered to have a mutation to reduce or abolish its natural receptor binding specificity.

43. The retroviral expression system of claim 41 or 42, comprising a third vector, wherein the third vector comprises a nucleotide sequence encoding a recombinant fusion protein in a forward orientation relative to the transcriptional direction of the third vector, wherein the recombinant fusion protein is optionally operably linked to one or more regulatory elements comprising a promoter or enhancer, the one or more regulatory’ elements able to drive expression of the recombinant fusion protein in a producer cell, and wherein the recombinant fusion protein comprises a targeting molecule and an envelope protein engineered to have a mutation to reduce or abolish its natural receptor binding specificity.

44. The retroviral expression system of any one of claims 1-43, comprising a nucleotide sequence encoding a recombinant protein comprising (A) a targeting molecule, (B) an oligomerization peptide, and one or both of (C)(1) a binding domain of a receptor protein, wherein the binding domain of the receptor protein is capable of binding to or interacting with a wild-type rhabdoviral G glycoprotein or functional fragment or derivative thereof and (C)(2) an antigen binding domain, wherein the antigen binding domain specifically binds a rhabdoviral G glycoprotein or functional fragment or derivative thereof.

45. The retroviral expression system of claim 44, wherein the recombinant protein comprises (C)(1), and wherein the binding domain of the receptor protein of the recombinant protein is of a cysteine rich region of a low-density lipoprotein receptor (LDLR).

46. The retroviral expression system of claim 45, wherein the binding domain comprises (i) cysteine rich domain 2 (CR2) of LDLR (SEQ ID NO: 67), (ii) cysteine rich domain 3 (CR3) of LDLR (SEQ ID NO: 68), (iii) cysteine rich domain 4 (CR4) of LDLR (SEQ ID NO: 69), or (iv) any combination of (i)-(iii).Leydig 775537Vyriad P-63-00615447. The retroviral expression system of claim 45, wherein the binding domain comprises cysteine rich domain 1 (CR1) of LDLR (SEQ ID NO: 66), CR2 (SEQ ID NO: 67) of LDLR, and CR3 (SEQ ID NO: 68) of LDLR.

48. The retroviral expression system of any one of claims 44-47, wherein the recombinant protein comprises (C)(1), and wherein the binding domain of the receptor protein of the recombinant protein is N terminal to the oligomerization peptide, optionally wherein the oligomerization peptide is N terminal to the targeting molecule.

49. The retroviral expression system of claim 44, wherein the recombinant protein comprises (C)(2).

50. The retroviral expression system of claim 49, wherein the antigen binding domain is a single chain variable fragment (scFv) or nanobody.

51. The retroviral expression system of claim 49 or 50, wherein binding of the antigen binding domain does not interfere with the fusion capability of the rhabdoviral G glycoprotein or functional fragment or derivative thereof.

52. A method of delivering a payload to a T lymphocyte, the method comprising(a) transducing or transfecting a producer cell with the retroviral expression system of any one of claims 1-51,(b) recovering an enveloped delivery vehicle (EDV) produced by the transduced or transfected producer cell, and(c) contacting the T lymphocyte with the EDV.Leydig 775537Vyriad P-63-00615553. A method for reducing or ablating expression of a chimeric antigen receptor (CAR) in a producer cell compared to expression in a T lymphocyte, the method comprising:(a) preparing a transfer vector comprising a nucleotide sequence encoding the CAR and one or more tissue-specific transcriptional regulatory elements operably linked to the nucleotide sequence encoding the CAR, optionally in a reverse orientation relative to the transcriptional direction of the transfer vector, and(b) transducing or transfecting the transfer vector into the producer cell, (c) recovering an enveloped delivery vehicle (EDV) produced by the transduced or transfected producer cell, and(d) contacting the T lymphocyte with the EDV.

54. A method for reducing or ablating expression of a chimeric antigen receptor (CAR) in an enveloped delivery vehicle (EDV) produced using lentivirus infection compared to expression in a T lymphocyte, the method comprising:(a) preparing a transfer vector comprising a nucleotide sequence encoding the CAR and one or more tissue-specific transcriptional regulatory elements operably linked to the nucleotide sequence encoding the CAR, optionally in a reverse orientation relative to the transcriptional direction of the transfer vector, and(b) transducing or transfecting the transfer vector into a producer cell, (c) recovering an EDV produced by the transduced or transfected producer cell, and(d) contacting the T lymphocyte cell with the EDV.

55. A method of producing a virus-like particle (VLP) produced using retrovirus infection with ablated, not detectable, or low expression of a transgene on the viral envelope of the VLP, the method comprising transfecting or transducing a producer cell with the retroviral expression system of any one of claims 1-51.Leydig 775537Vyriad P-63-00615656. A method for reducing or ablating expression of a transgene in an enveloped delivery vehicle (EDV) produced using lentivirus infection compared to expression in a target cell, the method comprising:(a) preparing a transfer vector comprising a nucleotide sequence encoding the transgene and one or more tissue-specific transcriptional regulatory elements operably linked to the transgene, optionally in a reverse orientation relative to the transcriptional direction of the transfer vector,(b) transducing or transfecting the transfer vector into a producer cell,(c) recovering an EDV produced by the transduced or transfected producer cell, and(d) contacting the target cell with the EDV.

57. A method for reducing or ablating expression of a transgene payload in a producer cell compared to expression in a target cell, the method comprising:(a) preparing a transfer vector comprising a nucleotide sequence encoding the transgene payload and one or more tissue-specific transcriptional regulatory elements operably linked to the transgene payload, optionally in a reverse orientation relative to the transcriptional direction of the transfer vector, and(b) transducing or transfecting the transfer vector into the producer cell, (c) recovering an enveloped delivery vehicle (EDV) produced by the transduced or transfected producer cell, and(d) contacting the target cell with the EDV.

58. The method of any one of claims 52-57, wherein the contacting is performed in vivo.

59. The method of any one of claims 52-58, wherein the retroviral vector expression system comprises one or more nucleic acids encoding (i) a recombinant fusionLeydig 775537Vyriad P-63-006157protein, and (ii) a rhabdoviral G glycoprotein or functional fragment or derivative thereof that is not within a recombinant fusion protein.

60. The method of claim 59, wherein the ratio of (i) to (ii) is 1:3.

61. A producer cell comprising the retroviral expression system of any one of claims 1-51.

62. An enveloped delivery vehicle (EDV) produced using retrovirus infection, comprising:(a) a viral envelope comprising a recombinant protein or protein complex able to mediate delivery of the vehicle to a target cell; and(b) a transfer vector comprising a nucleotide sequence encoding an expression cassette, optionally in reverse orientation relative to the transcriptional direction of the transfer vector, wherein the expression cassette comprises a transgene operably linked to one or more regulatory elements comprising a tissue-specific promoter or enhancer,wherein the enveloped delivery vehicle has ablated, low, or undetectable expression of the transgene on the viral envelope.

63. An enveloped delivery vehicle (EDV) produced in a producer cell transduced or transfected with the retroviral expression system of any one of claims 1-51.

64. A pharmaceutical composition comprising the EDV of claim 62 or 63.

65. A method of delivering a payload transgene to a target cell, the method comprising contacting the target cell with the pharmaceutical composition of claim 64.

66. A recombinant promoter comprising the nucleotide sequence of SEQ ID NO: 33.

67. A recombinant promoter comprising the nucleotide sequence of SEQ ID NO: 3.

68. A recombinant promoter comprising the nucleotide sequence of SEQ ID NO: 30.Leydig 775537Vyriad P-63-00615869. A recombinant promoter comprising the nucleotide sequence of SEQ ID NO: 31.

70. A recombinant promoter comprising the nucleotide sequence of SEQ ID NO: 32.

71. A recombinant promoter comprising the nucleotide sequence of SEQ ID NO: 34.

72. A recombinant promoter comprising a nucleotide sequence that has 90-99% sequence identity to SEQ ID NO: 33, wherein the promoter increases expression selectively in a target cell compared to expression in a producer cell.

73. The recombinant promoter of any one of claims 66-72, wherein the promoter increases expression selectively in a target cell compared to expression in a producer cell and the target cell is a T lymphocyte and the producer cell is a HEK293 cell or a derivative of aHEK293 cell.

74. A recombinant promoter consisting of the nucleotide sequence of SEQ ID NO: 33.

75. A recombinant promoter consisting of the nucleotide sequence of SEQ ID NO: 3.

76. A recombinant promoter consisting of the nucleotide sequence of SEQ ID NO: 30.

77. A recombinant promoter consisting of the nucleotide sequence of SEQ ID NO: 31.

78. A recombinant promoter consisting of the nucleotide sequence of SEQ ID NO: 32.

79. A recombinant promoter consisting of the nucleotide sequence of SEQ ID NO: 34.Leydig 775537Vyriad P-63-00615980. A method of increasing viral titers for lentiviral particles (LVPs) production in a retroviral vector expression system comprising:(a) preparing a transfer vector comprising an expression cassette, optionally in reverse orientation relative to the transcriptional direction of the transfer vector, wherein the expression cassette comprises a transgene operably linked to one or more tissue-specific transcriptional regulatory elements;(b) transducing or transfecting the transfer vector into a producer cell; and (c) recovering the LVPs produced by the transduced or transfected producer cell.

81. A retroviral transfer vector comprising a nucleotide sequence encoding an expression cassette,wherein the expression cassette comprises a transgene and one or more regulatory elements operably linked to the transgene, wherein the one or more regulatory elements reduce or ablate expression in a producer cell compared to expression in a target cell.

82. The retroviral transfer vector of claim 81, wherein the nucleotide sequence encoding an expression cassette is in reverse orientation relative to the transcriptional direction of the transfer vector,wherein the reverse orientation reduces or ablates expression of the expression cassette when the transfer vector is in a producer cell compared to when the transfer vector is in a target cell.

83. The retroviral transfer vector of claim 81 or claim 82, wherein the one or more regulatory elements are in reverse orientation relative to the transcriptional direction of the transfer vector,wherein the reverse orientation reduces or ablates expression of the expression cassette when the transfer vector is in a producer cell compared to when the transfer vector is in a target cell.Leydig 775537Vyriad P-63-00616084. The retroviral transfer vector of any one of claims 81-83, wherein the one or more regulatory elements comprise one or more regulatory elements that are specific to the target cell.

85. The retroviral transfer vector of claim 84, wherein the one or more specific regulatory elements comprise a promoter, an enhancer, a silencer, a poly A tail, or any combination thereof.

86. The retroviral transfer vector of any one of claims 81-85, wherein the transgene encodes a chimeric antigen receptor (CAR).

87. The retroviral transfer vector of any one of claims 81-86, wherein the target cell is a T lymphocyte.

88. The retroviral transfer vector of any one of claims 81-87, wherein the one or more regulatory elements comprise a T cell-specific promoter.

89. The retroviral transfer vector of any one of claims 81-88, wherein the one or more regulatory elements comprise a T cell-specific enhancer.

90. The retroviral transfer vector of any one of claims 81-89, wherein the one or more regulatory elements comprise (a) a cytomegalovirus (CMV) enhancer, transcriptional element of RSV gene, or EFla promoter or (b) a T cell-specific transcriptional element of CD2, CD3s. LCK, or a functional variant thereof.

91. The retroviral transfer vector of any one of claims 81-90, wherein the producer cell is a HEK293 cell or a derivative of a HEK293 cell.

92. The retroviral transfer vector of any one of claims 81-91, wherein the transgene is expressed following transduction of a target cell and not expressed in a producer cell.

93. The retroviral transfer vector of claim 88, wherein the T cell-specific promoter is a portion of the distal Lek (dLck) promoter comprising a nucleotide sequence that has at least 80% sequence identity with SEQ ID NO: 3.Leydig 775537Vyriad P-63-00616194. The retroviral transfer vector of any one of claims 81-93, wherein the one or more regulatory elements comprise a promoter comprising the nucleotide sequence of SEQ ID NO: 3, 30, 31, 32, 33, or 34.

95. The retroviral transfer vector of claim 88, 93, or 94, wherein the promoter comprises a modification that increases T cell specific transcriptional activity.

96. The retroviral transfer vector of claim 95, wherein the modification comprises an addition of splicing signals, insertion of a TATA box. insertion of an octamer motif, insertion of a consensus cap site sequence, deletion or replacement of endogenous putative promoter response elements (PRE) elements, endogenous transcription initiation sites, or any combination thereof.

97. The retroviral transfer vector of claim 86, wherein the CAR comprises an antigen binding domain that has antigenic specificity for B Cell Maturation Antigen (BCMA), CD22, CD20, or CD19.

98. The retroviral transfer vector of claim 97, wherein the antigen binding domain comprises a variable heavy domain of heavy chain (VHH) antibody comprising the amino acid sequence of SEQ ID NO: 1.Leydig 775537Vyriad P-63-00616299. The retroviral transfer vector of any one of claims 81-98, comprising a CAR nucleotide construct comprising:(a) a nucleotide sequence encoding a signal peptide comprising an amino acid sequence of a CD8a signal peptide comprising the amino acid sequence of SEQ ID NO: 5,(b) a nucleotide sequence encoding an antigen binding domain comprising an amino acid sequence of a BCMA-targeting VHH antibody comprising the amino acid sequence of SEQ ID NO: 1,(c) a nucleotide sequence encoding a hinge domain comprising an amino acid sequence of a CD28 hinge domain comprising the amino acid sequence of SEQ ID NO: 7,(d) a nucleotide sequence encoding a transmembrane domain comprising an amino acid sequence of a CD28 transmembrane domain comprising the amino acid sequence of SEQ ID NO: 17,(e) a nucleotide sequence encoding an intracellular signaling domain comprising an amino acid sequence of a costimulatory domain 4-1BB comprising the amino acid sequence of SEQ ID NO: 9, and(f) a nucleotide sequence encoding an activating domain comprising an amino acid sequence of a CD3 zeta activating domain comprising the amino acid sequence of SEQ ID NO: 11 or SEQ ID NO: 20.Leydig 775537Vyriad P-63-006163100. The retroviral transfer vector of any one of claims 81-99, comprising, in a 5’ to 3’ orientation:(a) a chimeric 5’ long terminal repeat (5’LTR) comprising enhancer and promoter nucleotide sequences in place of endogenous U3 enhancer and promoter sequences, positioned directly upstream of a 5' R - U5 region;(b) a Psi viral packaging signal nucleotide sequence;(c) a Rev response element (RRE) nucleotide sequence;(d) an expression cassette positioned in reverse orientation relative to the transcriptional direction of the transfer vector, the cassette comprising:i. a tissue specific regulatory element, andii. a chimeric antigen receptor (CAR) transgene nucleotide sequence;(e) optionally a woodchuck hepatitis virus post-transcriptional regulatory element (WPRE) nucleotide sequence or a functional variant thereof;(f) a 3’ long terminal repeat (3'LTR) comprising a self-inactivating (SIN) U3 region; and(g) optionally an SV40 polyadenylation (pA) signal nucleotide sequence.

101. The retroviral transfer vector of claim 100. wherein the expression cassette comprises iii. a polyadenylation (pA) signal nucleotide sequence.

102. The retroviral transfer vector of claim 101, wherein the pA is a bGH polyadenylation signal nucleotide sequence, and wherein i, ii. and iii are operably linked.

103. The retroviral transfer vector of any one of claims 100-102, wherein the enhancer and promoter nucleotide sequences of the chimeric 5’ LTR are of Rous sarcoma virus (RSV) or CMV.

104. The retroviral transfer vector of any one of claims 100-103, wherein the transfer vector comprises the WPRE nucleotide sequence or functional variant thereof.

105. The retroviral transfer vector of claim 104, wherein the WPRE nucleotide sequence or functional variant thereof comprises a nucleotide sequence that has at least 80% sequence identity with SEQ ID NO: 26Leydig 775537Vyriad P-63-006164106. The retroviral transfer vector of any one of claims 100-105, wherein the transfer vector comprises the SV40 polyadenylation (pA) signal nucleotide sequence.

107. The retroviral transfer vector of claim 100-106, wherein the 5'LTRenhancer comprises SEQ ID NO:

21. the 5'LTR promoter nucleotide sequence comprises SEQ ID NO: 22, the 5’ R - U5 region comprises SEQ ID NO: 23; the Psi viral packaging signal nucleotide sequence comprises SEQ ID NO: 24; the RRE nucleotide sequence comprises SEQ ID NO: 25; the CAR transgene nucleotide sequence has antigenic specificity for B Cell Maturation Antigen (BCMA). the tissue specific regulatory element comprises two regulatory elements comprising a distal Lek promoter nucleotide sequence and an enhancer nucleotide sequence; the bGH polyadenylation (pA) signal nucleotide sequence comprises SEQ ID NO: 43; the 3’LTR comprising the SIN U3 region comprises SEQ ID NO: 28; and the SV40 pA signal nucleotide sequence comprises SEQ ID NO: 27.

108. The retroviral transfer vector of claim 107, wherein the BCMA CAR transgene nucleotide sequence comprises SEQ ID NO: 42.

109. The retroviral transfer vector of claim 107 or 108, wherein the enhancer nucleotide sequence comprises SEQ ID NO: 44 or SEQ ID NO: 4.

110. The retroviral transfer vector of any one of claims 107-109, wherein the WPRE nucleotide sequence or functional variant thereof comprises SEQ ID NO: 26 or SEQ ID NO: 58.

111. The retroviral transfer vector of any one of claims 107-110, wherein the distal Lek promoter nucleotide sequence comprises SEQ ID NO: 3.

112. The retroviral transfer vector of any one of claims 107-110, wherein the distal Lek promoter nucleotide sequence comprises SEQ ID NO: 30.

113. The retroviral transfer vector of any one of claims 107-110, wherein the distal Lek promoter nucleotide sequence comprises SEQ ID NO: 31.

114. The retroviral transfer vector of any one of claims 107-110, wherein the distal Lek promoter nucleotide sequence comprises SEQ ID NO: 32.Leydig 775537Vyriad P-63-006165115. The retroviral transfer vector of any one of claims 107-110, wherein the distal Lek promoter nucleotide sequence comprises SEQ ID NO: 33.

116. The retroviral transfer vector of any one of claims 107-110, wherein the distal Lek promoter nucleotide sequence comprises SEQ ID NO: 34.

117. The retroviral transfer vector of any one of claims 82-116, wherein (a) the expression of the transgene in the producer cell and a lentiviral particle (LVP) produced by the producer cell is reduced or ablated compared to expression of the transgene in the target cell, or(b) wherein the expression of the transgene is increased in the target cell compared to the producer cell, or(c) wherein packaging efficiency of a transcript payload is improved in lentiviral particles produced by the producer cell compared to lentiviral particles produced by a producer cell wherein the expression cassette is in a forward orientation.

118. A retroviral transfer vector of any one of claims 82-117, wherein the retroviral transfer vector is of a lentiviral vector.

119. A pharmaceutical composition of claim 64 for use in treating a hematological malignancy in a subject.

120. The pharmaceutical composition of claim 119, wherein the hematological malignancy is multiple myeloma.

121. A pharmaceutical composition of claim 64 for use in treating systemic lupus erythematosus (SLE) in a subject.

122. A pharmaceutical composition of claim 64 for use in treating a B Cell Maturation Antigen (BCMA)-expressing tumor in a subject.